Pathology In Depth

Library › Skin tumors: epidermal and keratinocytic tumors, melanocytic lesions and melanoma staging, adnexal, mesenchymal, vascular and histiocytic neoplasms (WHO 5th edition)

Skin tumors: epidermal and keratinocytic tumors, melanocytic lesions and melanoma staging, adnexal, mesenchymal, vascular and histiocytic neoplasms (WHO 5th edition)

Last reviewed 2026-11-17 by a board-certified pathologist. 267 references.

Benign Epidermal Tumors, Cutaneous Cysts, Actinic Keratosis and Squamous Cell Carcinoma In Situ

Definition and classification. The WHO Classification of Skin Tumours, 5th edition (Skin5), places seborrheic keratosis, the acanthomas, actinic keratosis and squamous cell carcinoma (SCC) in situ among keratinocytic/epidermal tumours. In Skin5, "variant" refers only to a genetic variant, and histologic forms are "subtypes" (Goldman-Lévy et al. 2026). Cutaneous cysts are classified by their lining into cysts with stratified squamous epithelium, cysts with non-stratified epithelium and pseudocysts without epithelium (Hoang et al. 2019).

Related page: Keratoacanthoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma and Merkel Cell Carcinoma: Subtypes, Risk Stratification, Staging, CAP Reporting and Mohs Surgery (keratoacanthoma, invasive cutaneous SCC, basal cell carcinoma and their staging) Related page: Cutaneous Adnexal Neoplasms: Follicular, Sebaceous, Apocrine and Eccrine Tumors, Adnexal Carcinomas, Paget Disease and Associated Syndromes (nevus sebaceus, trichilemmoma, pilomatricoma and primary and secondary extramammary Paget disease) Related page: Non-Neoplastic and Reactive Soft Tissue and Skin Lesions on FNA (epidermal inclusion cyst and pilomatricoma on FNA) Related page: Paget Disease of the Nipple, Inflammatory Carcinoma, Male Breast Carcinoma and Hereditary Breast Cancer (mammary Paget disease histology and immunohistochemistry) Related page: Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing (familial adenomatous polyposis and Gardner syndrome)

Lichen planus-like keratosis is taught in Interface and Lichenoid Dermatoses, Cutaneous Lupus and Dermatomyositis, Graft-versus-Host Disease, and Sclerosing Dermal Disorders, and verruca vulgaris and condyloma in Skin Infections and Infestations: Bacterial, Mycobacterial, Spirochetal, Fungal, Viral, Protozoal and Parasitic Infections of Skin.

Seborrheic keratosis: clinical features, histologic types and genetics

  • Clinical features. Seborrheic keratoses (SKs) are benign epithelial tumors of adults whose incidence rises with age to a peak at 60 years. They favor the trunk and forehead. Dermatosis papulosa nigra is a clinical form of SK with multiple tiny papules, more frequent in Fitzpatrick skin type 3 or higher, in patients of African or Asian descent and in women; it affects about 10% of African Americans, has a positive family history in up to 85% and begins earlier than common SK. Its histology matches the acanthotic or reticulated type of SK, and it carries FGFR3 mutations (Wollina 2019).
  • Shared histologic features. All SK types show hyperkeratosis, acanthosis and papillomatosis. At low power, the base of the lesion lies on an imaginary line drawn between the dermoepidermal junctions of the adjacent normal skin (Roh et al. 2016).
  • Horn cysts and pseudohorn cysts. True horn cysts show complete keratinization surrounded by a very thin granular layer. Pseudohorn cysts are horny invaginations of the surface that appear as cysts on cross-section (Wollina 2019).
  • Genetics. Exome sequencing shows about 3 mutations per megabase with a UV signature. FGFR3 mutations are the most frequent (48% of lesions), followed by PIK3CA (32%), TERT promoter (24%) and DPH3 promoter mutations (24%) (Wollina 2019).
  • Leser–Trélat sign. The sudden appearance of multiple, often pruritic SKs in association with an underlying malignancy defines the Leser–Trélat sign. Targeted cancer treatments can cause a pseudo-Leser–Trélat sign (Wollina 2019).
SK type Histologic features Frequency in 206 biopsy-proven SKs Source
Acanthotic Greatly thickened epidermis of basaloid cells; horny invaginations appear as pseudohorn cysts 45.1% (most common) Roh et al. 2016
Hyperkeratotic Hyperkeratosis with horn cysts and pseudohorn cysts 17.0% Roh et al. 2016; Wollina 2019
Adenoid (reticulated) Thin anastomosing tracts of epidermal cells, often a double row of basaloid cells, branching within the dermis; often hyperpigmented; horn pearls uncommon; more common on sun-exposed sites (p=0.028) 4.4% Roh et al. 2016; Wollina 2019
Clonal Acanthosis and papillomatosis with orthohyperkeratosis and well-demarcated intraepidermal islands of basaloid cell nests 2.4% Roh et al. 2016; Wollina 2019
Irritated Spindle-shaped eosinophilic cells, sometimes in whorls, with dyskeratotic cells; can resemble verrucous SCC 1.9% Roh et al. 2016; Wollina 2019
Melanoacanthoma Hyperpigmented acanthotic type with basaloid cells, numerous intermingled melanocytes and dermal melanophages; rare on oral mucosa 9.2% Roh et al. 2016; Wollina 2019
Verrucous SK with keratoacanthoma-like features Classic SK features with a dome shape, marginal lips and a central keratin-filled crater; HPV16 detected; about 0.8% of keratoacanthomas in one series Rare Wollina 2019
Mixed More than one pattern in a single lesion 19.9% Roh et al. 2016
  • Clonal SK versus pagetoid Bowen disease. Cytokeratin 10 is expressed more strongly in clonal SK. Increased Ki-67-positive cells and p16 positivity in more than 75% of cells favor pagetoid Bowen disease. Diffuse or patchy p16 positivity in clonal nests without atypical histologic features is typical of SK (Wollina 2019).
  • Clinicopathologic mismatch. Of lesions clinically diagnosed as SK that proved to be another entity, 24.2% were premalignant or malignant, and mismatches were more frequent on sun-exposed sites (Roh et al. 2016).

Inverted follicular keratosis

Inverted follicular keratosis is a benign tumor of the follicular infundibulum with exo-endophytic growth. It shows an endophytic intradermal proliferation of basaloid and squamous cells with intraepithelial squamous eddies (whorled aggregates of eosinophilic squamous cells) and horn cysts, without cytologic atypia, and a lichenoid dermal infiltrate in most cases. In 13 cases, the mean age was 53 years, the male-to-female ratio was 3.3, the face was the main site (9 of 13; most often the moustache area), 92% of lesions were on sun-exposed skin and the diagnosis was never suspected clinically (Baklouti et al. 2023).

Clear cell, epidermolytic, acantholytic and large cell acanthomas and warty dyskeratoma

Lesion Histologic features Clinical and etiologic notes Source
Clear cell acanthoma Psoriasiform acanthosis of pale keratinocytes with sharp demarcation from the adjacent normal epidermis; cytoplasmic glycogen is PAS-positive and diastase-sensitive; parakeratosis, sometimes with neutrophils in the stratum corneum and upper spinous layer Usually solitary; shares histopathologic, immunohistologic and dermoscopic features with psoriasis Usmani and Qasim 2020
Epidermolytic acanthoma Hyperkeratosis without parakeratosis, hypergranulosis with coarse keratohyalin granules and perinuclear vacuolization of keratinocytes in the spinous and granular layers (epidermolytic hyperkeratosis) Proposed contributors include HPV, ultraviolet radiation, immunosuppression and trauma; focal epidermolytic change also occurs in SK, actinic keratosis and Bowen disease Jung et al. 2015
Acantholytic acanthoma Hyperkeratosis, papillomatosis, acanthosis and acantholysis at various levels of the epidermis Solitary keratotic papule of the elderly, most often on the trunk; association with immunosuppression or chronic UV damage proposed Elibol et al. 2025
Warty dyskeratoma Cup-shaped invagination filled with a keratotic plug; suprabasal clefts with acantholytic dyskeratotic cells; villi lined by a single layer of basaloid cells; corps ronds in a thickened granular layer Often follicle-associated; oral and subungual examples are reported Zhao et al. 2019
Large cell acanthoma Sharply demarcated orthohyperkeratosis, hypergranulosis and keratinocytes with enlarged polyploid nuclei, without atypical mitoses Sun-exposed skin; regarded variously as a form of solar lentigo, a cytologic subtype of Bowen disease or a distinct keratosis related to stucco keratosis Patsatsi et al. 2014

Epidermal nevi: keratinocytic epidermal nevus, ILVEN and nevus comedonicus

  • Keratinocytic epidermal nevus. Epidermal nevi arise from somatic mosaicism in pluripotent cells of the embryonic ectoderm and present as circumscribed lesions in a Blaschko-linear pattern. Mosaic activating FGFR3 and HRAS mutations are causal. Histology shows papillomatosis, acanthosis, hyperkeratosis and increased basal pigmentation. SCC arising in keratinocytic epidermal nevi is rare: 10 SCCs and 5 keratoacanthomas had been reported by 2019, with a mean age of 45 years, and SCC in this setting can metastasize (Dubois et al. 2019).
  • Inflammatory linear verrucous epidermal nevus (ILVEN). The diagnostic criteria are erythematous verrucous hyperkeratosis in a fine, whorled Blaschko-linear pattern, intense pruritus, early onset, histologic features and resistance to treatment. Mosaic CARD14 missense variants were identified in ILVEN, and keratinocytes carrying mutant CARD14 express more IL-12 and IL-23 (Riachi et al. 2021).
  • Nevus comedonicus. Nevus comedonicus is caused by somatic NEK9 mutations. Biopsy shows dilated follicular infundibula with keratin plugs that can contain rolled hairs (Tahara et al. 2021).

Actinic keratosis: histology, variants and risk of progression

  • Relationship to SCC and natural history. Actinic keratosis (AK) can be regarded as an early SCC, and it can evolve into invasive tumor (Paolino et al. 2017). In patients with multiple AKs, the cumulative lifetime risk of invasive SCC is 6%–10%. Between 25% and 60% of AKs regress spontaneously, and new lesions appear at about the same rate (Meyer et al. 2026).
  • Histology. AK shows horizontal alternation of parakeratotic and orthokeratotic hyperkeratosis over an atrophic or acanthotic epidermis. Atypical keratinocytes in the basal layer show increased cellularity, nuclear pleomorphism and scattered mitoses. A superficial lichenoid or perivascular lymphocytic infiltrate often contains plasma cells, and the papillary dermis usually shows solar elastosis (Paolino et al. 2017).
  • Acantholytic AK. Hyperkeratosis, acanthosis and suprabasal acantholysis accompany atypical basal keratinocytes. The differential diagnosis includes Grover disease, Darier disease, warty dyskeratoma and SK with acantholysis (Paolino et al. 2017).
  • Pigmented AK. Melanin is focally increased in basal keratinocytes, and melanophages are present (Paolino et al. 2017).
  • Histologic subtypes. AKs are classified histologically as hypertrophic, atrophic, bowenoid, acantholytic, epidermolytic, lichenoid and pigmented, and subtypes can overlap in one lesion (Reinehr and Bakos 2019).
  • Histologic grading (Röwert-Huber). Grade I shows atypical keratinocytes in the basal and suprabasal layers; grade II, in the lower two-thirds of the epidermis; grade III, in more than two-thirds of the epidermis with involvement of the adnexal epithelium. Agreement between clinical and histologic grades is low (Reinehr and Bakos 2019).
  • Actinic cheilitis. Actinic cheilitis is a clinical form of AK on the lip (Reinehr and Bakos 2019). In 161 cases, 97.5% involved the lower lip and 79.5% of patients were male, and 60.2% of 83 biopsied cases were graded low risk on a binary (low-risk and high-risk) system (Lopes et al. 2015).
  • Field cancerization. Patients with prior cutaneous SCC often show extensive areas of chronically UV-damaged skin containing numerous genetically altered keratinocytes (Meyer et al. 2026).

Squamous cell carcinoma in situ (Bowen disease) and bowenoid papulosis

  • Definition and histology. Bowen disease is an intraepidermal carcinoma with atypical keratinocytes in every layer of the epidermis. It shows parakeratosis, bulbous rete ridges, disordered maturation, individual cell keratinization, pleomorphic nuclei, atypical mitoses and multinucleated tumor cells with an intact basal layer. A perivascular or lichenoid lymphocytic infiltrate often contains plasma cells (Paolino et al. 2017).
  • Etiology and progression. Ultraviolet light, immunosuppression, arsenic and oncogenic HPV are the main causes. HPV-positive cutaneous lesions occur mostly on the distal extremities, especially periungual sites, and HPV16 is the type most often detected. Bowen disease progresses to invasive SCC in 3%–5% of cases. Bowen disease of the glans and prepuce (erythroplasia of Queyrat) carries a risk of invasive SCC of up to 33% (Scurtu et al. 2024).
  • Histologic subtypes. Psoriasiform, atrophic, acantholytic, epidermolytic, verrucous-hyperkeratotic, orthokeratotic, mucinous, sebaceous, papillated, irregular (highly pleomorphic), pigmented, pagetoid and clear cell patterns are described, some associated with HPV (Scurtu et al. 2024).
  • Bowenoid papulosis and erythroplasia of Queyrat. Bowenoid papulosis is a genital HPV infection whose atypical keratinocytes and mitoses are microscopically identical to Bowen disease. Erythroplasia of Queyrat is histologically identical to Bowen disease on mucosa (Paolino et al. 2017) and is now categorized as a clinical form of penile intraepithelial neoplasia (Scurtu et al. 2024).
  • Irritated SK in the differential. Irritated SK lacks keratinocyte atypia and shows intense inflammation with mitoses related to the inflammation (Paolino et al. 2017).

Pagetoid intraepidermal neoplasms: immunohistochemical distinction

Pagetoid Bowen disease shows large pale atypical cells scattered through the epidermis and mimics extramammary Paget disease (EMPD) and melanoma in situ. EMPD usually arises in apocrine-rich anogenital skin (Lee et al. 2018). Cytokeratin 7 and CAM5.2 positivity has been used to favor EMPD over SCC. In 15 pagetoid SCCs in situ, CK7 was positive in 13% and partially positive in 47%, and CAM5.2 was negative with partial staining in 20%. Diffuse nuclear p63 was present in 15 of 15 pagetoid SCCs in situ and 0 of 15 EMPDs, whereas CK7 was positive in 93% and CAM5.2 in 100% of EMPDs (Wieland et al. 2023). p63 is expressed by most SCCs and basal cell carcinomas, including intraepidermal tumors (Compton et al. 2015). Ber-EP4 is a sensitive marker of EMPD and basal cell carcinoma and is not expressed by pagetoid SCC or melanoma, so a panel of Ber-EP4, p63 and a melanocytic marker separates these lesions (Compton et al. 2015).

Marker Pagetoid Bowen disease Extramammary Paget disease Melanoma in situ Source
p63 Diffuse nuclear in 15 of 15 0 of 15 Negative Wieland et al. 2023; Compton et al. 2015
CK7 and CAM5.2 CK7 positive in 13% and partially positive in 47%; CAM5.2 partially positive in 20% CK7 93%; CAM5.2 100% Negative Wieland et al. 2023; Lee et al. 2018
CEA and GCDFP-15 Generally negative Positive Negative Lee et al. 2018
EMA Negative in most cases Positive Negative Lee et al. 2018
Ber-EP4 Negative Positive Negative Compton et al. 2015
S100, HMB45, MART-1 Negative Negative Positive Compton et al. 2015; Paolino et al. 2017

Epidermoid (infundibular) cyst

  • Origin and terminology. The epidermoid cyst originates from the follicular infundibulum. Synonyms are infundibular cyst, epidermal cyst and epidermal inclusion cyst. "Sebaceous cyst" is an inappropriate synonym because sebaceous glands are absent from the lining. A milium is a small transient epidermoid cyst. A dermoid cyst has a similar keratinizing squamous lining, but its wall contains skin appendages, which are absent from an epidermoid cyst (Hoang et al. 2019).
  • Histology. Stratified squamous epithelium resembling epidermis lines the cyst. A granular layer with keratohyalin granules is present, and the lumen contains laminated orthokeratotic keratin (Hoang et al. 2019).
  • Rupture. Rupture spills keratin squames into the dermis and causes an acute foreign body granulomatous reaction (Hoang et al. 2019).
  • Gardner syndrome. Early onset and atypical sites such as the limbs suggest autosomal dominant Gardner syndrome, in which epidermoid cysts can show hybrid or pilomatrixoma-like changes (Hoang et al. 2019).
  • Malignant change. About 1% of epidermoid cysts undergo malignant transformation to SCC or basal cell carcinoma (Hoang et al. 2019).

Trichilemmal (pilar) cyst and proliferating trichilemmal tumor

  • Trichilemmal cyst. About 90% occur on the scalp, where they are the most common cutaneous cyst. The cyst arises from the follicular isthmus of the external root sheath. Keratinization is abrupt, without an intervening granular layer, and the lumen contains homogeneous compact eosinophilic keratin, unlike the laminated keratin of an epidermoid cyst. The keratin can show dystrophic calcification and cholesterol clefts (Ramaswamy et al. 2013).
  • Proliferating trichilemmal tumor (PTT). About 2% of trichilemmal cysts develop single or multiple foci of proliferating cells. PTT can also arise de novo, is more common in women and grows rapidly. No clinical criteria separate benign from malignant PTT (Ramaswamy et al. 2013). PTT shows increased p53 expression and an intermediate Ki-67 index between trichilemmal cyst and SCC, and Ki-67, CD34 and p53 can help separate PTT from SCC (Martín-Sanz et al. 2021).
  • Classification of PTT into three groups (series of 76 cases). Group I tumors lack infiltration of the surrounding stroma, show minimal nuclear atypia, trichilemmal keratinization and dystrophic calcification, and are benign. Group II tumors are lobulated and bosselated masses with large hyperchromatic nuclei, single-cell necrosis and cords of atypical squamous epithelium extending into the dermis with a desmoplastic response, without marked cytologic atypia. Group III tumors are invasive and cytologically anaplastic and are malignant (Sharma et al. 2012).
  • Skin5 placement. The WHO 5th-edition list reproduced in the CAP cutaneous carcinoma protocol places proliferating trichilemmal tumor among malignant tumors with follicular differentiation (CAP 2026a). Rare TP53 and PIK3CA mutations are reported in PTT (Goldman-Lévy et al. 2026).

Steatocystoma, eruptive vellus hair cyst and hidrocystoma

  • Steatocystoma. The cyst lies in the mid-dermis and is lined by 2–3 layers of stratified squamous epithelium without a granular layer, covered by an eosinophilic crenulated cuticle with sharp invaginations into the lumen. Flattened sebaceous lobules lie close to the wall (Sharma et al. 2018). Steatocystoma multiplex arises from the pilosebaceous duct and is usually autosomal dominant. Pedigrees carry KRT17 mutations, which also cause pachyonychia congenita type 2 (Liu et al. 2015).
  • Eruptive vellus hair cyst. Eruptive vellus hair cysts are small (1–4 mm) reddish-brown papules on the chest, limbs and abdomen of children and young adults and are sporadic or autosomal dominant. Cystic spaces lined by stratified squamous epithelium contain laminated keratin and numerous transversely and obliquely cut vellus hairs. Steatocystoma multiplex is the main clinical differential (Anand et al. 2018).
  • Apocrine hidrocystoma. Apocrine hidrocystoma arises from a blocked duct of a gland of Moll at the eyelid margin. One or more cystic spaces are lined by an inner columnar epithelium with eosinophilic apical cytoplasm and decapitation secretion and an outer myoepithelial layer (Pe'er 2016).
  • Eccrine hidrocystoma. Eccrine hidrocystoma is a ductal retention cyst of eccrine sweat glands that presents as a solitary clear cyst on the eyelid skin away from the margin. Myoepithelial cells are absent (Pe'er 2016).

Developmental cutaneous cysts

Cyst Site and clinical features Lining and wall Source
Bronchogenic cyst Midline suprasternal notch, sometimes with a draining punctum; boys outnumber girls about 4:1 Ciliated pseudostratified columnar epithelium with PAS-positive goblet cells; smooth muscle in 80%, submucosal glands in 53% and cartilage in 7% Kim et al. 2011
Branchial cleft cyst Lateral neck, anterior to the sternocleidomastoid muscle Stratified squamous epithelium with abundant lymphoid tissue containing germinal centers in the wall Chavan et al. 2014
Median raphe cyst Anywhere in the ventral midline from the glans penis to the anus; from defective closure of the median raphe Pseudostratified columnar epithelium, ciliated in part, with apical mucin Syed et al. 2019
Cutaneous ciliated cyst Lower limbs of women aged 15–30 years; rare in men and other sites Ciliated cuboidal to columnar epithelium with pseudostratified areas and focal squamous metaplasia; estrogen and progesterone receptor-positive, resembling fallopian tube epithelium Kim and Kim 2015

Branchial and bronchogenic cysts overlap histologically, and lymphoid tissue in the wall and the type of lining are the most useful distinguishing features (Kim et al. 2011).

Cutaneous cysts classified by lining

Lining Cysts Source
Stratified squamous epithelium Epidermoid (infundibular) cyst, milium, trichilemmal cyst, proliferating trichilemmal cyst, proliferating epidermoid cyst, vellus hair cyst, steatocystoma, cutaneous keratocyst, pigmented follicular cyst, dermoid cyst, verrucous cyst, ear pit cyst, pilonidal cyst Hoang et al. 2019
Non-stratified epithelium Eccrine and apocrine hidrocystoma, bronchogenic cyst, thyroglossal duct cyst, branchial cleft cyst, cutaneous ciliated cyst, ciliated cyst of the vulva, median raphe cyst, omphalomesenteric duct cyst Hoang et al. 2019
No epithelium (pseudocysts) Mucocele, digital mucous cyst, ganglion, pseudocyst of the auricle, cutaneous metaplastic synovial cyst Hoang et al. 2019
Feature Epidermoid cyst Trichilemmal cyst Steatocystoma Eruptive vellus hair cyst Source
Lining Stratified squamous epithelium with a granular layer Squamous epithelium with abrupt keratinization and no granular layer 2–3 layers of squamous epithelium without a granular layer, covered by a crenulated cuticle, with sebaceous lobules in or near the wall Stratified squamous epithelium Hoang et al. 2019; Ramaswamy et al. 2013; Sharma et al. 2018; Anand et al. 2018
Luminal content Laminated orthokeratin Homogeneous compact eosinophilic keratin, calcification, cholesterol clefts Amorphous eosinophilic material Laminated keratin with many vellus hairs Hoang et al. 2019; Ramaswamy et al. 2013; Sharma et al. 2018; Anand et al. 2018
Site Skin and mucous membranes; limb cysts suggest Gardner syndrome Scalp (90%) Multiple cysts in steatocystoma multiplex Chest, limbs, abdomen Hoang et al. 2019; Ramaswamy et al. 2013; Liu et al. 2015; Anand et al. 2018

Keratoacanthoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma and Merkel Cell Carcinoma: Subtypes, Risk Stratification, Staging, CAP Reporting and Mohs Surgery

Definition and classification. The WHO Classification of Skin Tumours, 5th edition (Skin5), classifies keratoacanthoma, cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) among keratinocytic/epidermal tumours and designates Merkel cell carcinoma (MCC) a neuroendocrine carcinoma of the skin (Goldman-Lévy et al. 2026; Ho and Collie 2023). Head and neck cSCC is staged with the AJCC 8th edition and reported with the CAP Cutaneous Carcinoma of the Head and Neck protocol, version 1.2.0.0 (April 2026). That protocol is required for resections of node-positive and pT3 or pT4 cSCC of the head and neck, including the dry vermilion lip, and its template can also be used to report BCC and adnexal carcinoma. cSCC of other cutaneous sites has no current CAP protocol (CAP 2026a). MCC is staged with the AJCC 8th edition and reported with the CAP Merkel Cell Carcinoma of the Skin protocol, version 4.2.0.0 (April 2026), which applies to excisions (CAP 2026b).

Related page: Benign Epidermal Tumors, Cutaneous Cysts, Actinic Keratosis and Squamous Cell Carcinoma In Situ (actinic keratosis, Bowen disease and pagetoid intraepidermal neoplasms) Related page: Melanoma, Merkel Cell Carcinoma and Skin FNA (Merkel cell carcinoma and melanoma on FNA, cell-block immunohistochemistry) Related page: Cutaneous Adnexal Neoplasms: Follicular, Sebaceous, Apocrine and Eccrine Tumors, Adnexal Carcinomas, Paget Disease and Associated Syndromes (trichoblastoma, trichoepithelioma, microcystic adnexal carcinoma and adenoid cystic carcinoma) Related page: Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma (atypical fibroxanthoma and pleomorphic dermal sarcoma in the differential of spindle cell SCC) Related page: Ovarian Sex Cord-Stromal Tumors, Small Cell Carcinoma of Hypercalcemic Type and Wolffian and STK11 Adnexal Tumors (ovarian fibromas in nevoid basal cell carcinoma syndrome) Related page: Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma in Cytology (nodal squamous cell carcinoma of unknown primary on cytology)

Keratoacanthoma: histology, distinction from SCC and WHO 5th-edition position

  • Histology. Keratoacanthoma is a symmetrical, circumscribed proliferation of keratinocytes with a central keratin plug, lips of epidermis extending over the tumor and pale, ground-glass keratinocytes with uniform differentiation. Clinical forms include keratoacanthoma centrifugum marginatum, a giant lesion with centrifugal spread, and multiple keratoacanthomas (Paolino et al. 2017). Regression proceeds from thick glassy epithelium to thinner basophilic epithelium (Ho and Collie 2023). Symmetry, a keratin plug, an abrupt transition between tumor and epidermis, a deep fibrotic band beneath the lesion and intraepithelial neutrophilic microabscesses support keratoacanthoma, whereas asymmetry, a gradual transition and fibrosis around tumor nests favor SCC. Keratoacanthoma can contain a mixed infiltrate of histiocytes, eosinophils, neutrophils and plasma cells (Bahmad et al. 2024).
  • Ancillary studies. Ki-67 shows a peripheral-only pattern in keratoacanthoma. Irregular Ki-67 staining beyond the peripheral cells is relatively specific for conventional cSCC, and a peripheral graded pattern can occur in some well-differentiated cSCCs. Clinical correlation, adequate biopsy sampling and p53, Ki-67 and p16 immunohistochemistry separate keratoacanthoma from follicular SCC in many cases. In a reported squamoproliferative lesion that metastasized, the features of concern were a thickened proliferative border, increased nuclear-to-cytoplasmic ratio, slight hyperchromasia and aberrant, focally weak cytoplasmic p16 (Goldman-Lévy et al. 2026).
  • WHO 5th edition. Keratoacanthoma is likely to be considered an entity separate from SCC. When the two cannot be separated reliably, the uncertainty may be reported as "squamoproliferative tumour of uncertain malignant potential" (Goldman-Lévy et al. 2026). Ho and Collie (2023) describe Skin5 as keeping keratoacanthoma separate from SCC while recognizing it as a likely SCC subtype with self-resolving potential. Previous view: keratoacanthoma has been classified by many as a well-differentiated subtype of cSCC (Goldman-Lévy et al. 2026).
  • Subungual keratoacanthoma. The new Skin5 nail unit chapter includes subungual keratoacanthoma, a rapidly growing squamoproliferative tumor of the nail bed that can be histologically indistinguishable from SCC without clinical information and ancillary studies. Subungual tumors of incontinentia pigmenti are a subset (Goldman-Lévy et al. 2026).

Cutaneous squamous cell carcinoma: risk factors, grade and subtypes

  • Immunosuppression. Organ transplant recipients on chronic immunosuppression have a 65- to 250-fold increased risk of cSCC, and patients with chronic lymphoid malignancies an 8-fold increase. Risk rises with the intensity of immunosuppression, so thoracic organ recipients are at higher risk than renal recipients, and voriconazole prophylaxis is associated with a 73% increase in cSCC risk (Hwang and St John 2025).
  • Histologic grade. Grading of cSCC is not standardized. The qualitative 4-tier system grades well-differentiated tumors (G1) by abundant keratinization, readily apparent intercellular bridges, minimal pleomorphism and basal mitoses; moderately differentiated tumors (G2) by keratin pearls, horn cysts and individually keratinized cells; poorly differentiated tumors (G3) by rare intercellular bridges or small foci of keratinization; and undifferentiated tumors (G4) by anaplasia. The Broders system grades by the undifferentiated fraction: <25% (grade 1), 25% to <50% (grade 2), 50% to <75% (grade 3) and ≥75% (grade 4). For management, grade is reduced to two tiers with G3 and G4 as high risk. Moderately differentiated tumors may show more subclinical spread needing more Mohs layers and show the highest interobserver variability. "Not applicable" is used when a subtype with intrinsic behavior, such as verrucous SCC, forms the bulk of the tumor (CAP 2026a).
cSCC subtype (Skin5 list in CAP 2026a) Histologic features Behavior and ancillary studies Source
Squamous cell carcinoma, NOS Atypical keratinocytes in the dermis with enlarged pleomorphic nuclei and atypical mitoses; keratin pearls Graded G1–G4 Paolino et al. 2017; CAP 2026a
Verrucous SCC Well-differentiated stratified epithelium with broad bulbous rete ridges and pushing borders Grade reported as not applicable when it forms the bulk of the tumor Yanofsky et al. 2011; CAP 2026a
Acantholytic SCC Tumors formerly called pseudovascular SCC show lumen-like pseudovascular spaces connected to the epidermis, with hobnail cells and tumor cells dissecting through collagen and around adnexa "Pseudovascular SCC" is no longer a recommended term in Skin5 Paolino et al. 2017; Goldman-Lévy et al. 2026
Spindle cell SCC Atypical spindle cells in whorls, alone or with conventional SCC, often with an overlying actinic keratosis; stroma not significantly desmoplastic CK5/6 and p63 confirm squamous derivation; radiation-associated cases are aggressive Yanofsky et al. 2011
Desmoplastic SCC (growth pattern of conventional SCC) Moderately or poorly differentiated keratinocytes in desmoplastic stroma forming at least 30% of the tumor Associated with perineural invasion and higher metastatic risk Paolino et al. 2017
  • Clear cell SCC. Atypical clear cells show marked nuclear pleomorphism, foci of squamous differentiation, acantholysis and dyskeratotic cells in pseudoglandular spaces. Clear cell SCC is listed in the CAP histologic type list (Yanofsky et al. 2011; CAP 2026a).
  • SCC with sarcomatoid differentiation is the only uncommon subtype acknowledged in the Skin5 summary (Goldman-Lévy et al. 2026).
  • Subtypes removed in Skin5. Adenosquamous carcinoma is no longer a cSCC subtype because ductal differentiation places most of these tumors among squamoid eccrine ductal carcinomas. Pseudovascular SCC is no longer a subtype or a recommended term for acantholytic SCC. "Lymphoepithelioma-like SCC" is replaced by lymphoepithelial carcinoma, which is listed in the CAP histologic type list. Previous rule (4th edition, 2018): adenosquamous carcinoma and pseudovascular SCC were listed as cSCC subtypes (Goldman-Lévy et al. 2026; Ho and Collie 2023).
  • Spindle cell SCC versus atypical fibroxanthoma. Without keratin pearls or epidermal connection, spindle cell SCC resembles atypical fibroxanthoma, spindle cell melanoma and sarcoma, and p63 and high-molecular-weight keratins identify the squamous lineage (Yanofsky et al. 2011). The full spindle cell panel is taught in Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma.

Verrucous carcinoma of skin and carcinoma cuniculatum

Verrucous carcinoma occurs in the oral and aerodigestive tract (oral florid papillomatosis), in the anogenital region (Buschke–Löwenstein tumor), on the palms and soles (carcinoma cuniculatum, also termed epithelioma cuniculatum) and at other cutaneous sites. Plantar lesions occur in elderly men and are often mistaken for plantar warts before forming bulky ulcerated exophytic masses with foul-smelling discharge (Yanofsky et al. 2011).

Staging of cutaneous squamous cell carcinoma of the head and neck: AJCC 8th edition and BWH tumor classification

The AJCC 8th edition revised the T classification for head and neck cSCC only (Karia et al. 2018). Depth of invasion (DOI) is measured at a right angle from the granular layer of the adjacent normal epidermis to the deepest point of invasion. A tumor transected at the deep margin is reported as "at least" a given depth. Perineural invasion qualifies for T3 when tumor cells lie within the nerve sheath of a nerve deeper than the dermis or measuring 0.1 mm or more in caliber, or when named nerves are involved clinically or radiographically without skull base invasion. A nerve located deeper than the dermis is a surrogate for a caliber of 0.1 mm or more (CAP 2026a).

AJCC 8th edition pT (head and neck cSCC; CAP Cutaneous Carcinoma 1.2.0.0) Definition (CAP 2026a)
pTis Carcinoma in situ
pT1 Tumor ≤2 cm in greatest dimension
pT2 Tumor >2 cm but ≤4 cm in greatest dimension
pT3 Tumor >4 cm, or minor bone erosion, or perineural invasion, or deep invasion (beyond the subcutaneous fat or >6 mm from the granular layer of adjacent normal epidermis to the base of the tumor)
pT4a Gross cortical bone or marrow invasion
pT4b Skull base invasion and/or skull base foramen involvement
BWH tumor class Definition (CAP 2026a; Jambusaria-Pahlajani et al. 2013)
T0 In situ SCC
T1 0 high-risk factors
T2a 1 high-risk factor
T2b 2–3 high-risk factors
T3 4 high-risk factors or bone invasion

The BWH high-risk factors are clinical diameter ≥2 cm, poorly differentiated histology, perineural invasion of nerves ≥0.1 mm in caliber and invasion beyond the subcutaneous fat (CAP 2026a; Jambusaria-Pahlajani et al. 2013).

pN (AJCC 8th edition, head and neck cSCC) Definition (CAP 2026a)
pN0 No regional lymph node metastasis
pN1 Single ipsilateral node ≤3 cm and ENE(−)
pN2a Single ipsilateral node ≤3 cm and ENE(+); or single ipsilateral node >3 cm but ≤6 cm and ENE(−)
pN2b Multiple ipsilateral nodes, none >6 cm, ENE(−)
pN2c Bilateral or contralateral nodes, none >6 cm, ENE(−)
pN3a Node >6 cm and ENE(−)
pN3b Single ipsilateral node >3 cm and ENE(+); or multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+); or a single contralateral node of any size and ENE(+)
  • Nodal classification. The AJCC N categories for head and neck cSCC are adapted from HPV-unrelated mucosal head and neck SCC, and their performance in cutaneous SCC has been shown to be suboptimal. "U" or "L" may indicate metastasis above or below the lower border of the cricoid (CAP 2026a).
  • BWH staging. BWH T2b tumors formed 19% of a cohort of 256 high-risk cSCCs but accounted for 72% of nodal metastases and 83% of deaths from cSCC (Jambusaria-Pahlajani et al. 2013). Compared with the AJCC 8th edition, BWH staging had higher specificity and positive predictive value for metastasis or death, and BWH T2b and T3 tumors had a 29.4% rate of sentinel node positivity in a systematic review (CAP 2026a).
  • Previous rule (AJCC 7th edition). AJCC 7th-edition T3 and T4 required bone invasion. In a cohort of 256 high-risk cSCCs, only 4 (<2%) were T3 or T4, and T2 tumors accounted for 83% of nodal metastases and 92% of deaths (Jambusaria-Pahlajani et al. 2013). In 680 head and neck cSCCs, AJCC 8th-edition T3 and T4 tumors formed 17.8% of cases and accounted for 70.4% of poor outcomes, against 0.7% of tumors and 16.9% of poor outcomes classified as T3 or T4 under the 7th edition. AJCC 8th-edition T2 and T3 were not distinct in that cohort (Karia et al. 2018).

CAP reporting of cutaneous carcinoma of the head and neck (version 1.2.0.0)

  • Core elements. Procedure, multiple primary sites, focality, site, laterality, size, histologic type, histologic grade, depth of invasion, tumor extent when pT-defining, lymphatic and/or vascular invasion, perineural invasion with nerve caliber (<0.1 mm or ≥0.1 mm), margins for invasive and in situ tumor (peripheral and deep), regional lymph node findings (number positive, laterality, size of the largest deposit in cm, extranodal extension, number examined), distant sites and pTNM. Clark anatomic level, margin distances, closest margin and the BWH classification are optional (CAP 2026a).
  • Margins. Margin status is a required element because it is an adverse prognostic factor and influences adjuvant radiotherapy. Distance to the margin is optional, and limited evidence suggests prognostic value at a 5-mm cutoff in the head and neck. Curettage and electrodesiccation specimens do not allow margin assessment and often preclude thickness measurement (CAP 2026a).
  • Changes from version 1.1.0.0 (2024). Version 1.2.0.0 drops "Squamous Cell" from the protocol name, adds an optional tumor bed margin section (orientation to the true margin surface and status for invasive and in situ tumor), removes the Additional Findings section and removes the explanatory note on scope (CAP 2026a).

Basal cell carcinoma: histologic subtypes, immunohistochemistry and pathogenesis

All BCC subtypes contain aggregates of basaloid keratinocytes surrounded by stroma, usually connected to the epidermis. The cells have large, uniform, intensely basophilic nuclei and scant cytoplasm. Retraction of the stroma around tumor islands creates clefts, the nests often show peripheral palisading and apoptotic cells are common (Marzuka and Book 2015).

BCC subtype (Skin5 list in CAP 2026a) Histologic features Growth category Source
Superficial BCC Basaloid buds parallel to the surface confined to the papillary dermis, with slit-like retraction; foci that look multifocal connect in a net-like pattern Indolent; trunk and extremities, up to 15% of BCCs Marzuka and Book 2015
Nodular BCC Large basaloid nests in the papillary or reticular dermis with peritumoral retraction and palisading; cystic necrosis and central mucin (nodulocystic) Indolent Marzuka and Book 2015
Micronodular BCC Small round nests widely dispersed deep in the dermis, sometimes into the subcutis, with stromal proliferation Aggressive Marzuka and Book 2015
Infiltrating BCC Strands, cords and irregular nodules in fibrotic stroma, poorly circumscribed, sometimes into the subcutis Aggressive Marzuka and Book 2015
Sclerosing/morphoeic BCC Strands of basaloid cells 1–5 cells thick between dense collagen bundles; retraction uncommon; palisading absent Aggressive; 5%–10% of BCCs Marzuka and Book 2015
Basosquamous carcinoma Infiltrating jagged cords with abortive palisading and basaloid areas mixed with intercellular bridges and keratinization Aggressive Marzuka and Book 2015
Fibroepithelial BCC (fibroepithelioma of Pinkus) Fenestrated anastomosing strands of squamous and germinative cells from the epidermis in mucin-rich stroma Good prognosis; metastasis extremely rare Haddock and Cohen 2016

BCC with sarcomatoid differentiation and BCC with adnexal differentiation are also Skin5 subtypes in the CAP histologic type list (CAP 2026a).

  • Mixed histology. About 40% of primary BCCs combine patterns. Punch biopsy misclassified 28%–38% of aggressive-growth BCCs as indolent, so 1 in 7 to 1 in 14 patients may be undertreated (Marzuka and Book 2015).
  • Immunohistochemistry. Most BCCs express p63, and Ber-EP4 is a highly sensitive marker of BCC that pagetoid SCC does not express. Ber-EP4 in microcystic adnexal carcinoma is taught in Cutaneous Adnexal Neoplasms: Follicular, Sebaceous, Apocrine and Eccrine Tumors, Adnexal Carcinomas, Paget Disease and Associated Syndromes.
  • Hedgehog pathway. Most if not all BCCs show overactive Hedgehog signaling. Inactivating PTCH1 mutations release Smoothened (SMO) from inhibition. Activating SMO mutations occur in some sporadic BCCs, and SMO activates the GLI transcription factors (Marzuka and Book 2015).
  • Fibroepithelioma of Pinkus. CK20 identifies Merkel cells in 85%, androgen receptor is expressed in 77% and 30% of plantar BCCs in one series were fibroepitheliomas. Reticulated seborrheic keratosis, tumor of the follicular infundibulum and eccrine syringofibroadenoma have fenestrations of squamous cells only (Haddock and Cohen 2016).

Basal cell carcinoma: risk of recurrence and margin reporting

NCCN risk factors for recurrence of BCC, as summarized in 2015 (later NCCN versions revised the location and size criteria):

Factor Low risk High risk Source
Location and size Trunk and extremities (area L) <20 mm; cheeks, forehead, scalp and neck (area M) <10 mm; mask areas of face, genitalia, hands and feet (area H) <6 mm Area L ≥20 mm; area M ≥10 mm; area H ≥6 mm Marzuka and Book 2015
Borders Well defined Poorly defined Marzuka and Book 2015
Primary or recurrent Primary Recurrent Marzuka and Book 2015
Immunosuppression; prior radiotherapy site Absent Present Marzuka and Book 2015
Histologic subtype Nodular, superficial Aggressive growth (morpheaform, infiltrative, micronodular, basosquamous) Marzuka and Book 2015
Perineural involvement Absent Present Marzuka and Book 2015

Electrodesiccation and curettage is not indicated for high-risk BCC because of the high probability of recurrence, and Mohs surgery is indicated for tumors at increased risk of recurrence (Marzuka and Book 2015). The CAP head and neck cutaneous carcinoma template can be used to report BCC, with peripheral and deep margin status for invasive and in situ tumor (CAP 2026a).

Nevoid basal cell carcinoma (Gorlin) syndrome

  • Genetics. Nevoid basal cell carcinoma syndrome (NBCCS) is autosomal dominant with complete penetrance and variable expressivity (Lo Muzio 2008). A PTCH1 pathogenic variant is found in 50%–70% of patients with a clinical diagnosis and a SUFU variant in about 4%. SUFU inhibits the Hedgehog pathway by binding the GLI transcription factors and preventing their nuclear translocation. Prevalence is 1 in 31,000 to 1 in 256,000 (Verkouteren et al. 2022). BCCs, odontogenic keratocysts and ovarian fibromas show loss of heterozygosity (Lo Muzio 2008).
  • Major features. Multiple BCCs, which can appear by age 2 years, odontogenic keratocysts in the first three decades, palmar and plantar pits and calcification of the falx cerebri are major diagnostic criteria. Palmar or plantar pits are present in 30%–65% of patients by age 10 and in 80% by age 15 (Lo Muzio 2008).
  • Odontogenic keratocysts. Keratocysts have a thin fibrous capsule and a keratinized stratified squamous lining, arise in the tooth-bearing jaws and are often multiple in NBCCS (1–30, mean 5) (Lo Muzio 2008).
  • Medulloblastoma. Medulloblastoma occurs in 1%–4% of patients, is mainly desmoplastic and usually arises in the first 3 years of life. Risk with a PTCH1 variant is 1.2%–2.4% and about 20 times higher with a SUFU variant. Children with a SUFU variant, or a clinical diagnosis without genetic testing, have a baseline brain MRI repeated every 4 months until age 3 and twice yearly until age 5; routine MRI is not indicated for PTCH1 carriers (Verkouteren et al. 2022).
  • Other tumors. Meningiomas and ovarian and cardiac fibromas also occur (Lo Muzio 2008).

Merkel cell carcinoma: pathogenesis, histology and immunohistochemistry

  • WHO 5th edition. MCC is designated a primary neuroendocrine carcinoma of the skin. Its cell of origin remains unclear (Ho and Collie 2023).
  • Two etiologic groups. Most MCCs are caused by monoclonal integration of Merkel cell polyomavirus (MCPyV), and the rest are associated with ultraviolet light. Virus-negative MCCs have a high tumor mutational burden, a UV mutational signature and recurrent inactivation of TP53, RB1 and Notch-family genes. Virus-positive MCCs have a low mutational burden and lack TP53 and RB1 mutations. Integrated MCPyV carries a truncated large T antigen that binds and inactivates RB. MCC is associated with advanced age and immunosuppression (Harms et al. 2018). Chronic lymphocytic leukemia is the most common hematologic disorder associated with MCC (CAP 2026b).
  • Immunophenotype. MCC is CK20-positive in a paranuclear dot pattern, neurofilament-positive (also dot-like) and TTF-1-negative, and many tumors express MCPyV large T antigen. Metastatic small cell lung carcinoma is CK20-negative, neurofilament-negative, large T antigen-negative and TTF-1-positive (Harms et al. 2018). MCC is CK7-negative, CDX2-negative and SATB2-positive and expresses chromogranin, synaptophysin and CD56 (Selves et al. 2018). INSM1 is highly sensitive for primary and metastatic MCC, especially with pankeratin (CAP 2026b).
  • MCPyV testing. Immunohistochemistry with the CM2B4 or Ab3 antibody is the most widely used method; RNA in situ hybridization, DNA sequencing and serology are alternatives. MCPyV positivity is associated with a better outcome (CAP 2026b). CM2B4 can stain tonsillar and lymphoid tissue nonspecifically (Harms et al. 2018).
  • Pure and combined MCC. Most MCCs are purely neuroendocrine. Combined MCC shows morphologic diversity or heterologous differentiation, most often squamous and less often adnexal or sarcomatoid. Only divergent differentiation admixed within the main mass qualifies as combined MCC, and an adjacent or discontinuous tumor is recorded as a second malignancy (CAP 2026b).
  • Epidermotropic MCC. Exclusively intraepithelial (in situ) MCC is rare (CAP 2026b). Epidermotropic MCC frequently expresses Ber-EP4 (Compton et al. 2015).
  • Frozen sections. MCC cells can mimic lymphocytes on intraoperative margin evaluation (CAP 2026b).

Merkel cell carcinoma: AJCC 8th edition staging

Category AJCC 8th edition definition (Harms et al. 2016; CAP 2026b)
pT0 No evidence of primary tumor
pTis In situ primary tumor
pT1 Maximum clinical tumor diameter ≤2 cm
pT2 Maximum clinical tumor diameter >2 cm but ≤5 cm
pT3 Maximum clinical tumor diameter >5 cm
pT4 Primary tumor invades fascia, muscle, cartilage or bone
pN0 No regional lymph node metastasis on pathologic evaluation
pN1a(sn) Clinically occult nodal metastasis identified only by sentinel lymph node biopsy
pN1a Clinically occult regional nodal metastasis following lymph node dissection
pN1b Clinically or radiologically detected regional nodal metastasis, microscopically confirmed
pN2 In-transit metastasis without lymph node metastasis
pN3 In-transit metastasis with lymph node metastasis
pM1a Metastasis to distant skin, distant subcutaneous tissue or distant lymph nodes
pM1b Metastasis to lung
pM1c Metastasis to all other distant sites
Pathologic stage group TNM (Harms et al. 2016) Five-year overall survival (Harms et al. 2016)
0 Tis N0 M0 In situ tumors (n=11) excluded from the survival analysis
I T1 N0 M0 62.8%
IIA T2–3 N0 M0 54.6%
IIB T4 N0 M0 34.8%
IIIA T1–4 N1a(sn) or N1a M0; T0 N1b M0 40.3%
IIIB T1–4 N1b–3 M0 26.8%
IV T0–4 any N M1 13.5%
  • T category. The largest clinical diameter is preferred because histologic measurement underestimates size. If clinical size is unavailable, gross or microscopic measurement is used. Invasion of skeletal muscle other than superficial facial muscle qualifies as pT4 (CAP 2026b).
  • In-transit and locoregional cutaneous metastasis. An in-transit metastasis is a tumor distinct from the primary that lies between the primary and the draining node bed or distal to the primary (CAP 2026b).
  • Unknown primary. Nodal MCC without a primary tumor (about 4% of cases) had a five-year overall survival of 42.2%, against 26.8% for clinically detected nodal disease with a known primary, and is staged IIIA (Harms et al. 2016).
  • Clinical versus pathologic stage. The 8th edition separates clinical and pathologic stage groups. Pathologically node-negative T1 tumors had a five-year overall survival of 62.8%, against 45.0% for clinically node-negative T1 tumors (Harms et al. 2016).
  • Previous rule (AJCC 7th edition, 2010). Clinical and pathologic staging of local disease were combined, with IA and IIA for pathologically node-negative and IB and IIB for clinically node-negative disease. The former IIC is now IIB. Nodal disease with an unknown primary was stage IIIB. In-transit metastasis was a single category, now split into N2 (without nodal metastasis) and N3 (with nodal metastasis), and pN1a(sn) is new (Harms et al. 2016).

Merkel cell carcinoma: CAP reporting (version 4.2.0.0) and sentinel lymph node evaluation

  • Core elements. Procedure, laterality, tumor site, maximum tumor dimension, tumor extent (dermis, subcutis, fascia, skeletal muscle, cartilage, bone), lymphatic and/or vascular invasion, locoregional cutaneous metastases, margins (invasive, in situ and metastatic tumor at peripheral or deep margins), regional lymph nodes (sentinel and non-sentinel nodes involved, size of the largest deposit in mm, extranodal extension, matted nodes, number examined), distant sites and pTNM. Optional elements are method of measurement, histologic subtype (pure or combined), mitotic rate per mm², tumor thickness, tumor-infiltrating lymphocytes, growth pattern, second malignancy and MCPyV status with method (CAP 2026b).
  • Changes from version 4.1.0.0. Version 4.2.0.0 (April 2026) adds Skin5 content, a required locoregional cutaneous metastases question, optional MCPyV status, histologic subtype and mitotic rate questions, an N suffix, a T suffix and a Special Studies section, and renames "Lymphovascular Invasion" as "Lymphatic and/or Vascular Invasion" (CAP 2026b; CAP 2026c).
  • Locoregional cutaneous metastasis. A discontinuous deposit separated from the primary by normal stroma in the same anatomic region, in the dermis, subcutis or skeletal muscle, upstages pN to at least N2 after a second primary is excluded (CAP 2026b).
  • Optional prognostic elements. Tumor thickness is measured in mm to the nearest 0.1 mm from the top of the stratum corneum to the deepest tumor cell. More than 10 mitoses per high-power field and a Ki-67 index above 50% have been associated with a worse prognosis, but no accepted mitotic threshold exists. An infiltrative growth pattern (single cells, cords or trabeculae at the edge; a mixed tumor is classified as infiltrative) is associated with shorter five-year survival and more frequent sentinel node positivity (CAP 2026b).
  • Margins. Distance to the margin is recorded when the tumor is at or within 1 mm of it. Lymphatic or vascular invasion at a margin does not constitute metastasis (CAP 2026b).
  • Sentinel lymph nodes. Metastases of any size, including isolated tumor cells, are positive. At least 2 H&E levels and at least 1 immunohistochemical stain (for example AE1/AE3, CAM5.2, CK20, synaptophysin or chromogranin) are performed before a sentinel node is called negative (CAP 2026b). The 2026 EORTC protocol for MCC sentinel nodes standardizes specimen handling, sectioning, tumor-burden definitions and reporting, with an immunohistochemical algorithm that screens with sensitive markers and confirms with specific stains (Szumera-Ciećkiewicz et al. 2026).

Mohs micrographic surgery

Mohs micrographic surgery gives the highest cure rates for several cutaneous malignancies and is the standard of care for high-risk BCC and cSCC. After excision, the tissue is mapped with colored markings, flattened, frozen in OCT compound and cut in horizontal (en face) sections that display 100% of the peripheral and deep margins. The Mohs surgeon acts as surgeon and pathologist and correlates the slides with the wound map. Technical artifacts include poor staining, curled sections, missing epidermis from inadequate flattening, missing subcutis from insufficient freezing, freezing artifact and tumor floaters displaced into tumor-free areas (Bittner et al. 2021).

  • Toluidine blue and immunostains in Mohs sections. Some Mohs surgeons use toluidine blue, which shows magenta metachromasia around BCC nests and less intense metachromasia in SCC. MART-1 immunohistochemistry on frozen sections is the recommended method for melanoma in situ treated by Mohs surgery; in 1,120 melanomas in situ, a 6-mm margin cleared 86% and a 9-mm margin 98.9% (Bittner et al. 2021).

Differential diagnosis of basaloid and small cell tumors of the dermis

Tumor Distinguishing histology Immunohistochemistry and genetics Source
Basal cell carcinoma Asymmetric silhouette, cytologic atypia, mitoses, clefts between nests and mucinous stroma, peripheral palisading Ber-EP4-positive, p63-positive; Hedgehog pathway activation (PTCH1, SMO) Tellechea et al. 2015; Compton et al. 2015; Marzuka and Book 2015
Trichoblastoma and trichoepithelioma Distinction from BCC taught in Cutaneous Adnexal Neoplasms: Follicular, Sebaceous, Apocrine and Eccrine Tumors, Adnexal Carcinomas, Paget Disease and Associated Syndromes Panel in Cutaneous Adnexal Neoplasms: Follicular, Sebaceous, Apocrine and Eccrine Tumors, Adnexal Carcinomas, Paget Disease and Associated Syndromes Tellechea et al. 2015
Merkel cell carcinoma Small round cells in the dermis and subcutis CK20 paranuclear dots, neurofilament, SATB2, INSM1; TTF-1-negative Harms et al. 2018; Selves et al. 2018; CAP 2026b
Metastatic small cell lung carcinoma Small cell carcinoma in the dermis TTF-1-positive; CK20-negative; neurofilament-negative Harms et al. 2018
Adenoid cystic carcinoma Adnexal carcinoma taught in Cutaneous Adnexal Neoplasms: Follicular, Sebaceous, Apocrine and Eccrine Tumors, Adnexal Carcinomas, Paget Disease and Associated Syndromes MYB::NFIB fusion Goldman-Lévy et al. 2026

WHO Pathway Classification of Melanocytic Tumors, Lentigines and Melanocytic Nevi

Definition and classification. The WHO Classification of Skin Tumours, 5th edition (Skin5), recognizes nine distinct progression pathways to melanoma (Goldman-Lévy et al. 2026) and separates nevi, melanocytomas and melanomas (Ho and Collie 2023). Nevi are clonal neoplasms with a single mutation, no other pathogenic change, bland cytology and benign behavior. Melanocytomas are intermediate neoplasms carrying more than one driver alteration, with atypical histologic features and a potential for local recurrence (Ho and Collie 2023). Skin5 created a new "melanocytoma" category within melanocytic neoplasms of intermittently sun-exposed skin, and melanocytomas also occur in other pathways (Goldman-Lévy et al. 2026). Previous rule (4th edition, 2018): the WHO 4th edition introduced the nine pathways, dividing sun-related melanomas by the degree of cumulative solar damage (CSD) and proposing the general term "melanocytoma" for intermediate tumors with an increased but still low probability of progression (Elder et al. 2020).

Related page: Spitz Tumors, Melanocytomas and Ancillary Testing of Melanocytic Lesions (Spitz tumors, melanocytomas, ancillary tests for melanocytic lesions including PRAME and HMB45, and the uncertainty terms SAMPUS, IAMPUS and MELTUMP) Related page: Cutaneous Melanoma: Subtypes, AJCC 8th Edition Staging, CAP Reporting, Sentinel Lymph Node and Metastatic Melanoma (melanoma subtypes, AJCC 8th edition staging and sentinel lymph nodes) Related page: Metastatic Melanoma in Lymph Nodes (Cytology) (nodal nevi versus metastatic melanoma on cytology) Related page: Vitreous and Ocular Cytology (uveal and conjunctival melanocytic lesions, GNAQ and GNA11)

Pigmentary disorders are taught in Normal Skin, Biopsy Handling and the Reaction-Pattern Approach; Spongiotic, Psoriasiform, Keratinization and Pigmentary Disorders.

WHO pathway classification of melanoma and its precursors

Pathway Melanoma subtype Genetic hallmarks (Ferrara and Argenziano 2021) Primary driver frequency (Bastian 2014) Benign precursor and melanocytomas Source
1 Low-CSD melanoma (superficial spreading melanoma) High frequency of BRAF p.V600 mutations BRAF 70%, NRAS 15% Acquired nevi with BRAF V600E or NRAS Q61R/L; dysplastic nevi; BAP1-inactivated, deep penetrating and pigmented epithelioid melanocytomas Ferrara and Argenziano 2021; Bastian 2014
2 High-CSD melanoma (lentigo maligna melanoma, high-CSD nodular melanoma) Mutually exclusive NF1, NRAS, non-V600E BRAF and possibly KIT mutations NRAS 15%, KIT about 10%, inactivating NF1 30%, CCND1 gain 20%; BRAF V600K more frequent than V600E Precursor uncertain; lentigo maligna is grouped with high-CSD melanoma Ferrara and Argenziano 2021; Bastian 2014; Elder et al. 2020
3 Desmoplastic melanoma Inactivating NF1, NFKBIE promoter mutations, other MAPK-activating mutations (for example MAP2K1); about 62 mutations per megabase NF1 about 25% (unpublished observation cited by Bastian) No benign precursor Ferrara and Argenziano 2021; Bastian 2014
4 Spitz melanoma HRAS mutations; kinase fusions of ROS1, NTRK1, NTRK3, ALK, BRAF, MET and RET; CDKN2A homozygous deletion, TERT promoter mutation and MAP3K8 alterations in aggressive cases HRAS mutation with 11p gain in about 20% of Spitz neoplasms; kinase fusions (no frequency given) Spitz nevus; Spitz melanocytoma (atypical Spitz tumor) Ferrara and Argenziano 2021; Bastian 2014; Goldman-Lévy et al. 2026
5 Acral melanoma Multiple amplifications of CCND1, KIT and TERT; BRAF, NRAS and KIT mutations; rare ALK or RET fusions KIT, BRAF and NRAS 15% each Precursor uncertain Ferrara and Argenziano 2021; Bastian 2014
6 Mucosal melanoma Numerous copy number and structural variants; uncommon KIT and NRAS mutations KIT 15%, NRAS 15%; BRAF mutations absent Melanotic macule (uncertain) Ferrara and Argenziano 2021; Bastian 2014
7 Melanoma arising in congenital nevus NRAS in large and giant nevi; BRAF in small and medium nevi NRAS 85%; BRAF fusions; large and giant congenital nevi carry NRAS mutations in >80% Congenital nevus; proliferative nodule in congenital nevus (melanocytoma) Ferrara and Argenziano 2021; Bastian 2014; Goldman-Lévy et al. 2026
8 Melanoma arising in blue nevus Gαq pathway mutations (GNAQ, GNA11, CYSLTR2, PLCB4); monosomy 3 with BAP1 loss and 8q gain in aggressive cases GNAQ or GNA11 (no melanoma frequency given); GNAQ in 83% of blue nevi Blue nevus; cellular blue/atypical cellular blue melanocytoma Ferrara and Argenziano 2021; Bastian 2014; Van Raamsdonk et al. 2009; Goldman-Lévy et al. 2026
9 Uveal melanoma Mutually exclusive Gαq pathway mutations; BAP1, SF3B1 and EIF1AX mutations with progression GNAQ or GNA11 about 85%–90%; BAP1 loss-of-function in 49% (85% of metastasizing tumors) Uveal nevus Ferrara and Argenziano 2021; Bastian 2014
  • Acral and mucosal KIT. Activating mutations or amplifications of KIT occur in 15%–40% of acral and mucosal melanomas (Bastian 2014).
  • Sun exposure and mutational burden. Pathways 1–3 arise in sun-exposed skin with a UV signature (C>T transitions at dipyrimidine sites). Tumor mutational burden rises with CSD: about 15 mutations per megabase in low-CSD and 30 in high-CSD melanoma. Pathways 4–9 are UV-unrelated. Acral and mucosal melanomas have highly rearranged genomes with multiple amplifications, and Spitz, uveal, blue nevus-associated and congenital nevus-associated melanomas have a very low mutational burden (Ferrara and Argenziano 2021).
  • Grading solar damage. CSD is graded by dermal solar elastosis on a three-tier scale: single elastic fibers (grade 1), bunches of fibers (grade 2) and basophilic masses (grade 3) (Ferrara and Argenziano 2021).
  • Senescence of nevi. A single BRAF or NRAS mutation is insufficient for melanoma. Nevi enter replicative senescence regulated by CDKN2A (p16 and p14). Dysplastic nevi carry BRAF or NRAS mutations, and additional TERT promoter mutation and sometimes hemizygous CDKN2A loss accompany progression to superficial spreading melanoma in situ (Ferrara and Argenziano 2021).
  • CNS melanocytic tumors. Skin5 includes melanocytic tumors of the central nervous system. Some primary leptomeningeal melanocytic tumors share the Gαq pathway with uveal melanoma and blue nevi, and leptomeningeal proliferations associated with congenital nevi share their NRAS mutations (Goldman-Lévy et al. 2026).

Melanocytoma category and renamed entities in the WHO 5th edition

A melanocytoma is a dermal-based melanocytic neoplasm that has progressed about one step beyond a conventional nevus without meeting criteria for melanoma. It is formally defined by at least two pathogenic genetic alterations, for example a BRAF V600E mutation followed by BAP1 inactivation, and is also recognized by morphologic criteria of increased cellularity, cytologic atypia and mitotic activity. Spitz melanocytoma and cellular blue melanocytoma are, in general, morphologic exceptions to the genetic definition. Atypical (dysplastic) nevi of the common pathway with higher-grade architectural and cytologic atypia are intermediate lesions but are not melanocytomas. A lesion with two pathogenic variants and entirely bland histology without high-risk features may still be called a nevus, for example a BAP1-inactivated nevus (Goldman-Lévy et al. 2026).

Skin5 name Previous name (4th edition, 2018) Defining alteration Source
WNT-activated deep penetrating/plexiform melanocytoma (naevus) Deep penetrating nevus; plexiform spindle cell nevus WNT pathway activation (nuclear β-catenin, LEF1) Goldman-Lévy et al. 2026; Ho and Collie 2023
Pigmented epithelioid melanocytoma (subtypes by driver: common PEM, Spitz PEM) Pigmented epithelioid melanocytoma PRKAR1A inactivation Goldman-Lévy et al. 2026
BAP1-inactivated melanocytoma BAP1-inactivated nevus, previously grouped with combined nevus BRAF mutation followed by BAP1 inactivation Goldman-Lévy et al. 2026
Spitz melanocytoma (atypical Spitz tumour) Atypical Spitz tumor as a subtype of Spitz nevus Spitz-type drivers; defined morphologically Goldman-Lévy et al. 2026
Cellular blue/atypical cellular blue melanocytoma Cellular blue nevus, plaque-type blue nevus, atypical cellular blue nevus Gαq pathway; defined morphologically Goldman-Lévy et al. 2026
Proliferative nodule in congenital naevus (melanocytoma) Proliferative nodule in congenital nevus Whole-chromosome gains and losses Goldman-Lévy et al. 2026
MITF pathway-activated melanocytic tumours New in Skin5 ACTIN::MITF or MITF::CREM fusion Goldman-Lévy et al. 2026; Ho and Collie 2023
  • Combined nevus. In Skin5, "combined naevus" is reserved for nevi with two or more morphologically distinct melanocyte populations that lack clear genetic characterization. Previous rule (4th edition): combined nevus also included the lesions now separated as BAP1-inactivated melanocytoma (Goldman-Lévy et al. 2026).

Common acquired melanocytic nevi

  • Junctional, compound and dermal nevi. Acquired nevi are thought to begin as single melanocytes along elongated, hyperpigmented rete ridges and then form junctional nests (junctional nevus). Nests then appear in the papillary dermis (compound nevus). Intraepidermal proliferation eventually ceases and the nevus becomes entirely intradermal (dermal nevus), and nevus cells are gradually replaced by fibrous matrix, glycosaminoglycans and adipose tissue (Sardana et al. 2014).
  • Genetics. Most acquired nevi carry a single driver mutation, BRAF V600E or NRAS Q61R/L (Ferrara and Argenziano 2021). The VE1 antibody to BRAF V600E-mutant protein identifies tumors of the common pathway that carry the mutation (Ferrara and Argenziano 2021).
  • Maturation. Nevus cells become smaller and less pigmented with increasing distance from the surface epithelium, a feature termed maturation that helps separate nevi from melanoma (Yeh et al. 2017). HMB45 and PRAME staining of nevi are tabulated in Spitz Tumors, Melanocytomas and Ancillary Testing of Melanocytic Lesions.
  • Lentigo simplex and nevogenesis. Lentigo simplex is a flat pigmented macule with a subtle increase in basal melanocytes and is a possible early stage of a nevus. Focal proliferation of junctional melanocytes then forms nests (junctional nevus), some nests move into the dermis (compound nevus), and the epidermal nests finally disappear (dermal nevus) (Frischhut et al. 2022).
  • Clinicopathologic nevus types. The Miescher nevus is a dome-shaped, mostly skin-colored facial nevus with a wedge-shaped dermal component that incorporates adnexal structures. The Unna nevus is a papillomatous nevus of the neck, axillae and groin with an extensive dermal component. The Clark nevus is a flat, well-circumscribed truncal nevus with a mainly junctional melanocytic increase and a reticular dermoscopic pattern (Frischhut et al. 2022).
  • Nevus spilus. A café-au-lait macule, usually present at birth, is studded with speckles that develop during the first years of life and represent Clark, combined, Spitz or rarely blue nevi. The reported risk of malignant transformation is 0.13%–0.2%. A segmental nevus spilus may indicate a RASopathy, and phakomatosis pigmentokeratotica (HRAS) combines nevus spilus with nevus sebaceus (Frischhut et al. 2022).

Congenital melanocytic nevi

  • Size and frequency. Small congenital melanocytic nevi (CMN), defined as <1.5 cm projected adult size, occur in 1% of neonates. About 1 in 20,000 infants is born with a CMN larger than 20 cm projected adult size, usually with additional smaller CMN, and up to 80% of the skin surface can be involved (Kinsler et al. 2017).
Projected adult size category Diameter Source
Small <1.5 cm Frischhut et al. 2022
Medium 1.5–10 cm Frischhut et al. 2022
Large 11–20 cm Frischhut et al. 2022
Giant G1 21–30 cm Frischhut et al. 2022
Giant G2 31–40 cm Frischhut et al. 2022
Giant G3 >40 cm Frischhut et al. 2022
  • Projection and satellites. Projected adult size is the current size multiplied by about 1.7 on the head, 2.8 on the trunk and 3.3 on the lower limbs. A CMN with more than 50 satellite nevi is moved to the next higher category. Melanoma and extracutaneous disease are most likely with truncal CMN, a projected size >40 cm and numerous satellite nevi (Frischhut et al. 2022).
  • Histology. Congenital nevi extend into the deep dermis and often the subcutaneous septa, track along adnexa, nerves and vessels, and form cords of nevus cells between splayed collagen bundles, with maturation toward the base. In childhood the junctional component can show architectural disorganization including pagetoid scatter. Acquired nevi can show the same congenital pattern, so small congenital and acquired nevi are not reliably separated by histology alone (Plotzke et al. 2026).
  • Genetics. In multiple CMN and CMN syndrome, a postzygotic NRAS mutation shared by different skin lesions and neurological and malignant tissue is causal in about 80% of patients (Kinsler et al. 2017). Codon 61 NRAS mutations (Q61K, Q61R) were found in affected cutaneous and neurological tissue of 12 of 15 patients and were absent from blood and unaffected tissue (Kinsler et al. 2013).
  • Melanoma risk. Prospective studies and systematic reviews place the incidence of melanoma in CMN at about 1%–2%. An abnormal screening MRI of the central nervous system in the first months of life is the strongest risk factor for melanoma at any site in childhood (incidence 12% in that group), and CNS melanoma has had 100% mortality (Kinsler et al. 2017).
  • Proliferative nodules. Proliferative nodules in CMN often show atypical features that raise concern for melanoma but usually lack sufficient high-risk morphology. They typically have whole-chromosome gains and losses, in contrast to the structural copy number changes of melanoma, and biologic outcome remains the gold standard (Goldman-Lévy et al. 2026). The WHO 4th edition found no convincing evidence that bona fide proliferative nodules evolve into melanoma (Ferrara and Argenziano 2021).

Dysplastic (atypical) nevus: grading and MPATH-Dx classification

The WHO 4th edition placed dysplastic nevus and melanoma in situ among intermediate junctional or thin compound neoplasms and subclassified them as low grade or high grade (Ferrara and Argenziano 2021). Interobserver agreement for moderately atypical nevi was as low as 25%, so MPATH-Dx version 2.0 (2023) replaced the 3-tier mild, moderate and severe grading with two classes: low-grade (class I) and high-grade (class II), the latter including some high-end moderately atypical lesions and melanoma in situ. Degree of atypia is defined by both architectural disorder and cytologic atypia (Barnhill et al. 2023).

  • WHO definition. The WHO Working Group defines dysplastic nevus as a clinically atypical, histologically benign junctional or compound melanocytic tumor >4 mm in breadth on fixed sections (>5 mm clinically) with architectural disorder and cytologic atypia. Architectural disorder comprises irregular or dyscohesive intraepidermal nests, horizontally oriented and bridging adjacent rete, and an increased density of non-nested junctional melanocytes, for example more melanocytes than keratinocytes over ≥1 mm². Nevi with high-grade dysplasia or additional genetic alterations such as a TERT promoter mutation are considered for complete excision (Ferrara and Argenziano 2021).
  • Shouldering and fibroplasia. Dysplastic nevi often show asymmetric growth with a junctional shoulder, the extension of the junctional component beyond the lateral confines of the dermal component, together with bridging between adjacent rete ridges, lentiginous growth and concentric or lamellar papillary dermal fibroplasia. Mitotic figures are inconspicuous (Plotzke et al. 2026).
  • Lentiginous nevus. A lentiginous nevus is a benign junctional or compound tumor <4 mm wide on fixed sections, usually symmetric with poorly defined borders, with regularly spaced non-nested junctional melanocytes around the tips and sides of the rete ridges and no to mild cytologic atypia. It is excluded from the dysplastic nevus category because it is common, carries no relevant risk of progression and is poorly reproducible (Ferrara and Argenziano 2021).
  • Dysplastic nevus syndrome. Familial atypical multiple mole and melanoma (FAMMM) syndrome is diagnosed largely on clinical criteria: number of nevi, number of clinically atypical or large nevi and personal or family history of melanoma (Ferrara and Argenziano 2021). CDKN2A mutations cause about 25%–50% of FAMMM cases, and the syndrome includes pancreatic and other cancers (Frischhut et al. 2022).
Feature Low-grade dysplastic nevus (MPATH-Dx class I) High-grade dysplastic nevus (MPATH-Dx class II) Source
Nuclear size in ≥5 junctional melanocytes in the most atypical field <1.5 times a resting basal keratinocyte nucleus ≥1.5 to >2 times a resting basal keratinocyte nucleus Barnhill et al. 2023
Nuclear variability Minimal to moderate Marked (some nuclei ≥2 times larger than others) Barnhill et al. 2023
Chromatin and nucleoli Homogeneous or condensed chromatin; nucleoli absent or not prominent Dense hyperchromasia or dispersed chromatin with thick nuclear membranes; nucleoli up to prominent and lavender Barnhill et al. 2023
Diameter, symmetry, circumscription Variable diameter (<4 mm to >4 mm); symmetric; sharply circumscribed >5 mm; often asymmetric; often poorly circumscribed Barnhill et al. 2023
Junctional nesting Regular to progressively irregular nests, horizontal confluence, bridging Irregular nests, horizontal confluence, bridging Barnhill et al. 2023
Lentiginous proliferation Absent, slight or focal Contiguous melanocytes, including between rete ridges Barnhill et al. 2023
Effacement of epidermis Absent Often present Barnhill et al. 2023
Pagetoid spread Absent, low level or focal Focal or full-thickness; full-thickness involvement in at least 1 high-power field indicates melanoma in situ Barnhill et al. 2023
Papillary dermal fibroplasia (concentric or lamellar) Absent or present Often lamellar Barnhill et al. 2023
Lymphocytes; intraepidermal mitoses Absent or present; absent or few Often dense; often present Barnhill et al. 2023
MPATH-Dx v2.0 class Examples Estimated progression Recommended treatment Source
0 Nondiagnostic or unsatisfactory No estimate for a nondiagnostic sample Repeat biopsy Barnhill et al. 2023
I (low grade) Common acquired and congenital nevi without atypia; low-grade dysplastic nevi; common blue nevi 1 in 10,000 to 1 in 100,000 No further treatment Barnhill et al. 2023
II (high grade) High-grade dysplastic nevi; Spitz tumors and melanocytomas; cellular blue nevi or melanocytomas; deep penetrating nevi or melanocytomas; lentigo maligna; melanoma in situ 1 in 100 to 1 in 1000 Re-excision with margins <1 cm Barnhill et al. 2023
III Melanoma pT1a (<0.8 mm Breslow thickness) 1 in 10 to 1 in 100 National guidelines (for example wide excision with 1-cm margins) Barnhill et al. 2023
IV Melanoma ≥pT1b (≥0.8 mm) 1 in 2 to 1 in 10 National guidelines (wide excision with 1–2-cm margins and consideration of sentinel node staging) Barnhill et al. 2023
  • Previous rule (MPATH-Dx version 1). Version 1 had five classes with dysplastic nevi of moderate atypia in class II. Version 2.0 places low-grade lesions with positive margins in class I with no further treatment if adequately sampled, and class II lesions with positive margins generally require re-excision (Barnhill et al. 2023).
  • PRAME in high-grade dysplastic nevi. PRAME staining of severely dysplastic nevi and thin melanomas is taught in Spitz Tumors, Melanocytomas and Ancillary Testing of Melanocytic Lesions.

Special-site, recurrent, sclerosing and halo nevi

  • Acral nevus. Nests lie mainly in the crista profunda limitans beneath the surface furrows and form melanin columns in the cornified layer under the furrows, the histologic basis of the dermoscopic parallel furrow pattern. Lattice-like and fibrillar patterns are the other benign acral patterns, and acral melanoma shows a parallel ridge pattern (Park and Yun 2022).
  • Nevi with site-related atypia. Nevi in special sites show histologic atypia that is probably not associated with a significantly higher risk of progression to melanoma (Ferrara and Argenziano 2021).
Site group Sites Histologic features that raise concern Source
Acral Palms, soles and nail apparatus Nests in the crista profunda limitans under the furrows; melanin columns in the cornified layer Hosler et al. 2008; Park and Yun 2022
Genital Vulva, perineum and male genitalia Asymmetry with irregular junctional lentiginous growth and irregular nests, pagetoid spread, enlarged melanocyte nuclei and dermal fibrosis; clinically larger lesions with irregular borders Hosler et al. 2008; Jarutatsanangkoon et al. 2026
Flexural and milk line Axilla, breast, umbilicus, groin and other flexures Enlarged junctional nests with dyscohesive cells Mason et al. 2011; Dutt et al. 2017
Other special sites Ear, scalp, legs, back and shoulder Asymmetry, irregular nesting, pagetoid spread, cytologic atypia and rare mitoses Ahn et al. 2016
Conjunctiva Conjunctiva Site-related atypia in a separate fourth group Hosler et al. 2008
  • Behavior. Nevi with site-related atypia share features with melanoma and dysplastic nevi but follow a benign clinical course and need no further intervention (Ahn et al. 2016; Hosler et al. 2008).
  • Atypical melanocytic nevus of genital type. This genital nevus is often confused with dysplastic nevus or melanoma; a reported example was a 0.3-cm papule of the labia minora in a 30-year-old woman (Quddus et al. 2010).
  • PRAME at genital sites. All 13 benign vulvar melanocytic lesions were PRAME-negative, and diffuse PRAME (>75% of cells) gave 88.9% sensitivity and 100% specificity for vulvar melanoma. SOX10 stained every benign and malignant lesion (Jarutatsanangkoon et al. 2026).
  • Recurrent (persistent) nevus. Persistent nevi can show histologic features that mimic melanoma ("pseudomelanoma"). Melanoma can also arise in a persistent nevus. In one reported case, an asymmetric pigmented lesion extended beyond the scar, and pagetoid single melanocytes above and beyond the scar indicated melanoma. Attribution of melanoma features to a "persistent nevus effect" is a recognized pitfall (Helm et al. 2021).
  • Sclerosing nevus with pseudomelanomatous features. Of 90 sclerosing melanocytic lesions (dermal sclerosis with atypical, predominantly nevoid melanocytes), 29% were diagnosed morphologically as nevi and 71% as melanomas, and 45 of the 64 melanomas had an adjacent nevus. Prominent full-thickness pagetoid spread occurred in 48% of lesions and adjacent melanoma in situ in 61%. In the intrasclerotic component, maturation was absent in 44% and mitoses were present in 20%. Four-probe FISH was positive in 14 of 25 morphologic melanomas and in none of 16 nevi (Grcar-Kuzmanov et al. 2018).
  • Halo nevus. A halo (Sutton) nevus is a melanocytic nevus surrounded by symmetric depigmentation. It affects up to 5% of white children aged 6–15 years and is more common with many nevi or a personal or family history of vitiligo. A solitary halo lesion in a patient without vitiligo carries a higher risk of malignancy, because a regressing melanoma can produce a halo-nevus appearance (De Schrijver et al. 2021).

Balloon cell, ancient and desmoplastic nevi

Nevus Histology Immunohistochemistry and behavior Main mimic Source
Balloon cell nevus Junctional and/or dermal nests of large cells with clear, foamy cytoplasm Benign; clinical lesions can show a yellowish hue on dermoscopy Balloon cell melanoma (<1% of melanomas; >50% balloon-shaped melanocytes with finely vacuolated cytoplasm and peripheral hyperchromatic nuclei in a 4-case series); extensive sampling searches for conventional melanoma Micali et al. 2021; Cazzato et al. 2022
Ancient nevus Exo-endophytic, mostly intradermal nevus of older patients, usually on the face, with a population of large pleomorphic melanocytes beside small monomorphous ones; occasional mitoses; degenerative stroma with thrombi, hemorrhage, pseudoangiomatous change, perivenular sclerosis, fibrosis and mucin Low overall Ki-67 labeling index; benign on long follow-up Melanoma arising in an intradermal nevus Kerl et al. 1998; Kerl et al. 2011
Desmoplastic (sclerotic) nevus Small (mean 3.5 mm), symmetric, well-circumscribed nevus with spindle and other nevus cells in a fibrotic, keloidal or dermatofibroma-like stroma; greater cellularity superficially; mitoses exceptional S100 in 16 of 16 and Melan-A in all nevi tested; HMB45 decreasing with depth in 8 of 11; low Ki-67 Desmoplastic melanoma (spindle cells Melan-A-negative in 40 of 43; p75 positive in 10 of 10); dermatofibroma (adnexal induction absent in desmoplastic nevus) Harris et al. 1999; Sherrill et al. 2011; Kucher et al. 2004; Sidiropoulos et al. 2014
  • Desmoplastic nevus on sun-damaged skin. Desmoplastic nevi on chronically sun-damaged skin occur in adults (mean age 53.2 years) with a female predominance (70%) and can show notable pleomorphism. Symmetry, limited junctional growth with only focal pagetoid spread across a few rete ridges, and absence of deep extension favor the nevus (Sidiropoulos et al. 2014).

Blue nevi and dermal melanocytoses

  • Blue nevus genetics. Somatic GNAQ mutations occur in 83% of blue nevi and 46% of uveal melanomas. Mutant GNAQ Q209L transforms immortalized melanocytes (Van Raamsdonk et al. 2009). The blue nevus pathway also includes GNA11, CYSLTR2 and PLCB4 mutations (Ferrara and Argenziano 2021).
  • Dermal melanocytoses. Intradermal melanocytic proliferations range from discrete blue nevi to large blue-gray patches of the conjunctiva and periorbital skin (nevus of Ota), shoulder (nevus of Ito) and lower back (Mongolian spot). Nevus of Ota is a risk factor for uveal melanoma (Van Raamsdonk et al. 2009). Dermal melanocytosis (Mongolian spot) occurs in up to 95% of African neonates and about 10% of white neonates. Extensive dermal melanocytosis and phakomatosis pigmentovascularis are caused by mosaic activating GNAQ or GNA11 mutations, found in 8 of 11 patients tested (Thomas et al. 2016).
  • Nevus of Ota and Ito. Dermal melanocytoses contain pigmented spindle to dendritic melanocytes deep in the dermis, and the blue-gray color reflects the Tyndall effect. Nevus of Ota follows the first two branches of the trigeminal nerve and can involve the eye, oral and nasal mucosa; GNAQ is mutated in about 6%, and 5 of 11 reported melanomas arising in nevus of Ota metastasized. Nevus of Ito occupies the shoulder, breast and lateral arm (Frischhut et al. 2022).

Melanotic macules, lentigines and lentiginous melanoma

  • Melanotic macules are not nevi. Freckles, café-au-lait macules and solar lentigines show a circumscribed increase of pigment with a normal or only slightly increased number of epidermal melanocytes and are not classified as melanocytic nevi (Frischhut et al. 2022).
  • Ephelis. Ephelides are genetically determined pigment spots that appear in childhood in a photodistribution and show increased pigmentation without an increase in melanocytes (Tsatsou et al. 2012).
  • Solar lentigo. Solar lentigo shows increased basal melanocytes (Tsatsou et al. 2012) and acanthosis with elongated, clubbed or branched rete ridges, usually with solar elastosis (Barysch et al. 2019). Rabinowitz and Inghirami separated large cell acanthoma from solar lentigo by its lack of elongated hyperpigmented buds and its hyperploid keratinocytes (Patsatsi et al. 2014); it is taught in Benign Epidermal Tumors, Cutaneous Cysts, Actinic Keratosis and Squamous Cell Carcinoma In Situ.
  • Labial and oral melanotic macule. Melanin accumulates in the basal layer, melanocytes are normal in number, morphology and distribution, and melanophages are increased in the lamina propria (Duan et al. 2018).
  • Café-au-lait macule. Histology shows basal hyperpigmentation, sometimes with giant melanosomes (macromelanosomes); biopsy is rarely needed. In neurofibromatosis type 1 (NF1), café-au-lait macules occur in 99% of patients, melanocytes carry biallelic NF1 inactivation and melanocyte density is greater than in non-NF1 macules. Six or more macules >5 mm in children or >15 mm in adults are an NIH diagnostic criterion. NF1 macules have regular "coast of California" borders, and solitary large macules with jagged "coast of Maine" borders suggest sporadic lesions or other disorders (Ozarslan et al. 2021).
  • Genital melanosis. Genital melanosis presents as irregular hyperpigmented vulvar patches that mimic melanoma. It is divided histologically into genital lentigo, with melanocytic proliferation, and genital melanotic macule, with basal hyperpigmentation without melanocytic proliferation (Jarutatsanangkoon et al. 2026). In 129 women followed for a median of 13 years, vulvar melanosis involved mainly the labia minora (43%), changed in size or color in 30% before stabilizing, and never became malignant (De Giorgi et al. 2020).
Syndrome Gene Pigmentary lesions Other features Source
Neurofibromatosis type 1 NF1 Café-au-lait macules, axillary and inguinal freckling Neurofibromas, Lisch nodules, optic glioma, bone dysplasia Ozarslan et al. 2021; Frischhut et al. 2022
Legius syndrome SPRED1 Café-au-lait macules RAS–MAPK pathway disorder converging functionally with NF1 Okamura and Suzuki 2026
McCune–Albright syndrome GNAS (postzygotic) Fewer, segmental café-au-lait macules with irregular borders Precocious puberty, fibrous dysplasia, endocrinopathies Frischhut et al. 2022; Okamura and Suzuki 2026
Noonan syndrome with multiple lentigines (LEOPARD) PTPN11 Multiple facial lentigines, café-au-lait macules ECG abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, growth retardation, deafness Okamura and Suzuki 2026
Peutz–Jeghers syndrome STK11 Mucosal lentiginosis of lips, nose and cheeks Small intestinal polyps or adenocarcinomas, other internal neoplasms Frischhut et al. 2022
Carney complex (LAMB/NAME) PRKAR1A Lentigines, blue nevi Cutaneous and cardiac myxomas, myxoid fibroadenomas, testicular and pituitary tumors Frischhut et al. 2022
Tuberous sclerosis TSC1, TSC2 Café-au-lait macules, ash-leaf macules Angiofibromas, renal angiomyolipomas, cardiac rhabdomyomas Frischhut et al. 2022
  • Lentiginous melanoma of the elderly. Broad, irregular lentiginous melanocytic proliferations of the trunk and proximal limbs of elderly patients are probably the counterpart of lentigo maligna on skin without chronic sun damage. Histologic criteria alone are often weak and can lead to a provisional diagnosis of IAMPUS or SAMPUS, so the clinical picture is incorporated (Ferrara and Argenziano 2021).
  • Lentigo maligna. Lentigo maligna, the in situ phase of lentigo maligna melanoma on sun-exposed skin of middle-aged and elderly patients, progresses to invasive melanoma in an estimated 30%–50% of untreated cases and shows folliculotropism (Kasprzak and Xu 2015). Its histology and margins are taught in Cutaneous Melanoma: Subtypes, AJCC 8th Edition Staging, CAP Reporting, Sentinel Lymph Node and Metastatic Melanoma.

Spitz Tumors, Melanocytomas and Ancillary Testing of Melanocytic Lesions

Definition and classification. In the WHO Classification of Skin Tumours, 5th edition (Skin5), Spitz tumours comprise Spitz naevus, Spitz melanocytoma (atypical Spitz tumour) and Spitz melanoma. Spitz melanocytoma is recognized as the intermediate tier of the Spitz pathway. Spitz melanocytoma and cellular blue melanocytoma are morphologic exceptions to the genetic definition of melanocytoma given in WHO Pathway Classification of Melanocytic Tumors, Lentigines and Melanocytic Nevi (Goldman-Lévy et al. 2026). Previous rule (4th edition, 2018): atypical Spitz tumor was a subtype of Spitz nevus, and deep penetrating nevus, plexiform spindle cell nevus, cellular blue nevus and the BAP1-inactivated lesions now separated from combined nevus carried nevus names (Goldman-Lévy et al. 2026; Ho and Collie 2023).

Related page: WHO Pathway Classification of Melanocytic Tumors, Lentigines and Melanocytic Nevi (WHO pathways, nevi, dysplastic nevus grading and MPATH-Dx classes) Related page: Cutaneous Melanoma: Subtypes, AJCC 8th Edition Staging, CAP Reporting, Sentinel Lymph Node and Metastatic Melanoma (melanoma subtypes, staging and sentinel lymph nodes) Related page: Metastatic Melanoma in Lymph Nodes (Cytology) (PRAME in nodal nevi versus metastatic melanoma on cytology) Related page: Adrenal Cortex Pathology: Hyperplasia and Nodular Disease, Adrenalitis and Hemorrhage, Adrenal Cortical Adenoma and Carcinoma, Myelolipoma, Cysts and Metastases (Carney complex and PRKAR1A) Related page: Vitreous and Ocular Cytology (uveal melanoma, BAP1 and GNAQ/GNA11)

FISH and SNP array methods are taught in Cytogenetics and Cytogenomics: Karyotype and ISCN Nomenclature, Chromosome Abnormalities, FISH, Chromosomal Microarray, Optical Genome Mapping, and Constitutional, Prenatal and Cancer Cytogenetics, and next-generation sequencing in Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation.

Spitz tumors: Spitz nevus, Spitz melanocytoma and Spitz melanoma

  • Epidemiology. Spitz nevi account for 1%–2% of nevi removed from children and adults, are more common in children and young adults and were first described as "juvenile melanomas" (Cheng et al. 2022).
  • Spitz nevus histology. The prototypical Spitz nevus is a symmetric, slightly raised, compound and maturing proliferation with epidermal hyperplasia and a flat base. Large, clefted nests of spindle and epithelioid melanocytes have abundant eosinophilic cytoplasm, moderately pleomorphic vesicular nuclei and prominent nucleoli. Kamino bodies, dull eosinophilic globules of amorphous filaments, are scattered throughout the lesion (Dal Pozzo and Cappellesso 2022).
  • Genetics. Spitz neoplasms carry mutually exclusive HRAS or MAP2K1 mutations, 11p gains or kinase fusions of ALK, BRAF, MET, NTRK1, NTRK2, NTRK3, RET, ROS1 and MAP3K8 (Dal Pozzo and Cappellesso 2022). An estimated 20%–50% of Spitz tumors have no known driver (Cheng et al. 2022).
  • Spitz melanocytoma (atypical Spitz tumor). Clonal p16 loss and heterogeneous dermal HMB45 expression can occur. Spitz melanocytoma and Spitz melanoma lack consensus morphologic separation, and TERT promoter alterations favor malignancy (Cheng et al. 2022). In a systematic review of 22 studies (756 patients with atypical Spitz tumor), sentinel node biopsy was performed in a pooled 54% and was positive in a pooled 35%, yet overall survival ranged from 93% to 100% and disease-free survival from 87% to 100%. Outcome is almost always favorable, and sentinel node biopsy does not appear useful for staging or prognosis (Mazza et al. 2024).
  • Spitz melanoma. Spitz melanoma is a morphologically malignant Spitz tumor with Spitz-associated alterations involving HRAS, ALK, NTRK1, BRAF, MAP3K8 and CDKN2A. Spitzoid melanoma with a BRAF V600E mutation belongs to the conventional pathway. Spitz melanomas can retain genotype-specific features: p16 loss with HRAS, fascicular nests and dermal mitoses with ALK fusions and dermal rosette-like structures with NTRK1 fusions (Cheng et al. 2022). CDKN2A homozygous deletion, TERT promoter mutation and MAP3K8 alterations occur in aggressive or lethal Spitz tumors (Ferrara and Argenziano 2021).
  • Pigmented spindle cell nevus of Reed. The Reed nevus, described in 1975, is a heavily pigmented Spitz subtype with a starburst dermoscopic pattern (Cheng et al. 2022). The single reported NTRK2-fused Spitz nevus was a junctional Reed nevus with epidermal hyperplasia, large peripherally clefted nests of pigmented spindle melanocytes with abundant eosinophilic cytoplasm and widely distributed Kamino bodies (Dal Pozzo and Cappellesso 2022).
  • Reed nevus versus pigmented Spitz nevus. Reed described the pigmented spindle cell nevus in 1975 as distinct from Spitz nevus because of its plentiful melanin and lack of infiltrative growth. In 22 lesions, 91% could be classified histologically by melanin production and growth pattern. Reed nevi did not involve the reticular dermis, had horizontally oriented junctional nests (fascicles) at the periphery, abundant melanin in the stratum corneum and a band-like infiltrate of melanophages, corresponding to peripheral radial lines or pseudopods on dermoscopy. Pigmented Spitz nevi had junctional nests, sparse cornified-layer melanin and few melanophages, corresponding to a pattern of clods. Large epithelioid "Spitz cells" occurred in all 5 pigmented Spitz nevi and in 40% of Reed nevi, so cell type alone does not separate them (Bär et al. 2012). The Reed nevus is a predominantly junctional, highly cellular, densely pigmented lesion enriched for NTRK3 fusions (Plotzke et al. 2026).
  • Atypia in Spitz and Reed nevi. Atypical lesions that fall short of melanoma show at least one of asymmetry, poor lateral circumscription, predominance of single melanocytes over nests, ulceration, extensive involvement of the dermis and subcutis, impaired maturation, excessive mitotic activity and deep dermal mitoses (Pedrosa et al. 2016).
Feature Spitz nevus Atypical Spitz tumor (Spitz melanocytoma) Spitzoid melanoma Source
Size <6 mm 6–10 mm >1 cm Cheng et al. 2022
Symmetry and circumscription Symmetric, well circumscribed Symmetric or asymmetric; well or poorly circumscribed Asymmetric, poorly circumscribed Cheng et al. 2022
Ulceration Rare More common than in Spitz nevus Present Cheng et al. 2022
Nests Well-organized dermoepidermal nests ("banana bunch") Greater pleomorphism and nuclear-to-cytoplasmic ratio Irregular nesting Cheng et al. 2022
Pagetoid spread Uncommon and focal Peripheral, in the upper epidermis Present, may be extensive Cheng et al. 2022
Kamino bodies Present at the periphery of nests Infrequent, smaller Rare Cheng et al. 2022
Maturation Commonly present May be absent Absent Cheng et al. 2022
Mitotic rate 0–2/mm² 2–6/mm² >6/mm², deep or atypical mitoses Cheng et al. 2022
Epidermal hyperplasia Present Rare Rare Cheng et al. 2022
  • Spitz nevus variants. Desmoplastic Spitz nevi are small (average 3.5 mm), symmetric, wedge-shaped, often amelanotic lesions with large spindle or epithelioid cells between thick collagen bundles, and HRAS expression, low Ki-67 or isolated 11p gain favor them over desmoplastic melanoma. Pagetoid Spitz nevi show orderly single epithelioid melanocytes in the spinous layer and are small (<6 mm) and symmetric. Dysplastic (SPARK) Spitz nevi combine Spitz cytology with the architecture of dysplastic nevi and do not recur or metastasize (Cheng et al. 2022).
Driver Frequency or clinical setting Characteristic morphology Detection Source
HRAS mutation and/or 11p gain About 20% of Spitz neoplasms Often desmoplastic; most are recognizable as Spitz nevus; favorable prognosis when atypical Sequencing for HRAS; FISH or CGH for 11p gain; wild-type HRAS antibody for overexpression Dal Pozzo and Cappellesso 2022
ALK fusion Exophytic dermal lesions Plexiform intersecting fascicles of large non-pigmented spindle melanocytes with amphophilic cytoplasm, vesicular nuclei and prominent nucleoli ALK immunohistochemistry Dal Pozzo and Cappellesso 2022; Ferrara and Argenziano 2021
ROS1 fusion Pink-red papules in young adults No distinctive feature; plexiform and angiomatoid patterns more common; can be desmoplastic ROS1 immunohistochemistry Dal Pozzo and Cappellesso 2022; Ferrara and Argenziano 2021
NTRK1 fusion Most frequent NTRK fusion Filigree-like elongated rete, wedge or flat-base silhouette, lobulated nests, rosette-like structures, exaggerated maturation, frequent Kamino bodies, rare mitoses TRKA immunohistochemistry Dal Pozzo and Cappellesso 2022; Ferrara and Argenziano 2021
NTRK3 fusion Partners ETV6, MYO5A, MYH9, SQSTM1 Compound or dermal, dome-shaped; strong diffuse nuclear staining suggests ETV6::NTRK3; linear dendritic staining suggests MYO5A::NTRK3 Pan-TRK pattern; molecular confirmation Dal Pozzo and Cappellesso 2022
NTRK2 fusion Single reported case Pigmented spindle cell nevus of Reed pattern Molecular Dal Pozzo and Cappellesso 2022
RET fusion 3%–4% of Spitz neoplasms Plaque-like compound lesions with large expansile nests of dyscohesive, monotonous epithelioid melanocytes; uneventful follow-up Molecular Dal Pozzo and Cappellesso 2022
MET fusion Few cases Nonspecific NGS or FISH; MET immunohistochemistry Dal Pozzo and Cappellesso 2022; Ferrara and Argenziano 2021
BRAF fusion Pink papules, mainly of the lower extremities Superficial hypercellular sheet-like dermal component over a deep hypocellular desmoplastic component; nevoid features RNA-based NGS or FISH Dal Pozzo and Cappellesso 2022
MAP3K8 fusion or truncation More common in atypical and malignant lesions Epithelioid cells, high-grade atypia, multinucleated giant cells, p16 loss FISH or RT-PCR Cheng et al. 2022; Ferrara and Argenziano 2021

Melanocytomas of the WHO 5th edition

Melanocytoma (previous name) Morphology Genetics Immunohistochemistry Behavior and differential diagnosis Source
WNT-activated deep penetrating/plexiform melanocytoma (naevus) (deep penetrating nevus; plexiform spindle cell nevus) Often biphasic with a conventional nevus; pigmented spindle and epithelioid cells in nests and fascicles extending deep, without maturation, with visible nucleoli, nuclear pseudoinclusions and melanophages; deep-penetrating and plexiform spindle cell subtypes β-catenin pathway activation in 17 of 18 (CTNNB1 in 16, APC in 1) with MAPK pathway mutations in 16 of 18 (BRAF, MAP2K1 or HRAS); CTNNB1 mutation follows BRAF mutation and increases pigmentation, cell size and nuclear cyclin D1 Nuclear β-catenin and LEF1 Indolent in most cases; "naevus" retained Goldman-Lévy et al. 2026; Ho and Collie 2023; Yeh et al. 2017
Pigmented epithelioid melanocytoma (PEM) Heavily pigmented, monophasic or biphasic, with large pigmented epithelioid melanocytes, spindle cells and melanophages; historically animal-type melanoma; epithelioid blue nevus of Carney complex is indistinguishable PRKAR1A inactivation (essential); PRKCA fusions, both genes on 17q24; subtypes by driver (common PEM with BRAF V600E; Spitz PEM with kinase fusions) Loss of PRKAR1A (R1α) Regional nodal metastasis 41%, local recurrence 7.9%, systemic spread 3.2%; deaths very rare Goldman-Lévy et al. 2026; Bayraktar and Jour 2021; Ferrara and Argenziano 2021
BAP1-inactivated melanocytoma (BAP1-inactivated nevus; previously grouped with combined nevus) Dermal tumors composed entirely or predominantly of epithelioid melanocytes with abundant amphophilic cytoplasm and prominent nucleoli BRAF mutation (88% in familial cases) followed by BAP1 inactivation; sporadic or in BAP1 tumor predisposition syndrome Loss of nuclear BAP1 Sporadic or part of BAP1 tumour predisposition syndrome Goldman-Lévy et al. 2026; Wiesner et al. 2011; Ho and Collie 2023; Lalloo et al. 2023
Cellular blue/atypical cellular blue melanocytoma (cellular blue nevus, plaque-type blue nevus, atypical cellular blue nevus) Usually biphasic, with dendritic blue nevus and cellular ovoid or spindle cell components Gαq pathway; BAP1 or SF3B1 mutations with high-risk morphology support melanoma p16 is higher in mildly and moderately atypical cellular blue nevi than in melanoma; severely atypical lesions overlap with melanoma Atypical lesions short of melanoma have uncertain malignant potential Goldman-Lévy et al. 2026; Chang and Cassarino 2014
Proliferative nodule in congenital naevus (melanocytoma) Nodule with atypical features in a congenital nevus Whole-chromosome gains and losses; melanoma shows structural changes Copy number analysis is the discriminating study Usually fails to show high-risk features; outcome is the gold standard Goldman-Lévy et al. 2026
MITF pathway-activated melanocytic tumours (new) Dermal clear cell nodules; ACTIN::MITF type with inconspicuous mitoses and no ulceration or perineural invasion; MITF::CREM type with possible perineural invasion and increased mitoses ACTIN::MITF or MITF::CREM fusion MART-1, S100, SOX10, MITF diffuse; HMB45 patchy; pankeratin negative Differential includes clear cell sarcoma, PEComa, melanoma and carcinoma Ho and Collie 2023; Goldman-Lévy et al. 2026
  • BAP1 tumour predisposition syndrome. BAP1-TPDS is autosomal dominant. Its core tumors are uveal melanoma, pleural and peritoneal mesothelioma, renal cell carcinoma, cutaneous melanoma and BAP1-inactivated melanocytic tumours, and the lifetime risk of at least one associated tumor is up to 85%, likely an overestimate because of ascertainment bias. In a 2016 literature review of 174 carriers cited in the guideline, uveal melanoma occurred in 31%, mesothelioma in 22%, cutaneous melanoma in 13% and renal cell carcinoma in 10%. Meningioma is associated but is not part of the core phenotype, and hepatocellular carcinoma and cholangiocarcinoma need further evidence (Lalloo et al. 2023).

Diagnostic criteria separating melanocytomas from their malignant counterparts

  • General high-risk criteria. The ESP–EORTC–EURACAN recommendations assess dermal-based intermediate tumors by architectural criteria (diameter >6 mm, asymmetry, epidermal effacement, ulceration, high dermal cellularity, tumor clones, loss of the grenz zone, absent vertical maturation, expansile nodule, destructive growth, deep subcutaneous extension and pagetoid spread) and cytologic criteria (pleomorphism, macro-eosinophilic nucleoli, variable chromatin density, irregular nuclear membranes, >1 mitosis/mm², overlapping nuclei and necrosis). Melanocytomas with few criteria are low grade and those with roughly up to half of them are high grade, with excision margins of 2 mm and 5–10 mm, respectively. Pigmented epithelioid melanocytoma is by definition intermediate to high grade, and lesions labeled MELTUMP are managed as melanoma of the same thickness (Ferrara and Argenziano 2021).
Melanocytoma Favoring melanocytoma Favoring the malignant counterpart Source
WNT-activated deep penetrating/plexiform melanocytoma versus deep penetrating nevus-like melanoma Symmetric pigmented papule <1 cm, often head and neck; wedge-shaped dermal lesion of melanocytes about twice the size of basal keratinocytes; <2 mitoses/mm²; nuclear and cytoplasmic β-catenin in the deep cells Larger size, more atypia, more mitoses, sheet-like growth, subcutaneous involvement; TERT promoter, CDKN2A and SWI/SNF gene mutations Plotzke et al. 2026
Pigmented epithelioid melanocytoma versus PEM-like melanoma Bulbous or wedge-shaped intradermal tumor of large pigmented epithelioid cells with melanophages; loss of PRKAR1A by IHC (not fully sensitive) TERT promoter, TP53 or RB1 mutations and numerous copy number alterations Plotzke et al. 2026
BAP1-inactivated melanocytoma versus BAP1-inactivated melanoma Biphenotypic epithelioid and ordinary nevus cells with a brisk lymphocytic infiltrate; 0–6 copy number alterations (median 2) on SNP array Outgrowth of a third component with higher-grade atypia and mitoses; 6–10 copy number alterations (median 7) Plotzke et al. 2026
Proliferative nodule in congenital nevus versus melanoma in congenital nevus Multiple nodules; <2 mitoses/mm²; no high-grade atypia; whole-chromosome gains and losses; usually PRAME-negative; retained H3K27me3 ≥5 mitoses/mm²; segmental copy number changes including RREB1 gain; HMB45 homogeneous in both; TERT promoter mutation absent in both Plotzke et al. 2026
Cellular blue/atypical cellular blue melanocytoma versus melanoma in blue nevus Biphasic dendritic and cellular components short of melanoma criteria Sufficient high-risk morphology with BAP1 or SF3B1 mutation Goldman-Lévy et al. 2026
  • BAP1 testing pitfalls. Point mutations can leave nuclear BAP1 expressed but catalytically inactive, and BAP1 FISH misses inactivation without copy loss, such as uniparental disomy. Because BAP1-inactivated melanocytomas may be the presenting tumor of BAP1-TPDS, the report can alert the clinician to possible genetic evaluation (Plotzke et al. 2026).

Immunohistochemistry of melanocytic lesions

Marker Pattern in benign lesions Pattern favoring melanoma or a specific entity Pitfalls Source
PRAME 86.4% of cutaneous nevi negative; focal staining of a minor subpopulation in 13.6% (dysplastic, common, traumatized or recurrent and Spitz nevi) Diffuse nuclear staining (4+, ≥76% of cells) in 83.2% of primary and 87% of metastatic melanomas: 94.4% acral, 92.5% superficial spreading, 90% nodular, 88.6% lentigo maligna melanoma Only 35% of desmoplastic melanomas diffusely positive; isolated positive junctional melanocytes in solar lentigines and normal skin Lezcano et al. 2018
p16 Strong diffuse staining in Spitz nevus; a mosaic pattern is regarded as benign Complete loss or loss in sizable areas from homozygous 9p21 deletion suggests melanoma; variable in Spitz melanocytoma Uneven or clonal loss is an atypical feature for risk stratification Cheng et al. 2022; Ferrara and Argenziano 2021
HMB45 Decreasing expression with depth (maturation) in dermal nevi Uniform deep staining in melanoma; loss of the gradient in atypical lesions Nevoid melanomas are exceptions; never a single criterion Compton et al. 2015; Ferrara and Argenziano 2021
Ki-67 No proliferative clusters Usually >20% in melanoma; proliferative clusters in atypical lesions Mitotically active lymphocytes raise single-labeled indices in tumors with brisk infiltrates Goldman-Lévy et al. 2026; Ferrara and Argenziano 2021; Compton et al. 2015
BAP1 Retained nuclear staining Loss of nuclear staining in BAP1-inactivated tumors BAP1 loss also accompanies monosomy 3 in aggressive melanoma arising in blue nevus Ferrara and Argenziano 2021
β-catenin and LEF1 Nuclear β-catenin limited to superficial cells of common nevi Diffuse nuclear β-catenin and LEF1 in WNT-activated deep penetrating/plexiform melanocytoma Deep melanocytes near hair follicles can show nuclear β-catenin Ho and Collie 2023; Yeh et al. 2017
PRKAR1A (R1α) Retained Loss in PEM with PRKAR1A inactivation PEM can carry PRKCA fusions as the alternative driver Ferrara and Argenziano 2021; Bayraktar and Jour 2021
ALK, ROS1, TRKA (pan-TRK), MET, wild-type HRAS Positive in Spitz nevi with the corresponding kinase alteration Identify Spitz tumors with the corresponding kinase change Under ESP-EORTC-EURACAN recommendations, immunopositive Spitz neoplasms are confirmed for the genomic aberration by molecular testing Ferrara and Argenziano 2021
VE1 (BRAF V600E) Positive in BRAF-mutant common-pathway nevi Identifies conventional-pathway tumors and combined melanocytomas BRAF mutations are typically absent in Spitz nevi Ferrara and Argenziano 2021; Wiesner et al. 2011
SOX10 Strong nuclear staining in nevi Not discriminatory; positive in nearly 100% of primary melanomas and in nevi Some breast and salivary carcinomas are SOX10-positive Compton et al. 2015
MART-1 and MITF Highlight junctional melanocytes Gauge confluent junctional growth and pagetoid spread MART-1 overestimates confluence by staining dendrites; nuclear MITF is preferred for confluence Compton et al. 2015
  • PRAME in severely dysplastic nevi and thin melanoma. Diffuse PRAME staining of >75% of epidermal and dermal melanocytes identified 58.6% of thin melanomas and only 1 of 45 nevi, a lesion reported as SAMPUS favoring a severely dysplastic nevus. Most melanomas (67.6%) stained uniformly in the in situ and invasive components, whereas most severely dysplastic nevi (81.0%) showed a gradient decreasing with depth. Diffuse PRAME did not separate metastasizing from non-metastasizing thin melanomas (Gassenmaier et al. 2021).
  • PRAME in Spitz tumors and proliferative nodules. PRAME has relatively lower specificity in Spitz neoplasms, which can overexpress it. Most proliferative nodules in congenital nevi are PRAME-negative, although overexpression occurs (Plotzke et al. 2026).
  • p16 interpretation. True p16 loss requires complete absence of labeling in all melanocytes in an area of concern or throughout the lesion; the mosaic pattern of nevi does not qualify (Plotzke et al. 2026).

Molecular and cytogenetic testing of melanocytic lesions

Test Targets and findings Interpretation Limitations Source
FISH, original four-probe melanoma assay CCND1 (11q13), RREB1 (6p25), MYB (6q23) and centromere 6 Refines classification of ambiguous lesions; adding a CDKN2A/centromere 9 dual probe refines risk stratification Higher false-negative rate in Spitz lesions than array CGH; only a few loci tested Cheng et al. 2022; Ferrara and Argenziano 2021
FISH, five- and six-probe Spitz-adapted assays Five-probe: 6p25, 8q24, 11q13, 9p21, centromere 9; six-probe: RREB1, CCND1, MYB, centromere 6, CDKN2A, centromere 9 Homozygous 9p21 deletion in atypical Spitz tumors is associated with aggressive behavior; 6p25 or 11q13 gains carry intermediate risk compared with FISH-negative or 6q23-deleted lesions Probe sets differ between laboratories Cheng et al. 2022
Array CGH or SNP array Genome-wide copy number gains and losses Whole-chromosome changes favor proliferative nodule in congenital nevus; structural changes favor melanoma Misses point mutations and balanced translocations; false negatives when tumor cells are <50% of the sample; costly Goldman-Lévy et al. 2026; Cheng et al. 2022
TERT promoter mutation Hotspot mutations Favors malignancy in Spitz tumors and supports melanoma in other melanocytomas One component of a combined assessment Cheng et al. 2022; Goldman-Lévy et al. 2026
Targeted sequencing BRAF codon 600 and NRAS hotspots; NF1, KIT, MAP2K1 for conventional tumors; GNAQ, GNA11, PLCB4, CYSLTR2 for dendritic (blue nevus and uveal) tumors; HRAS for Spitz tumors Assigns a tumor to its pathway Interpretation depends on morphology Ferrara and Argenziano 2021
FISH or RT-PCR for fusions BRAF and RET in Spitz tumors; MAP3K8 in malignant epithelioid Spitz tumors; PRKCA in PEM Confirms the lineage suggested by immunohistochemistry Fusion partners vary Ferrara and Argenziano 2021
Gene expression profiling Diagnostic 23-gene assay (MyPath Melanoma; PRAME, S100 family and immune genes); pigmented lesion assay (PRAME, LINC00518; PLAplus adds TERT promoter); prognostic 31-gene assay (DecisionDx-Melanoma; class 1A lowest to 2B highest risk) 23-gene assay separates nevus from melanoma with reported sensitivity 90%–93.8% and specificity 91%–96.2% No randomized trials of GEP-guided management; society guidelines do not recommend molecular testing for melanoma clinical decision making outside clinical trials Sun et al. 2024
Next-generation sequencing Point mutations, small insertions and deletions, rearrangements, copy number and tumor mutational burden A high mutational burden assigns a tumor to conventional melanoma Cost and availability Ferrara and Argenziano 2021; Cheng et al. 2022
  • FISH scoring and performance. The Gerami criteria require at least 30 lesional nuclei and score cells with >2 copies of RREB1 or CCND1, RREB1 exceeding centromere 6, or MYB below centromere 6. The original four-probe panel had 86.7% sensitivity and 95.4% specificity for melanoma, and adding CDKN2A (9p21) and MYC (8q24) raised sensitivity and specificity to 94% and 98% from 75% and 96% in the same validation cohort (Plotzke et al. 2026).
  • FISH pitfalls. Validation cohorts consisted mostly of unequivocal melanomas and nevi, and in ambiguous lesions, mostly atypical Spitz tumors, sensitivity ranged from 43% to 100% and specificity from 33% to 100%. Tetraploidy can mimic gains, and probes without a paired centromere (CCND1, MYC) cannot separate whole-chromosome from focal gains. Large probes can miss small homozygous CDKN2A deletions, and copy number changes at unprobed loci are missed. MYB loss may not predict aggressive behavior in atypical Spitz tumors, so only the second-generation panel is used for Spitz neoplasms. A positive result strongly supports melanoma, and a negative result does not exclude it (Plotzke et al. 2026).
  • SNP array thresholds. Mean copy number alteration (CNA) burden rose from 0 in nevi to 0.6 in atypical nevi, 2.8 in ambiguous tumors and 18.1 in melanomas, and no tumor with an adverse event had ≤3 CNAs. In a meta-analysis, ≥3 CNAs gave 85% sensitivity and 84% specificity and ≥4 CNAs 81% and 91%. A higher threshold may be needed for BAP1-inactivated tumors, and sensitivity may be lower for blue nevus-like and deep penetrating nevus-like melanomas. SNP array needs about 1 mm² of tumor and gives false negatives when a precursor nevus dilutes the sample (Plotzke et al. 2026).
  • TERT promoter testing. The American Society of Dermatopathology appropriate use criteria rate TERT promoter testing of uncertain appropriateness, because mutations appear early, overlap with melanoma in situ and dysplastic nevi, and are absent from many acral and mucosal melanomas (Plotzke et al. 2026).
  • Stepwise approach. Morphology first assigns a lesion to the conventional pathway or to a melanocytoma or Spitz lineage. Lineage immunohistochemistry (VE1, BAP1, PRAME, kinase fusion proteins, β-catenin, R1α) follows, then a risk-stratification panel (p16, HMB45, Ki-67), FISH and targeted sequencing or NGS in referral centers (Ferrara and Argenziano 2021).
  • Combined immunohistochemical scores. Deep dermal Ki-67 proliferation with complete loss of p16 and/or HMB45 makes Spitz nevus less likely and prompts FISH. A combined p16, Ki-67 and HMB45 (PKH) score above 4 was associated with Spitz melanoma (Cheng et al. 2022).
  • Skin5 ancillary criteria. Loss of p16, Ki-67 usually above 20%, whole versus structural chromosomal changes, specific mutations or translocations and TERT promoter hotspot mutations inform the separation of melanocytoma from melanoma (Goldman-Lévy et al. 2026).

Reporting uncertainty in melanocytic lesions

  • SAMPUS and IAMPUS. Superficial atypical melanocytic proliferation of uncertain significance (SAMPUS) and intraepidermal atypical melanocytic proliferation of uncertain significance (IAMPUS) are used for lesions that fall short of radial growth phase melanoma or melanoma in situ, respectively, and imply virtually no risk of distant spread (Ho and Collie 2023).
  • MELTUMP. Melanocytic tumor of uncertain malignant potential applies when vertical growth phase melanoma is the main alternative and the uncertainty concerns metastatic risk (Ho and Collie 2023).
  • MPATH-Dx. Spitz tumors, melanocytomas and their atypical forms fall into MPATH-Dx version 2.0 class II, for which re-excision with margins <1 cm is recommended (Barnhill et al. 2023). The full schema is in WHO Pathway Classification of Melanocytic Tumors, Lentigines and Melanocytic Nevi.

Cutaneous Melanoma: Subtypes, AJCC 8th Edition Staging, CAP Reporting, Sentinel Lymph Node and Metastatic Melanoma

Definition and classification. Melanoma is the malignant tier of melanocytic neoplasia. The WHO Classification of Skin Tumours, 5th edition (Skin5), adds a section on melanoma metastatic to other organs (Goldman-Lévy et al. 2026). The pathway framework and its 4th-edition origin are taught in WHO Pathway Classification of Melanocytic Tumors, Lentigines and Melanocytic Nevi. The CAP excision protocol lists histologic types by pathways I–IX (tabulated below), with nodular, nevoid and dermal melanomas outside a single pathway (CAP 2025a). Staging follows the AJCC Cancer Staging Manual, 8th edition (Gershenwald et al. 2017).

Related page: WHO Pathway Classification of Melanocytic Tumors, Lentigines and Melanocytic Nevi (the WHO pathway framework, lentigines, common, congenital and dysplastic nevi) Related page: Spitz Tumors, Melanocytomas and Ancillary Testing of Melanocytic Lesions (Spitz melanoma, melanocytomas, and PRAME, p16, FISH, SNP array and TERT testing of melanocytic lesions) Related page: Metastatic Melanoma in Lymph Nodes (Cytology) (metastatic melanoma in lymph node aspirates; PRAME in nodal nevus versus metastasis) Related page: Melanoma, Merkel Cell Carcinoma and Skin FNA (melanoma on FNA of skin and subcutaneous nodules, cell-block immunostains and molecular testing on FNA) Related page: Vitreous and Ocular Cytology (uveal and conjunctival melanocytic lesions, GNAQ, GNA11 and BAP1) Related page: Anal Canal Neoplasia, Colorectal Neuroendocrine Tumors and Other Lower GI Tumors (anorectal melanoma) Related page: Other Lung Tumors: Hamartoma, Sclerosing Pneumocytoma, Adenomas, Salivary Gland-Type, Mesenchymal and Lymphoid Tumors, and Metastases (melanoma metastatic to lung) Related page: Diagnostic Enzymes and Serum Tumor Markers (lactate dehydrogenase, the AJCC M-category suffix) Related page: Vascular Anomalies and Vascular Tumors of Skin, Kaposi Sarcoma and Angiosarcoma, Cutaneous Histiocytic and Mast Cell Infiltrates, and Metastases to Skin (metastases of other tumors to skin) Related page: Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma (atypical fibroxanthoma and pleomorphic dermal sarcoma in the spindle cell differential)

Melanoma subtypes by pathway: site, histology and pattern of spread

Pathway-defining driver alterations are tabulated in WHO Pathway Classification of Melanocytic Tumors, Lentigines and Melanocytic Nevi.

Subtype (CAP pathway) Typical site and age Histology of early lesions Pattern of spread Source
Low-CSD melanoma, including superficial spreading melanoma (I) Intermittently sun-exposed trunk and extremities; 3rd to 6th decade; more common in patients with many acquired nevi Enlarged round melanocytes with dusty melanin in nests, with pagetoid scatter Lymph node involvement often the first metastasis Bastian 2014
High-CSD melanoma, including lentigo maligna melanoma (II) Chronically sun-exposed head, neck, forearms and lower legs; 7th decade and older; more common in patients with non-melanoma skin cancer Lentiginous growth of single melanocytes over pronounced solar elastosis Satellite or in-transit, nodal and distant metastases in equal proportions Bastian 2014
Desmoplastic melanoma (III) Head and neck in 53%, trunk in 21% and extremities in 27%; 7th decade and older Paucicellular atypical spindled melanocytes in a fibrotic dermis; lentiginous component in 80%; neurotropism in 30%–40% Primarily to the lung; lymph nodes in 7% Bastian 2014
Spitz melanoma (IV) Mostly children; head and neck and lower extremities Compound or intradermal large atypical epithelioid or spindled cells with ample cytoplasm and mitoses Lymph node involvement often the first metastasis Bastian 2014
Acral melanoma (V) Palms, soles and nail apparatus; 6th decade and older; female-to-male ratio 1:1 Extensive lentiginous growth, with early melanoma in situ around eccrine duct openings along the dermatoglyphic ridges Satellite, in-transit and nodal metastases as the first spread Bastian 2014
Mucosal melanoma (VI) Nasal cavity and sinuses, oral cavity, anorectum, vulva, vagina and tarsal conjunctiva; 6th decade and older; female-to-male ratio 2:1 Extensive lentiginous growth Frequent local recurrence; distant metastases more frequent than nodal metastases Bastian 2014
Melanoma arising in blue nevus (VIII) All age groups; scalp and trunk Dermal nodules of large atypical spindled or epithelioid melanocytes with mitoses and necrosis, often beside a cellular blue nevus Lymph nodes, liver, lung and bone Bastian 2014
Uveal melanoma (IX) Choroid, ciliary body and iris; average age 60 years Solid nodules of spindled or epithelioid melanocytes Liver and bone Bastian 2014

Melanoma arising in congenital nevus (VII) occurs mostly in children as nodular aggregates of atypical melanocytes with mitoses within a congenital nevus (Bastian 2014).

  • Acral field cells. FISH studies of acral melanoma show evenly spaced, morphologically normal but genetically aberrant melanocytes in skin up to 1 cm wide beside the visible melanoma in situ. These field cells share the amplifications of the melanoma at lower copy number (Bastian 2014).
  • Nodular melanoma. Nodular melanomas without an adjacent in situ component show genetic alterations indistinguishable from those of the corresponding pathway. They are interpreted as an accelerated transition from in situ to invasive growth and are not a separate genetic class (Bastian 2014).
  • Acral nevi as precursors. Acral nevi are infrequently found contiguous with acral melanoma and do not appear to be significant precursors (Bastian 2014).

Lentigo maligna and margin assessment on sun-damaged skin

  • Pattern. Lentigo maligna is the in situ phase of high-CSD melanoma: a lentiginous proliferation of single intraepidermal melanocytes over solar elastosis that can develop, often after many years, a nodular invasive component (lentigo maligna melanoma). Nodular melanomas on chronically sun-damaged skin share the genetics of lentigo maligna melanoma (Bastian 2014).
  • Background melanocytes in sun-damaged skin. In Melan-A-stained controls of uninvolved chronically sun-exposed skin, melanocyte confluence was present in 39%, stacking in 49%, junctional nests (theques) in 13%, adnexal extension in 87% and suprabasilar scatter in 33%. These features were nearly uniform in lentigo maligna and lentigo maligna melanoma. Epidermal melanocyte density separated the groups: 82.7 ± 29.3 per ×400 field in lentigo maligna and lentigo maligna melanoma against 25.6 ± 9.3 in sun-damaged controls. Pattern features alone can therefore overestimate the extent of lentigo maligna at surgical margins (Bowen et al. 2011). Melan-A tends to overestimate melanocyte numbers in sun-damaged skin, and MITF counting is more accurate (Voiculescu et al. 2025). Nuclear SOX10 and MITF stains detect lentigo maligna better than H&E, with higher measured melanocyte density and lower interobserver variability (Löper et al. 2025).
  • Pseudomelanocytic nests. In lichenoid dermatitis on sun-damaged skin (phototoxic reaction, lichen planus pigmentosus and pigmented lichenoid keratosis), Melan-A labeled single cells and small junctional nests, and the histologic and Melan-A findings were indistinguishable from melanoma in situ. Clinical correlation established the inflammatory diagnosis in all 3 patients (Beltraminelli et al. 2009).
  • Adnexal extension and margins. Melanoma in situ can extend down a hair follicle and involve a deep margin. Margin involvement by melanoma in situ is recorded when in situ disease is present and the margins are free of invasive melanoma (CAP 2025a).

Desmoplastic melanoma: pure and mixed types, immunohistochemistry and nodal risk

  • Definition. Desmoplastic melanoma is a spindle cell melanoma, usually on chronically sun-damaged skin of older patients, in which invasive melanoma is associated with abundant collagenous matrix and a pink, scar-like silhouette. It accounts for less than 4% of primary cutaneous melanomas. It arises de novo or with another subtype, most often lentigo maligna (Chen et al. 2013).
  • Pure versus mixed. The CAP protocol records pure desmoplastic melanoma when the desmoplastic component is ≥90% and mixed desmoplastic/non-desmoplastic melanoma when it is <90% (CAP 2025a). Mixed tumors have higher cellularity throughout or contain nodules of solid spindle or epithelioid melanocytes within otherwise paucicellular desmoplastic melanoma (Chen et al. 2013).
  • Histologic clues. Focal hyperchromatic spindle cells and lymphoid aggregates suggest desmoplastic melanoma in a scar-like dermis. Neurotropism ranges from focal perineural invasion to extensive involvement of nerves beyond the main mass (Chen et al. 2013). Neurotropism is most common in desmoplastic melanoma and may occur in any subtype (CAP 2025a).
  • Immunohistochemistry. S100 usually stains desmoplastic melanoma, and HMB45 and Melan-A are often negative. SOX10 was diffusely positive in 15 of 15 desmoplastic melanomas and negative in spindle cell or poorly differentiated carcinomas (0 of 18), atypical fibroxanthomas (0 of 13) and sarcomas with spindled morphology (0 of 20). Malignant peripheral nerve sheath tumors showed focal SOX10 staining in 3 of 10, without the diffuse pattern of desmoplastic melanoma (Palla et al. 2013). Scars contain only scattered isolated S100-positive cells, whereas desmoplastic melanoma is typically strongly and diffusely S100 positive (Chen et al. 2013).
  • Lymph node risk. In 239 Dutch patients (114 pure and 125 mixed), 6 of 36 patients with mixed desmoplastic melanoma (16.7%) and 0 of 26 with pure desmoplastic melanoma had a positive sentinel lymph node. Mixed type predicted shorter recurrence-free survival (HR 2.72) without an effect on overall survival (Laeijendecker et al. 2020).

Nevoid and primary dermal melanoma

  • Nevoid melanoma. In 43 cases (33 men, mean age 62 years, most often on the back), about 40% had a clinical diagnosis other than melanoma. Sheet-like confluence of melanocytes expanding the papillary dermis was present in 60%, and nests in parallel arrays at the base (parallel theque pattern) in about 81%. Mitoses were found in one-third, at fewer than 1 to 4 per mm², and genomic abnormalities of melanoma were detected in 7 of 8 tested cases (Idriss et al. 2015).
  • Primary dermal melanoma. Melanoma confined to the dermis or subcutis without a junctional component or nevus precursor simulates a metastasis. In 7 patients with negative staging, including sentinel node biopsy, survival was 100% at a mean follow-up of 41 months, and S100, HMB45, Ki-67, CD34 and p75 did not separate dermal melanoma from metastatic or nodular melanoma (Swetter et al. 2004). "Dermal melanoma" is a CAP histologic type (CAP 2025a).

Breslow thickness and the other microstaging elements of primary melanoma

  • Breslow thickness. Thickness is measured with a calibrated ocular micrometer at a right angle to the skin surface. The upper reference point is the upper edge of the granular layer of the overlying epidermis, or the ulcer base when the tumor is ulcerated. The lower reference point is the deepest invasive cell of the main mass or of an isolated group of cells deep to it. Melanomas without an intraepidermal component are measured from the top of the granular layer to the deepest invasive cell. A transected tumor is reported as "at least" the measured thickness (CAP 2025a).
  • Exclusions from thickness. Periadnexal (adventitial or extra-adventitial) extension is excluded unless it is the only invasive focus. In that case thickness is measured from the inner layer of the outer root sheath or the inner luminal surface of the sweat duct to the deepest periadnexal infiltration. Satellites, microsatellites, neurotropism and lymphovascular invasion are excluded (CAP 2025a). Partially regressed melanoma is measured to the deepest viable tumor cell and is not classified as TX or T0 (Gershenwald et al. 2017).
  • TX, T0 and Tis. TX is used when thickness cannot be assessed, for example in curettage fragments without a perpendicular section. T0 indicates no evidence of a primary tumor (unknown primary or complete regression). Melanoma in situ is Tis, and so is a melanoma whose invasive component has regressed under remaining in situ melanoma (Gershenwald et al. 2017).
  • Ulceration. Ulceration requires a full-thickness epidermal defect (including loss of the stratum corneum and basement membrane), reactive changes (fibrin, neutrophils) and thinning, effacement or reactive hyperplasia of the adjacent epidermis without trauma or recent surgery. Ulceration from a prior biopsy is not recorded for staging. Tumorigenic ulceration present in either the partial biopsy or the re-excision is recorded as ulceration. Ulceration in melanoma in situ does not affect staging (CAP 2025a). Squared-off scar edges suggest iatrogenic ulceration, and the tumor is staged as ulcerated when doubt remains (Gershenwald et al. 2017).
  • Mitotic rate. Counting starts in the dermal hot spot and extends to adjacent non-overlapping fields until 1 mm² is assessed. The result is a whole number per mm². A dermal component smaller than 1 mm² is counted as if it were 1 mm², so one mitosis in 0.5 mm² is 1/mm². No extra sections are cut to find mitoses, and immunostains are not used for the count, apart from dual stains such as MART1 with pHH3 to confirm that a dividing cell is melanocytic (CAP 2025a). In pN0 melanoma, 5- and 10-year melanoma-specific survival fell from 99% and 97% with <1 mitosis per mm² to 84% and 77% with ≥11 per mm² (Gershenwald et al. 2017).
  • Anatomic (Clark) level. Level I is intraepidermal (melanoma in situ), II is in but not filling the papillary dermis, III fills and expands the papillary dermis, IV invades the reticular dermis and V invades the subcutis. Clark level is less reproducible than thickness, is not used for pT and is an optional CAP element (CAP 2025a).
  • Growth phase. The vertical growth phase is defined by a dermal cluster larger than the largest intraepidermal cluster or by any dermal mitosis, and radial-growth-phase-confined melanoma lacks both features. Dermal clusters comparable in size to the intraepidermal clusters are regarded as early tumorigenic vertical growth phase. Radial-growth-phase-confined melanomas, with exceedingly rare exceptions, do not metastasize, and the vertical growth phase is associated with metastatic capability. In 4,236 stage I and II melanomas, increasing T category, ulceration, mitoses and vertical growth phase were independent determinants of melanoma-specific death (Elder 2026).
  • Microsatellites and macroscopic satellites. A microsatellite is a microscopic focus of melanoma adjacent or deep to the primary and separated from it by normal stroma, with no minimum size or distance. Fibrotic or inflamed intervening tissue can represent regression and does not qualify. Deeper levels are recommended to confirm discontinuity. A macroscopic satellite is a clinically or grossly detected metastatic focus separated from the primary by normal tissue (CAP 2025a).
  • Lymphovascular invasion. LVI is melanoma within the lumen of a blood vessel or lymphatic. CD31, CD34, ERG and D2-40 highlight lumina, and double stains (MITF with D2-40, SOX10 with D2-40 or SOX10 with CD31) increase detection. LVI does not change the T category (CAP 2025a).
  • Neurotropism. Melanoma cells abutting nerve sheaths, usually circumferentially, or within nerves, and neural transformation of the tumor, qualify. Nerves entrapped within the main mass do not. Neurotropism may correlate with an increased risk of local recurrence (CAP 2025a).
  • Tumor-infiltrating lymphocytes. Lymphocytes must surround and disrupt invasive tumor cells. TILs are brisk when they diffusely infiltrate the entire base or permeate the entire invasive tumor, non-brisk when focal, and not identified when absent or not infiltrating tumor. A paucity of TILs is adverse (CAP 2025a).
  • Regression. Regression is replacement of tumor by lymphohistiocytic inflammation with epidermal attenuation, non-lamellated dermal fibrosis, melanophages and telangiectasia. Its extent is recorded as focal (≤75%) or extensive (>75%), and regression at a peripheral margin prompts consideration of re-excision (CAP 2025a).
  • Margins. Optional elements record the distance from invasive melanoma to the peripheral and deep margins and from melanoma in situ to the peripheral margin, and measurement is recommended when the distance is ≤1.0 mm. An involved margin is specified as in situ, invasive or satellite (CAP 2025a).
  • Specimen handling. Shave biopsies without an intact base and punch biopsies without intact peripheral borders are suboptimal for melanocytic lesions. Frozen sections of melanocytic lesions and of sentinel nodes are strongly discouraged (CAP 2025a).

CAP Invasive Melanoma of the Skin protocols: excision 1.2.0.0 and biopsy 1.1.0.0

The excision and re-excision protocol, version 1.2.0.0 (posted March 2025; required for accreditation from December 2025), applies to invasive melanoma of cutaneous surfaces and uses AJCC 8th edition staging. It is not required for biopsies, for primary resections without residual melanoma after neoadjuvant therapy, for cytologic specimens, for recurrences or metastases resected separately from the primary, or for second-opinion review (CAP 2025a). The biopsy protocol, version 1.1.0.0 (March 2025), is recommended for clinical care and is not required for accreditation (CAP 2025b).

Element Excision 1.2.0.0 Biopsy 1.1.0.0 Source
Procedure Excision, re-excision, sentinel node biopsy, lymphadenectomy Shave, punch or incisional biopsy CAP 2025a; CAP 2025b
Tumor site, laterality, multiple primary sites Required (multiple sites conditional) Required (multiple sites conditional) CAP 2025a; CAP 2025b
Histologic type Conditional Conditional CAP 2025a; CAP 2025b
Breslow thickness (mm), ulceration, mitotic rate (per mm²) Required Required CAP 2025a; CAP 2025b
Extent of ulceration (mm), Clark level Optional Optional CAP 2025a; CAP 2025b
Macroscopic satellite lesions Conditional Conditional CAP 2025a; CAP 2025b
Microsatellites Required Optional CAP 2025a; CAP 2025b
Lymphatic and/or vascular invasion Required, with optional method of detection Conditional, with optional method of detection CAP 2025a; CAP 2025b
Neurotropism Required Conditional CAP 2025a; CAP 2025b
Tumor-infiltrating lymphocytes; regression with extent (focal ≤75%, extensive >75%) Optional Optional CAP 2025a; CAP 2025b
Margins for invasive melanoma, melanoma in situ, satellites and regression Required; distances optional, with measurement recommended at ≤1.0 mm Required; distances optional CAP 2025a; CAP 2025b
Regional lymph nodes: number examined and involved, sentinel nodes, largest sentinel and non-sentinel deposit (mm), extranodal extension, matted nodes Required when nodes are submitted; nodal site of tumor (subcapsular, intraparenchymal) optional Not part of the biopsy protocol CAP 2025a
pT, pN and pM Required, with prior-procedure information allowed Removed in version 1.1.0.0; pT is deferred to the definitive resection, which may incorporate biopsy parameters CAP 2025a; CAP 2025b
  • Prior-procedure rule. Because the re-excision may contain no residual melanoma, information from a prior procedure may be incorporated into the pathologic classification, and the report documents that procedure (CAP 2025a).
  • LDH and pM. The LDH suffixes (0) and (1) are not included in the surgical pathology report. pM is reported only when distant metastasis is documented in the specimen, and pMX and pM0 are not reported (CAP 2025a).
  • Biomarkers. Molecular results are reported with the CAP Melanoma Biomarker template (CAP 2025a).
  • Previous rule (excision 1.1.0.0, June 2024). Version 1.1.0.0 made macroscopic satellite lesions optional and histologic type conditional, added Clark level answers, added the optional method of detection for LVI and nodal tumor, updated the margins section and corrected pN category staging with the AJCC (CAP 2024). Version 1.2.0.0 updated the margins and regional lymph node sections, made macroscopic satellite lesions conditional, added extent of tumor regression and refined pT and pN terminology (CAP 2025a).
  • Previous rule (biopsy 1.0.0.0). Biopsy version 1.1.0.0 removed the pT staging elements, made histologic type conditional, added conditional macroscopic satellite lesions, optional margin involvement by satellites, the optional LVI method of detection and extent of regression, and updated tumor site, thickness, Clark level and margin items (CAP 2025b).

AJCC 8th edition T, N and M categories for cutaneous melanoma

Table: AJCC 8th edition primary tumor (T) categories from Gershenwald et al. 2017, Table 2, and CAP 2025a.

T category Thickness Ulceration status Source
TX: primary tumor thickness cannot be assessed (e.g., diagnosis by curettage) Not applicable Not applicable Gershenwald et al. 2017
T0: no evidence of primary tumor (e.g., unknown primary or completely regressed melanoma) Not applicable Not applicable Gershenwald et al. 2017
Tis (melanoma in situ) Not applicable Not applicable Gershenwald et al. 2017
T1 ≤1.0 mm Unknown or unspecified Gershenwald et al. 2017
T1a <0.8 mm Without ulceration Gershenwald et al. 2017
T1b <0.8 mm With ulceration Gershenwald et al. 2017
T1b 0.8–1.0 mm With or without ulceration Gershenwald et al. 2017
T2 >1.0–2.0 mm Unknown or unspecified Gershenwald et al. 2017
T2a >1.0–2.0 mm Without ulceration Gershenwald et al. 2017
T2b >1.0–2.0 mm With ulceration Gershenwald et al. 2017
T3 >2.0–4.0 mm Unknown or unspecified Gershenwald et al. 2017
T3a >2.0–4.0 mm Without ulceration Gershenwald et al. 2017
T3b >2.0–4.0 mm With ulceration Gershenwald et al. 2017
T4 >4.0 mm Unknown or unspecified Gershenwald et al. 2017
T4a >4.0 mm Without ulceration Gershenwald et al. 2017
T4b >4.0 mm With ulceration Gershenwald et al. 2017
  • Rounding. Thickness is recorded to the nearest 0.1 mm. Values ending in 1–4 in the hundredths place are rounded down and those ending in 5–9 are rounded up. A melanoma measured at 0.75 mm is recorded as 0.8 mm (T1b), and 0.95–1.04 mm is recorded as 1.0 mm (T1b) (Gershenwald et al. 2017).
  • Multiple primaries. Each primary melanoma is categorized separately. Synchronous primaries without metastasis take the highest T category with the (m) suffix or the number of tumors, e.g., T2a(m) or T2a(2) (Gershenwald et al. 2017).

Table: AJCC 8th edition regional lymph node (N) categories from Gershenwald et al. 2017, Table 3.

N category Number of tumor-involved regional lymph nodes In-transit, satellite and/or microsatellite metastases Source
NX Regional nodes not assessed (e.g., SLN biopsy not performed, regional nodes previously removed for another reason); pathological N category is not required for T1 melanomas, which use clinical N information No Gershenwald et al. 2017
N0 No regional metastases detected No Gershenwald et al. 2017
N1 One tumor-involved node or any number of in-transit, satellite and/or microsatellite metastases with no tumor-involved nodes Defined by subcategory Gershenwald et al. 2017
N1a One clinically occult (detected by SLN biopsy) No Gershenwald et al. 2017
N1b One clinically detected No Gershenwald et al. 2017
N1c No regional lymph node disease Yes Gershenwald et al. 2017
N2 Two or 3 tumor-involved nodes or any number of in-transit, satellite and/or microsatellite metastases with one tumor-involved node Defined by subcategory Gershenwald et al. 2017
N2a Two or 3 clinically occult (detected by SLN biopsy) No Gershenwald et al. 2017
N2b Two or 3, at least one of which was clinically detected No Gershenwald et al. 2017
N2c One clinically occult or clinically detected Yes Gershenwald et al. 2017
N3 Four or more tumor-involved nodes or any number of in-transit, satellite and/or microsatellite metastases with 2 or more tumor-involved nodes, or any number of matted nodes without or with in-transit, satellite and/or microsatellite metastases Defined by subcategory Gershenwald et al. 2017
N3a Four or more clinically occult (detected by SLN biopsy) No Gershenwald et al. 2017
N3b Four or more, at least one of which was clinically detected, or the presence of any number of matted nodes No Gershenwald et al. 2017
N3c Two or more clinically occult or clinically detected and/or presence of any number of matted nodes Yes Gershenwald et al. 2017
  • Any tumor cells count. A node with any metastatic tumor cells, on H&E or immunostained sections and however small the deposit, is tumor-involved. Melanoma cells in a lymphatic channel within or immediately adjacent to a node make that node tumor-involved (Gershenwald et al. 2017).
  • Matted nodes and extranodal extension. Matted nodes are 2 or more nodes adherent through metastatic disease, identified at gross examination, and remain an N3 criterion. Extranodal extension is metastasis through the capsule into adjacent tissue, microscopically confirmed, and is recorded without changing N (Gershenwald et al. 2017).
  • Satellite and in-transit metastases. Satellites have classically been defined as clinically evident cutaneous or subcutaneous metastases within 2 cm of the primary, and in-transit metastases as those more than 2 cm from the primary between the primary and the first regional nodal basin. Survival did not differ significantly among microsatellites, satellites and in-transit metastases, so they are grouped in the N "c" subcategories (Gershenwald et al. 2017).
  • Regional basin. Regional nodal metastasis is disease in one draining basin or 2 contiguous basins, or in any basin identified by lymphoscintigraphy. Metastasis to a non-draining basin is M1 (CAP 2025a).
  • pN1a(sn). A positive SLN without completion lymph node dissection is recorded as pN1a(sn) (Gershenwald et al. 2017).
  • CAP wording. The pN1b, pN2b and pN3b subcategories depend on clinical information that the pathologist may lack. When it is unavailable, the parent category (pN1, pN2 or pN3) is assigned (CAP 2025a).

Table: AJCC 8th edition distant metastasis (M) categories from Gershenwald et al. 2017, Table 4.

M category Anatomic site LDH level Source
M0 No evidence of distant metastasis Not applicable Gershenwald et al. 2017
M1 Evidence of distant metastasis Defined by subcategory Gershenwald et al. 2017
M1a Distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node Not recorded or unspecified; M1a(0) not elevated; M1a(1) elevated Gershenwald et al. 2017
M1b Distant metastasis to lung with or without M1a sites of disease Not recorded or unspecified; M1b(0) not elevated; M1b(1) elevated Gershenwald et al. 2017
M1c Distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease Not recorded or unspecified; M1c(0) not elevated; M1c(1) elevated Gershenwald et al. 2017
M1d Distant metastasis to CNS with or without M1a, M1b or M1c sites of disease Not recorded or unspecified; M1d(0) not elevated; M1d(1) elevated Gershenwald et al. 2017

No suffix is used when LDH is not recorded or unspecified. CNS includes the brain, spinal cord and leptomeninges (Gershenwald et al. 2017). MX does not exist in the AJCC/UICC system (CAP 2025a).

Changes from the AJCC 7th to the 8th edition (previous rules)

Element AJCC 8th edition AJCC 7th edition (previous rule) Source
Precision of Breslow thickness Recorded to the nearest 0.1 mm Implied (without an explicit statement) to the nearest 0.01 mm Gershenwald et al. 2017
T1a and T1b T1a: <0.8 mm without ulceration; T1b: <0.8 mm with ulceration or 0.8–1.0 mm with or without ulceration Mitotic rate <1 versus ≥1 per mm² was a T1 criterion Gershenwald et al. 2017
T2 range after rounding >1.0–2.0 mm (measured 1.05–2.04 mm) 1.01–2.0 mm Gershenwald et al. 2017
Microsatellite No minimum size or distance; discontinuous from the primary with unaffected stroma between Tumor nest >0.05 mm in diameter separated from the main invasive component by normal dermis over a distance of >0.5 mm Gershenwald et al. 2017
Nodal descriptors Clinically occult (detected by SLN biopsy) and clinically detected Microscopic and macroscopic Gershenwald et al. 2017
Non-nodal regional disease Microsatellites, satellites and in-transit metastases stratified as N1c, N2c or N3c by the number of involved nodes Satellite and in-transit metastases merged into a single staging entity since the 6th edition Gershenwald et al. 2017
Extranodal extension Gross extranodal extension no longer an N criterion; matted nodes retained Gross extranodal extension used in N Gershenwald et al. 2017; CAP 2025a
CNS metastasis M1d M1c Gershenwald et al. 2017
LDH Suffix (0) or (1) on each M1 subcategory, e.g., M1a(1) Elevated LDH defined M1c regardless of site Gershenwald et al. 2017
pT1b N0 Pathological stage IA Stage IB Gershenwald et al. 2017
Stage III Four subgroups (IIIA–IIID) combining T and N elements Three subgroups (IIIA–IIIC) Gershenwald et al. 2017

AJCC 8th edition stage groups and melanoma-specific survival

Table: clinical and pathological stage groups for node-negative melanoma from Gershenwald et al. 2017, Tables 5 and 6.

T N M Clinical stage (cTNM) Pathological stage (pTNM) Source
Tis N0 M0 0 0 Gershenwald et al. 2017
T1a N0 M0 IA IA Gershenwald et al. 2017
T1b N0 M0 IB IA Gershenwald et al. 2017
T2a N0 M0 IB IB Gershenwald et al. 2017
T2b N0 M0 IIA IIA Gershenwald et al. 2017
T3a N0 M0 IIA IIA Gershenwald et al. 2017
T3b N0 M0 IIB IIB Gershenwald et al. 2017
T4a N0 M0 IIB IIB Gershenwald et al. 2017
T4b N0 M0 IIC IIC Gershenwald et al. 2017
Any T, Tis ≥N1 M0 III Substaged below Gershenwald et al. 2017
Any T Any N M1 IV IV Gershenwald et al. 2017

Pathological stage 0 and T1 melanomas do not require pathological evaluation of lymph nodes, and clinical N information is used. Clinical stage III has no substages, and stage IV is not substaged (Gershenwald et al. 2017).

Table: AJCC 8th edition pathological stage III groups from Gershenwald et al. 2017, Table 6.

T N M Pathological stage Source
T0 N1b, N1c M0 IIIB Gershenwald et al. 2017
T0 N2b, N2c, N3b or N3c M0 IIIC Gershenwald et al. 2017
T1a/b–T2a N1a or N2a M0 IIIA Gershenwald et al. 2017
T1a/b–T2a N1b/c or N2b M0 IIIB Gershenwald et al. 2017
T2b/T3a N1a–N2b M0 IIIB Gershenwald et al. 2017
T1a–T3a N2c or N3a/b/c M0 IIIC Gershenwald et al. 2017
T3b/T4a Any N ≥N1 M0 IIIC Gershenwald et al. 2017
T4b N1a–N2c M0 IIIC Gershenwald et al. 2017
T4b N3a/b/c M0 IIID Gershenwald et al. 2017
  • Stage IV data. Stage IV categories were revised without new stage IV analyses (Gershenwald et al. 2017).
  • T1 analysis. Among 7,568 patients with T1 N0 melanoma, thickness ≥0.8 mm (HR 1.7, P = .057) and ulceration (HR 2.6, P = .035) were stronger predictors of melanoma-specific survival than mitotic rate ≥1 per mm² (HR 0.85, P = .57), and mitotic rate was removed as a T1 criterion. SLN metastases occur in fewer than 5% of melanomas <0.8 mm thick and in about 5%–12% of those 0.8–1.0 mm thick (Gershenwald et al. 2017).
  • Survival by T category (pN0). Five- and 10-year melanoma-specific survival ranged from 99% and 98% for T1a to 82% and 75% for T4b. An ulcerated melanoma had survival similar to a non-ulcerated melanoma of the next thickness category: 93% and 88% for T2b against 94% and 88% for T3a (Gershenwald et al. 2017).
  • Clinical versus pathological T1b N0. Five- and 10-year melanoma-specific survival was 97% and 93% for clinical T1b N0 and 99% and 96% for pathological T1b N0, the basis for placing pathological T1b N0 in stage IA (Gershenwald et al. 2017).
  • Stage III. Five-year melanoma-specific survival ranged from 93% in stage IIIA to 32% in stage IIID. In the 7th edition, 5-year survival for stages IIIA, IIIB and IIIC was 78%, 59% and 40% (Gershenwald et al. 2017).
  • Unknown primary with nodal disease. These patients have survival equal to or slightly better than patients with a known primary and a similar number of clinically detected nodes. They are staged as T0 with the N category set by the number of involved nodes and the presence of satellite, microsatellite or in-transit metastases (Gershenwald et al. 2017).

Sentinel lymph node examination: the EORTC 2019 protocol and tumor burden

  • Indications. Sentinel lymph node (SLN) biopsy may be performed for clinically localized melanomas ≥1 mm thick or for selected thinner tumors with adverse features (CAP 2025a). The SLN is any node receiving direct lymphatic drainage from the primary, and a basin often contains more than one (CAP 2025a).
  • Gross handling. The entire SLN is submitted. Routine bisection with H&E of the cut surfaces may give a false-negative rate of 10%–15%, and multiple levels through serially sliced nodes increase sensitivity. Nodes ≥5 mm in routine lymphadenectomies may be bisected or sliced at 2–3 mm, and nodes <5 mm may be submitted whole (CAP 2025a).
  • Immunohistochemistry. Immunostains for HMB45, MART1/Melan-A, SOX10 or melanocytic cocktails increase detection and supplement H&E. SOX10 is a sensitive screening marker, particularly for desmoplastic primaries with reduced Melan-A and HMB45 expression. PRAME is useful only when the primary expresses it, because a negative stain does not exclude metastasis (Barnachea and Lee 2026).
  • EORTC 2019 protocol. The updated EORTC protocol extends the distance between step sections according to the short-axis dimension of the node and optimizes sectioning and staining, including immunohistochemistry. It reports presence or absence of metastasis, intranodal location (subcapsular, parenchymal, combined, extensive confluent or extensive multifocal), number of deposits (1, 2–5, 6–10, 11–20 or >20), maximum dimension of the largest metastasis with its site, extracapsular extension and the presence of naevus cells (Cook et al. 2019).
  • Previous rule (EORTC 2009). The 2009 recommendations specified a single one-dimensional measurement of the maximum diameter of the largest metastasis in any direction, because cumulative measurements reduce accuracy. Tumor burden was reported by the Rotterdam criteria as an absolute number and as <0.1 mm, 0.1–1.0 mm or >1.0 mm. Microanatomic location was reported for the entire node by the Dewar system. A lesion with any parenchymal infiltration is no longer solely subcapsular, and a subcapsular metastasis has a smooth, usually curved outline (van Akkooi et al. 2009).
  • AJCC tumor burden. The AJCC 8th edition panel recommends recording, at a minimum, the single largest maximum dimension of the largest discrete metastatic deposit in the SLN, in millimeters to the nearest 0.1 mm with an ocular micrometer. SLN tumor burden is a regional prognostic factor and does not define N category (Gershenwald et al. 2017). Adjuvant trials (EORTC 18071 and COMBI-AD) required a deposit >1 mm in patients with a single positive SLN (Gershenwald et al. 2017).
  • CAP deposit measurement. A single focus is measured in 2 perpendicular dimensions. Closely placed deposits may be measured together, and widely spaced foci are measured only within the closest cluster. When few cells are scattered over a large area, the approximate number of tumor cells is added to the size (CAP 2025a).
  • Location and extranodal extension. Subcapsular metastases are associated with more favorable outcomes than parenchymal involvement, and parenchymal, multifocal or extensive involvement predicts non-sentinel node metastases. In 1,047 SLN-positive patients, 5-year overall survival was 62.5% with extranodal extension and 71.7% without it (Barnachea and Lee 2026).

Nodal nevus, tumoral melanosis and histiocytes in sentinel lymph nodes

Finding Location and morphology Immunohistochemistry Source
Nodal (capsular) nevus Small bland melanocytes in nests or cords in the capsule or trabeculae; naevus cells in 10% of index melanoma SLNs (13% axillary, 0% cervical), 93% capsular or pericapsular and 7% trabecular SOX10 and Melan-A positive; HMB45 often weak or negative; PRAME negative Barnachea and Lee 2026; Green et al. 2024; Lezcano et al. 2020
Metastatic melanoma Subcapsular sinus or parenchyma; nuclear enlargement, pleomorphism and prominent nucleoli; can be confined to the capsular fibrous tissue SOX10 and Melan-A positive; HMB45 more often positive; PRAME diffusely positive Barnachea and Lee 2026; Lezcano et al. 2020
Tumoral melanosis Aggregates of melanin-laden macrophages without viable melanoma cells after regression or neoadjuvant therapy SOX10 and Melan-A negative; CD68 and CD163 positive Barnachea and Lee 2026
Reactive histiocytes Sheets of histiocytes, sometimes atypical or pigmented Melanocytic markers negative; CD68 and CD163 positive Barnachea and Lee 2026

PRAME is most useful for capsular metastases, intraparenchymal nevi and small metastases coexisting with a nevus in the same node (Lezcano et al. 2020). The PRAME series of nodal nevi and metastases, and its cytologic use, are taught in Metastatic Melanoma in Lymph Nodes (Cytology).

  • Completion dissection. In MSLT-II, immediate completion lymph node dissection improved regional disease control without improving melanoma-specific survival, and many SLN-positive patients are now observed (Barnachea and Lee 2026).

Metastatic melanoma: locoregional, distant and unknown primary

  • Routes of spread. Microsatellites, satellites and in-transit metastases are attributed to intralymphatic or angiotropic spread (Gershenwald et al. 2017). Skin5 adds angiotropic extravascular migratory metastasis: tumor cells migrate along the abluminal surfaces of vessels without entering the circulation. It is frequent in satellite and in-transit metastases and in the replacement growth pattern of liver metastases (Goldman-Lévy et al. 2026).
  • Growth patterns of organ metastases. The replacement (angiotropic infiltrating) growth pattern in liver and other organs indicates an aggressive phenotype with therapy resistance, and diffuse micrometastatic replacement of the liver is termed miliary metastasis. The desmoplastic growth pattern forms an expansile nodule with a collagenous rim and carries a more favorable prognosis (Goldman-Lévy et al. 2026).
  • Epidermotropic metastasis. Epidermotropic metastases can simulate primary melanoma, including an epidermis-only pagetoid pattern that mimics melanoma in situ. In 2 patients with 35 and 22 epidermotropic metastases, the lesions were small (2.8 mm average histologic diameter), symmetric and numerous, and these features supported metastasis over multiple primaries (Abernethy et al. 1994).
  • Blue nevus-like metastasis. Metastatic melanoma can mimic a blue nevus, most often near the site of the primary. In a 78-year-old man with an untreated melanoma, a new gray nodule near the primary site was diagnosed as blue nevus-like metastasis after FISH showed RREB1 gains, and a new blue nevus-like lesion in a patient with prior melanoma raises this possibility (Campa et al. 2016).
  • Melanoma of unknown primary. Melanoma of unknown primary accounted for 3.2% of 136,991 melanomas in a systematic review, with a male-to-female ratio of 2:1. With nodal disease, 5-year survival ranged from 28.6% to 75.6%; with visceral disease it ranged from 5.9% to 18% (Kamposioras et al. 2011).
  • Multiple primaries and metastasis assignment. When multiple primaries drain to the same basin, the primary with the highest T category is assigned as the origin of the nodal metastases. The stage recorded is the highest stage of any primary (Gershenwald et al. 2017).
  • Sites. Melanoma metastatic to lymph nodes, lung, liver and serosal fluids on cytology is taught in Metastatic Melanoma in Lymph Nodes (Cytology), Metastatic Tumors to the Lung (Cytology), Metastases, Lymphoma and Angiosarcoma in Liver FNA and Uncommon Nonlymphoid Malignancies in Serous Effusions.

Biomarker testing in melanoma: BRAF, NRAS and KIT

Gene Frequency and hotspots Therapeutic relevance Source
BRAF Up to 50% of melanomas; 95% at codon 600, most often V600E and sometimes V600K; V600R and V600D are listed in the template Vemurafenib and dabrafenib (BRAF inhibitors) and trametinib (MEK inhibitor) in V600-mutated melanoma; V600K can also respond; non-V600 mutations are often weaker activators with less marked responses CAP 2019
NRAS About 20%; about 80% in exon 3 (codons 60 and 61) and 20% in exon 2 (codons 12 and 13); usually mutually exclusive with BRAF V600 in untreated tumors No effective direct NRAS inhibitor CAP 2019
KIT Fewer than 5% of all melanomas; mainly mucosal, acral and chronically sun-damaged skin; L576P and K642E account for close to 50%; exons 11 and 13 most common, with more exon 13 and 17 mutations than in GIST Responses to KIT inhibitors in mutated tumors, best at L576 and K642; copy number gain alone does not predict response CAP 2019
  • Pathway alterations. Somatic mutations of BRAF, NRAS, KIT, PTEN or NF1 occur in 70%–80% of cutaneous melanomas (CAP 2019).
  • BRAF V600E (VE1) immunohistochemistry. VE1 correlates well with molecular testing. Laboratories using it validate the assay and keep confirmatory molecular testing available (CAP 2019).
  • Resistance. Relapse after BRAF inhibition shows increased ERK phosphorylation, with acquired MEK1 or NRAS mutations in a subset (CAP 2019).

Methods for BRAF, NRAS and KIT testing are taught in Nucleic Acids, Specimens and Non-NGS Molecular Methods: Extraction, PCR, Quantitative and Digital PCR, Isothermal Amplification, Hybridization, Sanger Sequencing, Fragment Analysis, Methylation Analysis and MLPA and Next-Generation Sequencing: Library Preparation, Target Enrichment, Bioinformatics, Long-Read and RNA Fusion Assays, Circulating Tumor DNA, Assay Validation, HGVS Nomenclature, Companion Diagnostics and Regulation.

Differential diagnosis of melanoma and its histologic mimics

Mimic Features favoring the mimic Features favoring melanoma Source
Background melanocytes of chronically sun-damaged skin (versus lentigo maligna) Confluence, stacking, small nests, adnexal extension and suprabasilar scatter occur in Melan-A-stained sun-damaged controls; mean density 25.6 per ×400 field Mean density 82.7 per ×400 field Bowen et al. 2011
Lichenoid dermatitis with pseudomelanocytic nests Lichenoid inflammation; Melan-A-positive junctional nests in phototoxic reaction, lichen planus pigmentosus or pigmented lichenoid keratosis; clinical correlation Clinical and histologic findings of melanoma in situ beyond Melan-A staining Beltraminelli et al. 2009
Intradermal or compound nevus (versus nevoid melanoma) Nevus-like silhouette shared with nevoid melanoma Sheet-like confluence of melanocytes expanding the papillary dermis (60%), parallel theque pattern at the base (81%), dermal mitoses, melanoma-type genomic abnormalities Idriss et al. 2015
Scar (versus desmoplastic melanoma) Scattered isolated S100-positive cells Strong diffuse S100; diffuse SOX10; lymphoid aggregates; hyperchromatic spindle cells Chen et al. 2013; Palla et al. 2013
Atypical fibroxanthoma, spindle cell sarcoma or spindle cell carcinoma (versus desmoplastic melanoma) SOX10 negative in AFX (0/13), sarcomas (0/20) and spindle cell carcinomas (0/18); focal in 3 of 10 MPNSTs SOX10 diffusely positive in 100% Palla et al. 2013
Epidermotropic metastasis (versus primary melanoma) Prior melanoma; numerous small (2.8 mm average) symmetric lesions; a spectrum from epidermis-only pagetoid lesions to dermal-predominant lesions Pagetoid intraepidermal melanocytes occur in both, and the distinction rests on lesion size, symmetry, number and clinical course Abernethy et al. 1994
Dermal metastasis (versus primary dermal melanoma) Other metastases on staging Solitary dermal or subcutaneous nodule without a junctional component or nevus and with negative staging; S100, HMB45, Ki-67, CD34 and p75 do not separate the two Swetter et al. 2004

AJCC 8th edition melanoma pathological stage calculator with Breslow rounding

Cutaneous Adnexal Neoplasms: Follicular, Sebaceous, Apocrine and Eccrine Tumors, Adnexal Carcinomas, Paget Disease and Associated Syndromes

Definition and classification. Adnexal (appendageal) neoplasms show differentiation toward the hair follicle, the sebaceous gland or the apocrine and eccrine sweat apparatus. The WHO Classification of Skin Tumours, 5th edition (2022), groups them as appendageal tumours, summarizes their recurrent molecular alterations, renames cribriform carcinoma as cribriform tumour and adds primary cutaneous NUT carcinoma as a provisional entity (Goldman-Lévy et al. 2026; Ho and Collie 2023). Nevus sebaceus, traditionally regarded as a hamartoma, is classified in the 5th-edition sebaceous tumour family because it shares RAS alterations with benign sebaceous tumours. Sebaceous hyperplasia is not recognized as a tumour entity (Wiedemeyer et al. 2026). Many adnexal tumors carry gene fusions or point mutations that are shared with homologous tumors of the salivary gland, breast and other exocrine organs (Macagno et al. 2022).

Related page: Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing (Lynch syndrome genetics, mismatch repair immunohistochemistry principles, MLH1 promoter methylation and BRAF testing, PTEN hamartoma tumor syndrome) Related page: Renal Cell Carcinoma and Oncocytic Renal Tumors (renal tumors of Birt–Hogg–Dubé syndrome) Related page: Follicular Cell-Derived Thyroid Neoplasms: WHO 2022 Classification, Follicular and Oncocytic Adenoma and Carcinoma, Low-Risk Neoplasms and Invasion Criteria (thyroid lesions in Cowden syndrome) Related page: Paget Disease of the Nipple, Inflammatory Carcinoma, Male Breast Carcinoma and Hereditary Breast Cancer (mammary Paget disease histology and immunohistochemistry, Toker cells) Related page: Papillary Neoplasms, Adenomyoepithelioma and Nipple Lesions of the Breast (nipple adenoma and syringomatous tumor of the nipple) Related page: Anal Canal Neoplasia, Colorectal Neuroendocrine Tumors and Other Lower GI Tumors (perianal Paget disease in the anal canal setting) Related page: Lower Anogenital Cytology Outside the Cervix and Anus (Paget disease in vulvar cytology) Related page: Non-Neoplastic and Reactive Soft Tissue and Skin Lesions on FNA (pilomatricoma on fine-needle aspiration) Related page: Benign Epidermal Tumors, Cutaneous Cysts, Actinic Keratosis and Squamous Cell Carcinoma In Situ (proliferating trichilemmal tumor, cutaneous cysts and the pagetoid Bowen disease, Paget disease and melanoma in situ table) Related page: Keratoacanthoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma and Merkel Cell Carcinoma: Subtypes, Risk Stratification, Staging, CAP Reporting and Mohs Surgery (basal cell carcinoma subtypes, Merkel cell carcinoma and Mohs surgery) Related page: Vascular Anomalies and Vascular Tumors of Skin, Kaposi Sarcoma and Angiosarcoma, Cutaneous Histiocytic and Mast Cell Infiltrates, and Metastases to Skin (primary adnexal carcinoma versus carcinoma metastatic to skin) Related page: Cytogenetics and Cytogenomics: Karyotype and ISCN Nomenclature, Chromosome Abnormalities, FISH, Chromosomal Microarray, Optical Genome Mapping, and Constitutional, Prenatal and Cancer Cytogenetics (FISH methods, including break-apart probes for MAML2, EWSR1 and PLAG1) Related page: Molecular Oncology of Solid Tumors: Oncogenes and Tumor Suppressors, MSI and Mismatch Repair, Tumor Mutational Burden, Tumor-Agnostic and Organ Biomarkers, CNS Tumor Molecular Testing and Germline Findings on Tumor Sequencing (NTRK fusion testing and pan-TRK immunohistochemistry)

WHO 5th-edition changes to adnexal tumor classification

Topic WHO 5th edition (2022) Previous rule (WHO 4th edition, 2018) Source
Cribriform lesion with apocrine differentiation Cribriform tumour: solid and cribriform structures of eosinophilic cells with small lumina and no myoepithelial layer; no reported recurrence or metastasis Cribriform carcinoma Goldman-Lévy et al. 2026
NUT carcinoma of skin Primary cutaneous NUT carcinoma, provisional: BRD3 or NSD3 fused to NUTM1 or NUTM2B No entry; added as a new provisional entity Goldman-Lévy et al. 2026
Trichodiscoma and fibrofolliculoma Both included as appendageal tumours Spindle-cell-predominant trichodiscoma only Goldman-Lévy et al. 2026
Adenosquamous carcinoma of skin Removed as a subtype of squamous cell carcinoma; most cases classified as squamoid eccrine ductal carcinoma Subtype of cutaneous squamous cell carcinoma Goldman-Lévy et al. 2026; Ho and Collie 2023
Genetic tumour syndromes Chapter renamed "Genetic tumour syndromes associated with skin malignancies"; new Brooke–Spiegler section "Inherited tumour syndromes involving the skin" without a Brooke–Spiegler section Goldman-Lévy et al. 2026

Lines of differentiation, behavior and syndromes of adnexal neoplasms

Line of differentiation Benign tumors Malignant counterparts Syndromic associations Source
Follicular germinative Trichoblastoma, trichoepithelioma (including desmoplastic), adamantinoid trichoblastoma, trichogerminoma Trichoblastic carcinoma CYLD cutaneous syndrome (multiple trichoepitheliomas); Rombo and Bazex–Dupré–Christol syndromes (trichoepitheliomas with basal cell carcinoma) Tellechea et al. 2015; Nagy et al. 2021
Follicular matrix Pilomatricoma Pilomatrical carcinoma Familial adenomatous polyposis (Gardner syndrome), myotonic dystrophy Tellechea et al. 2015; Riva et al. 2025
Follicular infundibulum and isthmus Trichilemmoma, desmoplastic trichilemmoma, tumor of the follicular infundibulum, dilated pore, pilar sheath acanthoma, trichoadenoma Proliferating trichilemmal tumor (recurrence rare, metastasis exceptional) Cowden syndrome (PTEN) Tellechea et al. 2015; Pilarski 2019
Follicular mesenchyme Fibrofolliculoma, trichodiscoma, trichofolliculoma Benign only Birt–Hogg–Dubé syndrome (FLCN) Tellechea et al. 2015; Ntinidi et al. 2025
Sebaceous Sebaceous adenoma, sebaceoma, nevus sebaceus Sebaceous carcinoma Muir–Torre syndrome (mismatch repair genes) Wiedemeyer et al. 2026
Apocrine and anogenital mammary-like gland Syringocystadenoma papilliferum, tubular adenoma, hidradenoma papilliferum, apocrine-type mixed tumor Apocrine carcinoma Nevus sebaceus (secondary syringocystadenoma papilliferum) Macagno et al. 2022; Liau et al. 2016; Zagala et al. 2026
Cylindromatous and spiradenomatous Cylindroma, spiradenoma, spiradenocylindroma Malignant tumors arising in cylindroma or spiradenoma CYLD cutaneous syndrome (Brooke–Spiegler syndrome) Goldman-Lévy et al. 2026; Nagy et al. 2021
Sweat duct and gland Syringoma, poroma, poroid hidradenoma, hidradenoma, eccrine-type mixed tumor, myoepithelioma Porocarcinoma, hidradenocarcinoma, microcystic adnexal carcinoma, squamoid eccrine ductal carcinoma, mucinous carcinoma, adenoid cystic carcinoma, digital papillary adenocarcinoma, secretory carcinoma Down syndrome and diabetes mellitus (syringoma) Macagno et al. 2022; Samia et al. 2021

Presentation of cylindroma and spiradenoma at hair-bearing sites and their expression of hair follicle markers suggest origin from hair follicle stem cells (Nagy et al. 2021).

Molecular alterations of sporadic adnexal neoplasms

Tumor Alteration (WHO 5th edition) Reported frequency or surrogate test Source
Adenoid cystic carcinoma MYB::NFIB; MYBL1::NFIB (rare) MYB::NFIB 73%–83%, MYBL1::NFIB 20%–23%; MYB rearrangement in up to 83% of cutaneous cases Goldman-Lévy et al. 2026; Macagno et al. 2022
Cutaneous mixed tumor PLAG1 fusions; HMGA2 fusions (rare) PLAG1 rearrangement by FISH in 33%; PLAG1 protein in 87%–100%; TRPS1::PLAG1 in 3 of 4 acral cases Macagno et al. 2022; Kervarrec et al. 2023a
Cylindroma CYLD inactivation 15 of 15 cylindromas; DNMT3A mutations in some Rashid et al. 2019
Spiradenoma and spiradenocarcinoma CYLD inactivation or ALPK1 p.V1092A, mutually exclusive; TP53 in high-grade spiradenocarcinoma ALPK1 hotspot in 43% of spiradenomas and 28% of spiradenocarcinomas Rashid et al. 2019; Macagno et al. 2022
Digital papillary adenocarcinoma BRAF in a subset; TP53 (rare) HPV42 genome in 10 of 11 cases (Kervarrec et al. 2023a) Goldman-Lévy et al. 2026; Kervarrec et al. 2023a
Hidradenoma and hidradenocarcinoma CRTC1::MAML2; CRTC3::MAML2 (rare) MAML2 rearrangement in 18 of 20 hidradenomas; MAML2 break-apart FISH detects either partner Russell-Goldman and Hanna 2022; Wiedemeyer et al. 2026
Microcystic adnexal carcinoma TP53, JAK1 pathway mutations (rare) Usually no ultraviolet signature Goldman-Lévy et al. 2026; Macagno et al. 2022
Myoepithelioma EWSR1 fusions; FUS fusions (rare) EWSR1 82%, FUS 18%; EWSR1::PBX3 in syncytial myoepithelioma Macagno et al. 2022
Poroma and porocarcinoma YAP1::MAML2, YAP1::NUTM1; PAK1/2/3 fusions YAP1 fusions in 88.5% of poromas and 63.6% of porocarcinomas; loss of C-terminal YAP1 and nuclear NUT by IHC Sekine et al. 2019; Macagno et al. 2022
NUT adnexal carcinoma BRD3 or NSD3 fused to NUTM1 or NUTM2B Diffuse nuclear NUT; BRD4::NUTM1 in 3 of 7 later cases (Legrand et al. 2025) Goldman-Lévy et al. 2026; Legrand et al. 2025
Secretory carcinoma ETV6::NTRK3; NFIX::PKN1 (rare) Nuclear pan-TRK, sensitivity up to 100% Macagno et al. 2022
Signet-ring cell (histiocytoid) carcinoma PIK3CA, CDH1 mutations (rare) Each alteration rare Goldman-Lévy et al. 2026
Syringocystadenoma papilliferum and tubular adenoma BRAF p.V600E; HRAS, KRAS (rare) BRAF V600E in 50%–64% of syringocystadenoma papilliferum and 66% of tubular adenomas; VE1 antibody Macagno et al. 2022
Trichoblastoma (including trichoepithelioma) CTNNB1, HRAS, PTCH1 mutations HRAS in 2 of 18 sporadic trichoblastomas Goldman-Lévy et al. 2026; Shen et al. 2015
Adamantinoid trichoblastoma (lymphadenoma) EGFR, PIK3CA, FGFR3 mutations Lymphocytes permeate the nests, with S100- and CD1a-positive dendritic cells Goldman-Lévy et al. 2026; Tellechea et al. 2015
Trichogerminoma FOXK1::GRHL1/2 and GPS2::GRHL1/2/3 fusions Fusion absent in 66 other follicular tumors and basal cell carcinomas Kervarrec et al. 2022
Trichilemmoma HRAS mutations (sporadic) Trichilemmomas occur in 6%–25% of germline PTEN variant carriers Goldman-Lévy et al. 2026; Pilarski 2019
Pilomatricoma and pilomatrical carcinoma CTNNB1; CDX2 and LEF1 mutations (rare) CTNNB1 in at least 75% of pilomatricomas; nuclear β-catenin and LEF1 Chan et al. 1999; Battistella et al. 2014
Sebaceous adenoma and sebaceoma HRAS, KRAS, TP53, CDKN2A, EGFR, CTNNB1 (each rare) HRAS in about 50%; NOTCH1 and RREB1 drivers; GRHL1/2 fusions in organoid-patterned sebaceoma; PAK2 fusions Goldman-Lévy et al. 2026; Wiedemeyer et al. 2026
Sebaceous carcinoma TP53, RB1, ZNF750, NOTCH1, PIK3CA and others Biallelic TP53 inactivation except in HPV-driven tumors Goldman-Lévy et al. 2026; Wiedemeyer et al. 2026
Nevus sebaceus HRAS, KRAS, NRAS Postzygotic HRAS in about 95% and KRAS in about 5% Wiedemeyer et al. 2026

Fusion detection places a tumor in a family. YAP1, NUTM1, MAML2, EWSR1, FUS, CYLD and ALPK1 alterations occur in both benign and malignant members and do not predict malignancy, which rests on morphology and proliferation (Macagno et al. 2022).

Histologic markers of hair follicle differentiation

  • Infundibulum. Epidermis-like epithelium with a granular layer and basket-weave cornification (Tellechea et al. 2015).
  • Outer root sheath (isthmus and stem). Pale PAS-positive glycogenated cells that cornify abruptly without a granular layer (trichilemmal keratinization) and lie on a thickened hyaline (vitreous) membrane (Tellechea et al. 2015).
  • Inner root sheath. Bright eosinophilic trichohyalin granules and compact blue-gray corneocytes (Tellechea et al. 2015).
  • Hair matrix and shaft. Crowded basophilic matrical cells with mitoses and single-cell necrosis; ghost (shadow) cells are anucleate eosinophilic cells with an empty space in place of the nucleus (Tellechea et al. 2015).
  • Follicular germ and papilla. Basaloid aggregates with peripheral palisading recapitulate the hair germ; fibroblast condensations beside the basaloid nests (papillary mesenchymal bodies) recapitulate the follicular papilla (Tellechea et al. 2015).

Trichoblastoma and trichoepithelioma versus basal cell carcinoma

  • Trichoblastoma. A symmetric, well-circumscribed dermal or subcutaneous tumor of germinative basaloid cells without epidermal connection, arranged in nodular, adenoid, cystic, cribriform, racemiform, retiform or rippled patterns. Hair germ and papilla formation are present, and the cellular stroma is separated from the surrounding dermis by clefts, usually without clefts between stroma and epithelium. Cytologic atypia, mitoses and confluent necrosis are absent. It is relatively infrequent outside nevus sebaceus (Tellechea et al. 2015).
  • Trichoepithelioma. A superficial intradermal trichoblastoma with prominent infundibulocystic differentiation, papillary mesenchymal bodies and loosely collagenous stroma, usually without inflammation except around ruptured keratocysts. Multiple trichoepitheliomas begin in childhood or adolescence with autosomal dominant inheritance and coexist with cylindromas or spiradenomas in CYLD cutaneous syndrome (Tellechea et al. 2015; Nagy et al. 2021).
  • Desmoplastic trichoepithelioma. An annular plaque with a depressed center, most often on the malar region or forehead of adult women. Histology shows a symmetric discoid superficial dermal lesion of thin basaloid cords, often one cell thick, with calcified keratinous cysts in a compact hypocellular stroma (Tellechea et al. 2015).
  • Adamantinoid trichoblastoma (cutaneous lymphadenoma). Nests with peripheral palisaded germinative cells and pale glycogen-rich central cells, permeated by small lymphocytes and scattered S100- and CD1a-positive dendritic cells (Tellechea et al. 2015).
  • Trichogerminoma. Basaloid lobules containing concentric pale "cell balls", with CK15, CK17 and PHLDA1 expression, numerous CK20-positive Merkel cells and FOXK1::GRHL or GPS2::GRHL fusions (Kervarrec et al. 2022).
Feature Trichoblastoma or trichoepithelioma Basal cell carcinoma Source
Silhouette Symmetric, circumscribed Asymmetric, infiltrative in many subtypes Tellechea et al. 2015
Clefts Within the stroma and between stroma and dermis Between tumor nests and mucinous stroma Tellechea et al. 2015
Stroma Cellular, fibrocytic, with papillary mesenchymal bodies; stromal CD10 and CD34 Mucinous; epithelial CD10 more frequent Tellechea et al. 2015; Leblebici et al. 2019; Wiedemeyer et al. 2026
Merkel cells Scattered CK20-positive Merkel cells Significantly less frequent Leblebici et al. 2019
PHLDA1 (TDAG51) Positive; 100% specific for trichoblastoma against basal cell carcinoma in one series; positive in all desmoplastic trichoepitheliomas Negative in all morpheaform basal cell carcinomas Leblebici et al. 2019; Sellheyer et al. 2013
Bcl-2 and androgen receptor Bcl-2 negative; androgen receptor less frequent Bcl-2 positive; androgen receptor more frequent Tellechea et al. 2015; Leblebici et al. 2019
BerEP4 Positive in trichoblastoma and in 16 of 21 desmoplastic trichoepitheliomas Positive in all morpheaform basal cell carcinomas Sellheyer et al. 2013; Wiedemeyer et al. 2026

BerEP4 does not separate desmoplastic trichoepithelioma (16 of 21 positive) from morpheaform basal cell carcinoma (17 of 17 positive) (Sellheyer et al. 2013). On a partial biopsy, CK15 positivity and scattered CK20-positive cells favor trichoblastoma (Tellechea et al. 2015). Rombo syndrome (autosomal dominant) and Bazex–Dupré–Christol syndrome (X-linked) combine multiple trichoepitheliomas with atrophoderma vermiculatum, milia, hypotrichosis and basal cell carcinoma (Tellechea et al. 2015).

Pilomatricoma and pilomatrical carcinoma

  • Clinical features. Pilomatricoma is the most common adnexal tumor in children. It is a firm to hard dermal or subcutaneous nodule of the head, neck and upper limbs. Multiple tumors occur in myotonic dystrophy and in familial adenomatous polyposis (Gardner syndrome) (Tellechea et al. 2015).
  • Histology. A circumscribed nodule with a pseudocapsule contains peripheral basophilic matrical cells without palisading and central ghost (shadow) cells, with abrupt or gradual transition. Older lesions show calcification, occasional ossification and a foreign-body giant cell reaction that can replace the tumor (Tellechea et al. 2015).
  • Molecular findings. At least 75% of pilomatricomas carry activating CTNNB1 mutations in the amino-terminal degradation domain. Nuclear LEF1 in the dividing cells indicates hair matrix origin (Chan et al. 1999). Germinative matrical cells in matrical tumors show nuclear β-catenin with LEF1 and PHLDA1 expression and are CK17-negative (Battistella et al. 2014).
  • Pilomatrical carcinoma. It arises from a pilomatricoma or de novo. In a review of 101 published cases, recurrence followed 34.5% of standard excisions and none of 17 Mohs procedures, with a mean follow-up of about 7.5 months (Riva et al. 2025). In a prospective French registry, pilomatrical carcinoma belonged to the low-recurrence group of adnexal carcinomas (Zagala et al. 2026).

Trichilemmoma, desmoplastic trichilemmoma and Cowden syndrome

  • Trichilemmoma. A folliculocentric lobular proliferation of clear PAS-positive isthmic cells with peripheral palisading on a thickened hyaline basement membrane, often with squamous eddies (Tellechea et al. 2015). Sporadic tumors carry HRAS mutations (Goldman-Lévy et al. 2026).
  • Desmoplastic trichilemmoma. Sclerotic stroma dissects the lobules and produces a pseudoinvasive pattern. Clefting, atypia and apoptosis are absent. BerEP4 negativity and CD34 positivity separate it from basal cell carcinoma on superficial biopsies (Tellechea et al. 2015). It also arises in nevus sebaceus (Wiedemeyer et al. 2026).
  • Cowden syndrome criterion. Three or more trichilemmomas, at least one biopsy-proven, form one major criterion of the revised PTEN hamartoma tumor syndrome criteria. An individual diagnosis requires three or more major criteria, one of which must be macrocephaly, Lhermitte–Duclos disease or gastrointestinal hamartomas, or two major and three minor criteria. Germline PTEN variants are found in 30%–35% of patients who meet consortium criteria (Pilarski 2019).
  • Solitary trichilemmoma. None of 95 patients with trichilemmoma or related lesions met clinical criteria for Cowden syndrome. Reduced PTEN staining was seen in 13.5% of sporadic lesions, so PTEN immunohistochemistry does not establish the syndrome (Jin et al. 2013).

Fibrofolliculoma, trichodiscoma and Birt–Hogg–Dubé syndrome

  • Histology. Fibrofolliculoma is a vertically oriented papule centered on a follicular infundibulum from which thin anastomosing epithelial cords, sometimes with sebocytes, radiate into an abundant mucinous stroma. Trichodiscoma is horizontally oriented and stroma-dominant, with peripheral epithelial cords and a stroma devoid of elastic fibers. The two patterns often coexist in one lesion (Tellechea et al. 2015).
  • Birt–Hogg–Dubé syndrome. An autosomal dominant syndrome caused by FLCN (folliculin) on 17p11.2, with a second somatic hit in tumors. Cutaneous lesions are fibrofolliculomas, trichodiscomas and acrochordons. More than 80% of patients develop bilateral lower-zone subpleural lung cysts with risk of spontaneous pneumothorax, and renal cell carcinoma risk is increased (Ntinidi et al. 2025). Renal tumors include oncocytoma and chromophobe, papillary and clear cell carcinomas (Tellechea et al. 2015).
  • Frequency. Prevalence is commonly estimated at 1 in 200,000. Loss-of-function FLCN variants were found in 1 in 4190 to 1 in 2710 individuals in UK genomic registries (Ntinidi et al. 2025).

Dilated pore, pilar sheath acanthoma, trichoadenoma, tumor of the follicular infundibulum and trichofolliculoma

Tumor Diagnostic features Main mimic and distinction Source
Dilated pore (Winer) Vertical infundibulocystic cavity filled with lamellar orthokeratin; wall with regular elongated infundibular rete ridges Pilar sheath acanthoma (radiating lobules with horn cysts and isthmic cells) Tellechea et al. 2015
Pilar sheath acanthoma Vertical cyst opening to the surface (upper lip, central face) with radiating lobules of infundibular or isthmic pale cells, small horn cysts and occasional sebocytes Dilated pore; trichofolliculoma (secondary follicles producing vellus hairs) Tellechea et al. 2015
Trichoadenoma Horizontal dermal nodule of large infundibulocystic structures in scant stroma (epithelium-to-stroma ratio about 10:1), no calcification Desmoplastic trichoepithelioma (dense stroma, germinative cells, calcification); microcystic adnexal carcinoma (asymmetry, deep extension, perineural invasion) Tellechea et al. 2015
Tumor of the follicular infundibulum Subepidermal horizontal plate of pale PAS-positive keratinocytes with peripheral palisading and a network of elastic fibers at its base; CK5/6 positive; BerEP4, Bcl-2, CK7 and CK20 negative Superficial basal cell carcinoma (clefts, atypia, BerEP4 and Bcl-2 positive) Tellechea et al. 2015
Trichofolliculoma Central depression with emerging hairs; dilated infundibulum from which secondary follicles radiate and produce vellus hairs Folliculosebaceous cystic hamartoma (sebaceous lobules and stromal adipocytes) Tellechea et al. 2015

Sebaceous adenoma and sebaceoma

Feature Sebaceous adenoma Sebaceoma Source
Clinical Solitary yellow or tan papule of about 5 mm on the head and neck of older adults (mean age about 69 years); often mistaken for basal cell carcinoma Skin-colored or yellow nodule of 5–20 mm; median age 70 years in one series Wiedemeyer et al. 2026
Architecture Circumscribed lobules with central mature sebocytes and an expanded peripheral germinative layer; organoid maturation Uni- or multilobular; mature sebocytes haphazardly distributed; rippled, labyrinthine or carcinoid-like patterns in about one quarter Wiedemeyer et al. 2026
Germinative (basaloid) cells <50% of tumor cells >50% of tumor cells Wiedemeyer et al. 2026
Atypia, mitoses, necrosis Minimal atypia, low mitotic activity, no necrosis Mitoses can be brisk; no atypical mitoses, pleomorphism or necrosis Wiedemeyer et al. 2026
Immunohistochemistry EMA in mature sebocytes, nuclear androgen receptor, cytoplasmic PRAME, adipophilin around lipid vacuoles, BerEP4 usually negative Same panel; CK7, GATA3 and GATA6 positive; CK20 negative Wiedemeyer et al. 2026
Treatment Excision is curative Recurrence and progression risk after complete excision negligible Wiedemeyer et al. 2026

Sebaceous hyperplasia is an increase of normal-appearing sebaceous lobules without architectural or cytologic abnormality. It does not define Muir–Torre syndrome (Wiedemeyer et al. 2026).

Muir–Torre syndrome and mismatch repair testing of sebaceous neoplasms

  • Definition. Muir–Torre syndrome is a phenotypic variant of Lynch syndrome defined by at least one sebaceous neoplasm (sebaceous adenoma, sebaceoma or extraocular sebaceous carcinoma) and at least one Lynch syndrome-related visceral malignancy, synchronous or metachronous (Wiedemeyer et al. 2026).
  • Genetics. MSH2 is the most frequently mutated gene (68%–93% of cases), ahead of MLH1 and MSH6. MUTYH-associated polyposis is also listed among the syndromic associations of mismatch repair-deficient sebaceous adenoma and sebaceoma. Muir–Torre syndrome is present in about 28% of Lynch syndrome families and 9.2% of individuals with Lynch syndrome (Wiedemeyer et al. 2026). EPCAM 3′ deletions that silence MSH2 are taught in Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing.
  • Tumors. Sebaceous adenoma is the most common cutaneous lesion (about 67% of patients), and sebaceoma has been suggested as the most predictive. Sebaceous lesions present at a mean age of 53 years and precede or accompany the first visceral cancer in 9%–52% of patients. Sebaceous hyperplasia, periocular sebaceous carcinoma and nevus sebaceus do not define the syndrome (Wiedemeyer et al. 2026).
  • Clinical clues. Multiple sebaceous tumors, tumors outside the head and neck and onset before 50 years are strongly associated with the syndrome (Wiedemeyer et al. 2026).
  • Morphologic clues to mismatch repair deficiency. Cystic change, keratoacanthoma-like architecture, intratumoral mucin, squamous metaplasia, tumor-infiltrating lymphocytes, intertumoral heterogeneity, absent epidermal connection and a peripheral collarette (Wiedemeyer et al. 2026).
  • Immunohistochemistry. MLH1, MSH2, MSH6 and PMS2 immunohistochemistry should be considered on all sebaceous tumors except periocular sebaceous carcinoma. Loss of at least one protein raises suspicion of the syndrome, which remains a clinical diagnosis. BRAF p.V600E is essentially absent from sebaceous neoplasms, and somatic MLH1 promoter hypermethylation is not a major mechanism in them, so neither test separates sporadic from syndromic tumors as in colorectal cancer (Wiedemeyer et al. 2026). National Comprehensive Cancer Network guidelines classify sebaceous carcinoma as a Lynch syndrome-related neoplasm and recommend mismatch repair screening of all sebaceous neoplasms regardless of age (Wiedemeyer et al. 2026).
  • Mayo Muir–Torre risk score. The score combines age at the first sebaceous neoplasm, the number of sebaceous neoplasms, a personal history of a Lynch-related cancer and a family history of Lynch-related cancers. Points: age <60 years at the first sebaceous neoplasm, 1; two or more sebaceous neoplasms, 2; personal history of a Lynch-related cancer, 1; family history of a Lynch-related cancer, 1 (Bagga et al. 2023). Muir–Torre syndrome was present in 28 of 29 patients scoring 3 or more, in 12 of 20 scoring 2 and in no patient scoring 0 or 1. Abnormal mismatch repair immunohistochemistry of a sebaceous neoplasm was a poor predictor of Lynch syndrome (Roberts et al. 2014).
  • Testing strategy. In 123 unselected sebaceous neoplasms, 70.7% lost at least one mismatch repair protein. Immunohistochemistry detected all 13 patients with confirmed syndrome (sensitivity 100%, specificity 34.1%), and the Mayo score had a sensitivity of 92% and specificity of 89%. The authors favored the Mayo score first, followed by immunohistochemistry. Two of the 13 patients with confirmed syndrome scored only 1 point (Sinson et al. 2023).

Sebaceous carcinoma: periocular and extraocular tumors

  • Epidemiology. Incidence is about 1–2 per million and has risen since the 1970s. Men are affected about twice as often as women overall. Periocular tumors are more frequent in women and extraocular tumors in men. Median age at diagnosis is 73–79 years. Periocular sebaceous carcinoma accounts for about 30% of eyelid malignancies in India and East Asia and 1.5%–5% in Western countries. Risk factors include immunosuppression, ultraviolet radiation, prior radiotherapy (including for retinoblastoma) and high-risk HPV (Wiedemeyer et al. 2026).
  • Clinical features. Periocular tumors favor the upper eyelid (meibomian glands) and are often treated as chalazion or blepharoconjunctivitis. Extraocular tumors are firm, often ulcerated nodules of the head and neck, trunk, extremities or genitalia (Wiedemeyer et al. 2026).
  • Histology. An ill-defined nodular, lobular or diffusely infiltrative tumor of atypical basaloid cells with vesicular nuclei, prominent nucleoli and variable sebocytic differentiation with multivacuolated cytoplasm and scalloped nuclei. Mitoses are brisk with atypical forms, and comedo-type necrosis is classic. Periocular and some genital tumors show pagetoid intraepithelial spread. Lymphovascular and perineural invasion are reported in about 5%–20% (Wiedemeyer et al. 2026).
  • Immunohistochemistry. CK7, EMA, androgen receptor, adipophilin and PRAME are positive and BerEP4 is negative, with weaker staining in poorly differentiated tumors. Adipophilin can show only dot-like staining when lipid vacuoles are minimal. Patchy BerEP4 occurs, and strong diffuse BerEP4 suggests basal cell carcinoma. Ki-67 is about 25%–30% in sebaceous carcinoma and about 10% in sebaceoma (Wiedemeyer et al. 2026).
  • Molecular subgroups. Most carcinomas show biallelic TP53 inactivation with ZNF750 and/or RB1 mutations and chromosomal instability. HPV-driven tumors, mostly genital, are TP53 and RB1 wild-type. Periocular tumors are pauci-mutated with gains of 8q12.1 (PLAG1), 20q13.33 and 8q (MYC). Extraocular tumors include mismatch repair-deficient, ultraviolet- or APOBEC-driven and pauci-mutated subgroups (Wiedemeyer et al. 2026).
  • Prognosis. Five-year overall survival is about 78% for localized or regional disease and 50% for metastatic disease. Regional or distant metastasis occurs in up to 14%–25% (Wiedemeyer et al. 2026).
Mimic of sebaceous carcinoma Distinguishing findings Source
Basal cell carcinoma Peripheral palisading, retraction artifact, strong diffuse BerEP4; EMA, adipophilin and androgen receptor negative Wiedemeyer et al. 2026
Basaloid or clear cell squamous cell carcinoma Adipophilin and androgen receptor negative; CK7 absent or weak; p63, p40 and EMA positive in both Wiedemeyer et al. 2026
Squamous cell carcinoma in situ or HSIL (genital) Adipophilin negative; adipophilin is the most discriminating marker against intraepithelial sebaceous carcinoma Wiedemeyer et al. 2026
Endocrine mucin-producing sweat gland carcinoma (eyelid) Circumscribed cribriform or papillary tumor with mucin and mild atypia; androgen receptor, EMA and BerEP4 positive; INSM1, chromogranin, synaptophysin, CAM5.2, ER and PR positive Wiedemeyer et al. 2026
Hidradenoma with clear cells Glycogen-rich cytoplasm (PAS-positive, diastase-sensitive); adipophilin and androgen receptor negative; MAML2 rearrangement Wiedemeyer et al. 2026
Trichoblastoma (versus basaloid sebaceoma) Dense fibroblastic stroma with mesenchymal bodies; no sebaceous ducts; BerEP4 positive; EMA, androgen receptor, PRAME and adipophilin negative Wiedemeyer et al. 2026
Extramammary Paget disease Intracytoplasmic mucin (mucicarmine and PAS positive), GCDFP-15 positive, adipophilin negative Wiedemeyer et al. 2026
Merkel cell carcinoma Perinuclear dot-like keratin; INSM1, chromogranin and synaptophysin positive Wiedemeyer et al. 2026

Nevus sebaceus and its secondary neoplasms

  • Clinical features. Nevus sebaceus (of Jadassohn) is present in about 0.3% of newborns, most often on the scalp (66.4%) and face (26.1%) (Wiedemeyer et al. 2026).
  • Histology by age. Early lesions show mild acanthosis with immature pilosebaceous units. After puberty they show papillomatous epidermal hyperplasia, sebaceous gland hyperplasia, malformed sebaceous lobules, reduced terminal follicles and prominent ectopic apocrine glands (Wiedemeyer et al. 2026).
  • Genetics. It is a mosaic RASopathy caused by postzygotic HRAS (about 95%) or KRAS (about 5%) mutations. Schimmelpenning syndrome is the syndromic form (Wiedemeyer et al. 2026).
  • Secondary neoplasms. They arise in about 12.8% overall and retain the RAS mutation. Syringocystadenoma papilliferum and trichoblastoma are the most common, followed by trichilemmoma. Basal cell carcinoma occurs almost exclusively in adults, and trichoblastoma misdiagnosed as basal cell carcinoma inflated older estimates of malignant transformation (Wiedemeyer et al. 2026). Syringocystadenoma papilliferum arising in nevus sebaceus lacked BRAF mutation in one series (Shen et al. 2015).

Syringocystadenoma papilliferum, tubular adenoma and hidradenoma papilliferum

  • Syringocystadenoma papilliferum and tubular adenoma. Related tumors with an inner luminal and outer myoepithelial layer (SMA, calponin, SOX10 and p63) and tubulopapillary architecture. Most cases contain plasma cells in the papillary cores (MUM1 and CD138 positive). Both arise sporadically or in nevus sebaceus, and verrucous epidermal hyperplasia beside syringocystadenoma papilliferum carries the same BRAF mutation (Macagno et al. 2022).
  • Mutations. BRAF V600E was found in 12 of 23 (52%) sporadic syringocystadenomas papilliferum, HRAS in 6 of 23 and KRAS in 1, with BRAF and RAS mutations mutually exclusive (Shen et al. 2015). All 4 acral tubular adenomas in one series carried BRAF V600E (Kervarrec et al. 2023a).
  • Hidradenoma papilliferum. A benign tumor most common on the vulva, derived from anogenital mammary-like glands and histologically similar to mammary intraductal papilloma. PIK3CA or AKT1 activating mutations were found in 20 of 30 tumors (Liau et al. 2016).

Cylindroma, spiradenoma and CYLD cutaneous syndrome

  • Histology. Cylindroma is a non-encapsulated dermal tumor of basaloid "cylinders" arranged in a jigsaw pattern and separated by thickened basement membrane. Spiradenoma is a nodular, disorganized basophilic proliferation with lymphocytes. Spiradenocylindroma shows both patterns in one tumor (Nagy et al. 2021).
  • Immunohistochemistry. SOX10 is strongly expressed. Myoepithelial cells express calponin, SMA and p63, and luminal cells express CD117 (43%), EMA, CEA and cytokeratins. MYB is expressed and does not separate these tumors from adenoid cystic carcinoma. Spiradenoma contains CD3-positive lymphocytes and CD1a-positive Langerhans cells. Malignant transformation of spiradenoma is associated with higher Ki-67 and loss of MYB (Macagno et al. 2022).
  • Genetics. CYLD alterations were found in 15 of 15 cylindromas, 5 of 17 spiradenomas and 2 of 24 spiradenocarcinomas. A recurrent ALPK1 kinase-domain missense mutation, mutually exclusive with CYLD mutation, activates NF-κB in spiradenoma and spiradenocarcinoma. High-grade spiradenocarcinomas carry TP53 loss-of-function mutations (Rashid et al. 2019). MYB fusions define adenoid cystic carcinoma and were not detected in CYLD-defective cylindromas (Macagno et al. 2022).
  • CYLD cutaneous syndrome. Brooke–Spiegler syndrome, familial cylindromatosis and multiple familial trichoepitheliomas share autosomal dominant germline CYLD variants. Tumors appear at puberty and accumulate on the head and torso. Multiple cylindromas or spiradenomas, and multiple trichoepitheliomas with cylindromas, occur only in this syndrome. Malignant transformation is infrequent, and the resulting carcinomas can metastasize to liver, lung and bone. Membranous basal cell adenoma of the parotid gland and pulmonary cylindromas also occur (Nagy et al. 2021).

Syringoma

Syringoma consists of small ducts with tadpole or paisley-tie shapes, lined by two layers of cells, in a fibrotic stroma (Samia et al. 2021). It is more superficial than desmoplastic trichoepithelioma, shows ductal differentiation and lacks germinative cells and clefting within the stroma (Tellechea et al. 2015). Clinical forms are localized, disseminated (including eruptive), familial and Down syndrome-associated, and syringomas are also associated with diabetes mellitus (Samia et al. 2021). The clear cell variant of eyelid syringoma was associated with uncontrolled diabetes in 2 of 3 reported patients (Lin et al. 2023).

Poroma and porocarcinoma

  • Histology. Poroma contains poroid and cuticular cells with ductal differentiation. A dermal nodular poroma is termed poroid hidradenoma. Porocarcinoma is the malignant counterpart (Macagno et al. 2022).
  • Fusions. YAP1::MAML2 and YAP1::NUTM1 fusions were found in 92 of 104 poromas (88.5%) and 7 of 11 porocarcinomas (63.6%), and WWTR1::NUTM1 in one poroma (Sekine et al. 2019). Poromas with folliculo-sebaceous differentiation ("apocrine poroma") carry PAK2 fusions and lack YAP1 fusions (Kervarrec et al. 2023b). A subset of porocarcinomas without YAP1 rearrangement carries PAK1, PAK2 or PAK3 fusions, with HRAS mutations in 6 of 12 (Kervarrec et al. 2024).
  • Immunohistochemical surrogates. Loss of the C-terminal portion of YAP1 and nuclear NUT indicate a fusion. NUT immunohistochemistry has 100% specificity and 87% sensitivity for NUTM1 fusion and is most often positive in poroid hidradenoma. Neither marker separates poroma from porocarcinoma. Higher Ki-67 and aberrant p53, RB and p16 expression are more frequent in porocarcinoma (Macagno et al. 2022).

Hidradenoma and hidradenocarcinoma

Hidradenoma is a dermal nodule of clear, squamoid, ductal, oxyphilic and mucinous cells. It expresses p40, p63, CK5/6 and AE1/AE3, is usually S100- and SMA-negative, and shows EMA and CEA in ducts (Macagno et al. 2022). MAML2 rearrangement was found in 18 of 20 hidradenomas, and hidradenoma shares CRTC1::MAML2 with mucoepidermoid carcinoma (Russell-Goldman and Hanna 2022). Hidradenocarcinoma carries MAML2 rearrangement less often than hidradenoma, and a subset has TP53, AKT1 or PIK3CA mutations or HER2 amplification (Macagno et al. 2022). In acral sites, CRTC1::MAML2 was found in 9 of 12 hidradenomas and 9 of 12 hidradenocarcinomas (Kervarrec et al. 2023a). Clear cell myoepithelial tumors with EWSR1::POU5F1 can mimic hidradenoma (Macagno et al. 2022).

Cutaneous mixed tumor and myoepithelioma

  • Cutaneous mixed tumor (chondroid syringoma). An epithelial, myoepithelial and mesenchymal tumor with fibrous, myxoid, chondroid, lipomatous or osseous stroma, often with follicular or matrical differentiation; its homolog in salivary gland and breast is pleomorphic adenoma. PLAG1 is expressed in 87%–100% of cutaneous mixed tumors, and eccrine-type mixed tumors lack PLAG1 expression (Macagno et al. 2022).
  • Myoepithelioma. It is composed only of myoepithelial cells and lacks ducts. It expresses cytokeratins, S100 (70%–80%), SOX10 (30%–82%) and calponin (86%). About half of cutaneous cases show a syncytial sheet-like pattern with EWSR1::PBX3 and lack cytokeratin. Malignant cases are extremely rare (Macagno et al. 2022).

Microcystic adnexal carcinoma and sclerosing basaloid mimics

Microcystic adnexal carcinoma is a slow-growing, locally aggressive carcinoma of the sun-exposed head and neck with a high recurrence rate and low metastatic potential (Macagno et al. 2022; Aslam 2017). It is asymmetric and deeply infiltrative, with a vertical gradient of superficial keratinizing cysts, central solid aggregates and deep tubules. The superficial part resembles syringoma and basal cell carcinoma, so a superficial biopsy is often nondiagnostic (Macagno et al. 2022). The tumor extends along nerves, and diagnosis requires a deep full-thickness biopsy (Harnisch et al. 2026). Mohs surgery is recommended because subclinical extension causes recurrence after wide local excision (Aslam 2017).

Feature Microcystic adnexal carcinoma Desmoplastic trichoepithelioma Morpheaform basal cell carcinoma Source
Architecture Asymmetric; deep extension into fat or muscle; perineural invasion Symmetric discoid superficial dermal lesion with central depression Asymmetric infiltrative strands Tellechea et al. 2015; Macagno et al. 2022
Epithelial elements Keratinizing cysts, cords and deep ducts Thin basaloid cords, calcified keratocysts Basaloid strands with atypia, mitoses and apoptosis Tellechea et al. 2015; Samia et al. 2021
BerEP4 Positive in 0%–38% across series; all but 1 of 10 negative in one series Positive in 16 of 21 Positive in all Sellheyer et al. 2013; Compton et al. 2015; Tellechea et al. 2015
PHLDA1 Mixed Positive in all Negative in all Sellheyer et al. 2013
CK15 Mostly negative Positive in 20 of 21 Mostly negative Sellheyer et al. 2013
CK20-positive Merkel cells Absent Present in the epidermis in all cases Absent Mohanty et al. 2022; Tellechea et al. 2015
D2-40 Positive in all 6 cases Negative Negative Mohanty et al. 2022
p63 and Ki-67 Scattered p63 in the upper tumor, deep part often negative; Ki-67 <5% Ki-67 about 3% Diffuse p63; Ki-67 about 8% Macagno et al. 2022; Mohanty et al. 2022
Molecular TP53, JAK1 kinase-domain indels; CDKN2A loss; no ultraviolet signature in most; Hedgehog signaling not significantly altered CTNNB1, HRAS or PTCH1 mutations (trichoblastoma family) Hedgehog pathway activation Macagno et al. 2022; Goldman-Lévy et al. 2026

Because up to 38% of microcystic adnexal carcinomas are BerEP4-positive, BerEP4 separates them from morpheaform basal cell carcinoma only when negative (Compton et al. 2015).

Other primary adnexal carcinomas

Carcinoma Diagnostic features Immunohistochemistry and molecular findings Behavior Source
Mucinous carcinoma Tumor islands floating in mucin; incidence 0.07 per million; an in situ component with myoepithelial cells favors a primary tumor GCDFP-15 and mammaglobin shared with breast mucinous carcinoma; most are neuroendocrine (INSM1-positive) INSM1-positive cases had no lymphovascular invasion or metastasis; INSM1-negative cases metastasized to nodes in 2 of 3; associated breast and urothelial cancers Tinguria 2024; Adkins et al. 2023
Endocrine mucin-producing sweat gland carcinoma Circumscribed solid, cystic, papillary or cribriform nodule of monomorphic cells with salt-and-pepper chromatin and mucin; periocular in most of 253 reported patients; 57.7% female INSM1 (100%), synaptophysin (90%), chromogranin (71%), ER (98%), PR (96%), androgen receptor; preserved p63-positive myoepithelial layer Recurrence and metastasis rare; regarded as a precursor of neuroendocrine-type mucinous carcinoma Macagno et al. 2022; Cazzato et al. 2023
Adenoid cystic carcinoma Epithelial and myoepithelial cribriform tumor SOX10, CD117 (78%–100%), MYB (90%); MYB::NFIB or MYBL1::NFIB Infiltrative, with perineural spread Macagno et al. 2022; Harnisch et al. 2026
Digital papillary adenocarcinoma Acral sweat gland carcinoma HPV42 in most; mutually exclusive with MAML2, YAP1::NUTM1 and BRAF drivers of its mimics Metastasis in about 30% Sohier et al. 2025; Kervarrec et al. 2023a
Secretory carcinoma Intracytoplasmic secretory vacuoles and bubbly eosinophilic secretions Nuclear pan-TRK; SOX10, MUC4, S100, mammaglobin; p63 negative; ETV6::NTRK3 Eligible for TRK inhibitor therapy when advanced Macagno et al. 2022; Harnisch et al. 2026
Cribriform tumour (5th edition) Solid and cribriform eosinophilic cells with small lumina, no myoepithelial layer Apocrine differentiation No reported recurrence or metastasis Goldman-Lévy et al. 2026
Primary cutaneous NUT adnexal carcinoma (provisional) Dermal islands of poorly differentiated cells with large vesicular nuclei, prominent nucleoli, ducts and abrupt keratinization Diffuse nuclear NUT; SOX10 in 5 of 7; CEA and EMA in ductules; BRD3, NSD3 or BRD4 fused to NUTM1, or BRD3::NUTM2B; methylation profile distinct from extracutaneous NUT carcinoma Metastatic death in 1 of 6 with follow-up; diagnosis requires exclusion of metastasis and YAP1::NUTM1 poroid tumors Goldman-Lévy et al. 2026; Ho and Collie 2023; Legrand et al. 2025
Squamoid eccrine ductal carcinoma Superficial squamous component over deeper ductal component; superficial biopsies diagnosed as Bowen disease or squamous cell carcinoma EMA and CEA in ducts; CK7, p40, GATA3, CK5/6 and BerEP4 positive 9 of 10 patients immunocompromised; locoregional recurrence in 8 of 10; perineural invasion in 5 of 10 Tan et al. 2026

In a prospective registry of 980 skin adnexal carcinomas, adnexal carcinoma not otherwise specified, apocrine carcinoma, mucinous adenocarcinoma and squamoid eccrine ductal carcinoma had a 3-year cumulative recurrence rate of 29.3%. Low-grade trichoblastic carcinoma, pilomatrical carcinoma, proliferating trichilemmal tumor and digital papillary adenocarcinoma had a rate of 1.5% (Zagala et al. 2026).

Primary adnexal carcinoma versus adenocarcinoma metastatic to skin

p63, p40, D2-40, CK5/6 and CD117 in this distinction are tabulated in Vascular Anomalies and Vascular Tumors of Skin, Kaposi Sarcoma and Angiosarcoma, Cutaneous Histiocytic and Mast Cell Infiltrates, and Metastases to Skin.

Extramammary Paget disease: primary versus secondary

Primary extramammary Paget disease is an intraepidermal adenocarcinoma thought to arise from cells of adnexal structures. Secondary disease is epidermotropic spread of an underlying visceral carcinoma, most often anorectal or urothelial (Kiratikanon et al. 2025).

Marker Primary (n = 480) Colorectal secondary (n = 86) Urothelial secondary (n = 41) Source
CK7 98% 71% 100% Kiratikanon et al. 2025
CK20 22% 89% 83% Kiratikanon et al. 2025
CDX2 9% 96% 20% Kiratikanon et al. 2025
SATB2 14% (1 of 7) 83% 0% Kiratikanon et al. 2025
GATA3 100% 14% 100% Kiratikanon et al. 2025
GCDFP-15 68% 0% 15% Kiratikanon et al. 2025
TRPS1 90% 0% 0% Kiratikanon et al. 2025
p63 1% 0% 92% Kiratikanon et al. 2025
HER2 62.1% 0% 70% Kiratikanon et al. 2025
  • Panel. The proposed first panel is TRPS1, CK7 and CK20. In TRPS1-negative cases, CDX2 and SATB2 identify colorectal origin, p63, GATA3 and uroplakin II/III identify urothelial origin, and PSA and NKX3.1 identify prostatic origin. Perianal primary disease can lack TRPS1 (Kiratikanon et al. 2025).
  • Single-marker errors. CK20 is positive in 22% of primary cases. Uroplakin II/III was negative in 14 of 14 primary cases and positive in 71% of urothelial secondary cases. GATA3 is positive in both primary and urothelial secondary disease, and p63 separates them (Kiratikanon et al. 2025).
  • Pagetoid squamous cell carcinoma in situ and melanoma in situ. Diffuse nuclear p63 was present in 15 of 15 pagetoid squamous cell carcinomas in situ and in 0 of 15 extramammary Paget disease cases. CK7 was positive in 93% of extramammary Paget disease and positive in 13% and partially positive in 47% of pagetoid squamous cell carcinomas in situ (Wieland et al. 2023). Primary extramammary Paget disease was S100-negative in 22 of 22 cases (Kiratikanon et al. 2025). The melanocytic-marker distinction from melanoma in situ is tabulated in Benign Epidermal Tumors, Cutaneous Cysts, Actinic Keratosis and Squamous Cell Carcinoma In Situ.

Mammary Paget disease and nipple adenoma in skin biopsies of the nipple

Nipple adenoma histology and immunohistochemistry are taught in Papillary Neoplasms, Adenomyoepithelioma and Nipple Lesions of the Breast, and mammary Paget disease in Paget Disease of the Nipple, Inflammatory Carcinoma, Male Breast Carcinoma and Hereditary Breast Cancer.

Lesion of nipple skin Distinguishing findings Source
Mammary Paget disease Intraepidermal carcinoma cells; CK7 and CAM5.2 positive in all; diffuse nuclear p63 absent (0 of 15); TRPS1 expressed Wieland et al. 2023; Kiratikanon et al. 2025
Pagetoid squamous cell carcinoma in situ Diffuse nuclear p63 in 15 of 15; CK7 positive in 13% and partial in 47%; CAM5.2 positive in none and partial in 20% Wieland et al. 2023
Nipple adenoma Dense ductal proliferation close to the nipple epidermis, clinically mistaken for Paget disease or squamous cell carcinoma; no recurrence in 44 patients followed for a median of 66 months; simple excision is curative Weigelt et al. 2023
Nipple adenoma (immunohistochemistry) Ducts keep a dual epithelial and myoepithelial layer without atypia; p63 confirms the myoepithelial cells Cha et al. 2026

Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma

Definition and classification. The WHO Classification of Skin Tumours, 5th edition (Skin5), covers mesenchymal tumors that arise in the dermis and superficial subcutis (Goldman-Lévy et al. 2026). The WHO Classification of Tumours of Soft Tissue and Bone, 6th edition (STB6, 2026), postdates Skin5 and changes several dermal entities (Hornick et al. 2026).

Related page: Molecular and Ancillary Testing of Soft Tissue FNA Material (soft tissue fusion testing methods, including COL1A1::PDGFB detection) Related page: Benign Soft Tissue Tumors on FNA (benign soft tissue tumors on FNA) Related page: The WHO Reporting System for Soft Tissue Cytopathology and the Approach to Soft Tissue FNA (WHO reporting system for soft tissue cytopathology) Related page: Round Cell, Spindle Cell and Pleomorphic Sarcomas on FNA (FNCLCC grading of sarcomas) Related page: Renal Cell Carcinoma and Oncocytic Renal Tumors (FH-deficient renal cell carcinoma in hereditary leiomyomatosis and renal cell cancer syndrome) Related page: Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes (MEN1, and the mucosal neuromas of MEN2B) Related page: Adrenal Cortex Pathology: Hyperplasia and Nodular Disease, Adrenalitis and Hemorrhage, Adrenal Cortical Adenoma and Carcinoma, Myelolipoma, Cysts and Metastases (Carney complex and PRKAR1A) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (gastric glomus tumor) Related page: Keratoacanthoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma and Merkel Cell Carcinoma: Subtypes, Risk Stratification, Staging, CAP Reporting and Mohs Surgery (spindle cell squamous cell carcinoma in the differential diagnosis of atypical fibroxanthoma) Related page: Vascular Anomalies and Vascular Tumors of Skin, Kaposi Sarcoma and Angiosarcoma, Cutaneous Histiocytic and Mast Cell Infiltrates, and Metastases to Skin (vascular tumors, angiosarcoma and juvenile xanthogranuloma) Related page: Spitz Tumors, Melanocytomas and Ancillary Testing of Melanocytic Lesions (MITF pathway-activated melanocytic tumours with ACTIN::MITF and MITF::CREM)

Classification changes for dermal mesenchymal tumors in WHO Skin 5th and Soft Tissue and Bone 6th editions

Skin5 changes, with the previous WHO 4th-edition rule:

Entity WHO Skin 5th edition (Skin5) Previous rule (WHO 4th edition) Source
EWSR1::SMAD3-rearranged fibroblastic tumour, NTRK-rearranged spindle cell neoplasm, superficial CD34-positive fibroblastic tumour, CRTC1::TRIM11 cutaneous tumour New entities Absent from the 4th edition Goldman-Lévy et al. 2026
Atypical intradermal smooth muscle neoplasm Preferred term for dermal smooth muscle tumors with atypia; leiomyosarcoma restricted to deeply located tumors Cutaneous leiomyosarcoma Goldman-Lévy et al. 2026
Epithelioid fibrous histiocytoma Tumour of uncertain differentiation Fibroblastic, myofibroblastic and fibrohistiocytic tumours Goldman-Lévy et al. 2026
Myofibroma and myofibromatosis Pericytic and perivascular tumours Fibroblastic, myofibroblastic and fibrohistiocytic tumours Goldman-Lévy et al. 2026
Myxofibrosarcoma Fibroblastic, myofibroblastic and fibrohistiocytic neoplasms, based on smooth muscle actin expression Tumour of uncertain differentiation Goldman-Lévy et al. 2026

STB6 (2026) changes that affect tumors seen in the dermis:

Skin5 or previous term STB6 (2026) change Source
EWSR1::SMAD3-rearranged fibroblastic tumour Renamed SMAD3-rearranged fibroblastic tumor, to allow fusion partners from other FET-family genes Hornick et al. 2026
Superficial CD34-positive fibroblastic tumour Renamed superficial CD34-positive pleomorphic fibroblastic tumor, because pleomorphism aids recognition and causes confusion with pleomorphic sarcomas Hornick et al. 2026
NTRK-rearranged spindle cell neoplasm (emerging entity) Expanded to kinase-altered spindle cell neoplasms, which include other kinase fusions and point mutations Hornick et al. 2026
Myofibroma, "atypical cellular variant" A subset reclassified as SRF-rearranged myoid neoplasm, a new pericytic tumor type Hornick et al. 2026
Deep fibrous histiocytoma Removed from the soft tissue volume because it is a subtype of cutaneous benign fibrous histiocytoma (dermatofibroma), which the skin volume classifies Hornick et al. 2026
Atypical fibroxanthoma No longer included in the soft tissue volume Hornick et al. 2026
Adult fibrosarcoma Removed; former cases are reclassified with contemporary methods, for example as fibrosarcomatous DFSP, monophasic synovial sarcoma or MPNST Hornick et al. 2026

Acrochordon, fibrous papule and angiofibromas in tuberous sclerosis complex and MEN1

  • Acrochordon (skin tag). Acrochordons are associated with insulin resistance, hormonal dysregulation and genodermatoses. Whole-exome sequencing found activating FGFR3 hotspot mutations in 3 of 5 acrochordons, with PIK3CA, HRAS, KRAS and BRAF mutations in others (Jia et al. 2025). Acrochordons (fibroepithelial stromal polyps) arise in intertriginous skin and rarely exceed 1–5 mm. Acrochordons have a central vascular core, and giant pedunculated lesions show a flat squamous epidermis, an intermediate layer of loose collagen and a core of mature fat (Ahkami et al. 2025). Acrochordons occur in 23% of patients with tuberous sclerosis complex (Cascarino and Leclerc-Mercier 2021).
  • Angiofibroma and fibrous papule. Angiofibromas are skin-colored to red-brown papules of the central face. Histology shows a dome-shaped lesion with normal or hyperplastic epidermis, hypertrophy of dermal collagen and vessels with widely dilated venules, increased oval or stellate stromal cells, decreased elastic tissue and a tendency to concentric perifollicular collagen; older lesions are more sclerotic. Sporadic fibrous papules of the face share these histologic features (Cascarino and Leclerc-Mercier 2021).
  • Tuberous sclerosis complex. In the consensus criteria tabulated from the 2012 conference, four of the 11 major criteria are cutaneous: hypomelanotic macules, angiofibromas (≥3) or fibrous cephalic plaque, ungual fibromas (≥2) and shagreen patch. One or two isolated angiofibromas can occur in the general population. Shagreen patches are collagenomas (Cascarino and Leclerc-Mercier 2021).
  • MEN1. Multiple facial angiofibromas were found in 28 of 32 patients (88%) with MEN1 and were clinically and histologically identical to those of tuberous sclerosis. Collagenomas were found in 72% and lipomas in 34%. Multiple angiofibromas are therefore not pathognomonic for tuberous sclerosis (Darling et al. 1997).

Dermatofibroma (benign fibrous histiocytoma): histology and immunophenotype

  • Frequency and clinical features. Dermatofibroma accounts for about 3% of skin specimens in dermatopathology laboratories. In 192 lesions it was more common in women (median age 48 years) and occurred on the limbs in 74%. Many lesions follow minor trauma such as insect bites. Eruptive lesions occur with immunosuppression, HIV infection, antiretroviral therapy and pregnancy. Simple excision is usually curative, with local recurrence below 2% (Alves et al. 2014).
  • Histology. The common type is an unencapsulated, ill-defined dermal lesion of interlacing spindle cell fascicles with focal storiform areas, admixed foamy or multinucleated macrophages and vessels. A grenz zone was present in 55% of common lesions. Lesional cells surround individual collagen bundles at the periphery (collagen trapping) (Alves et al. 2014).
  • Epidermal induction. The overlying epidermis shows hyperkeratosis, acanthosis or pseudoepitheliomatous hyperplasia with basal hyperpigmentation. Follicle-like proliferations can mimic basal cell carcinoma (Alves et al. 2014).
  • Immunophenotype. Factor XIIIa is generally positive and CD34 usually negative in dermatofibroma, with exceptions in both directions. CD34 and factor XIIIa remained the most reliable pair for separating dermatofibroma from DFSP; S100A6 was negative and p75 was weakly positive only in about half of DFSPs (West et al. 2014). In cellular fibrous histiocytoma, factor XIIIa often highlights non-neoplastic background cells, and CD34 is negative or focal at the periphery (Alves et al. 2014).
Variant Diagnostic features Behavior Source
Aneurysmal Blue-brown nodule; blood-filled cleft-like and cystic spaces without endothelial lining; hemosiderin; subcutis involved in 82% Local recurrence about 19% Alves et al. 2014
Hemosiderotic Numerous small vessels, extravasated erythrocytes and hemosiderin; probably a stage of the aneurysmal variant Clinical mimic of melanoma Alves et al. 2014
Cellular Fascicular, highly cellular, often extends into the subcutis; central necrosis possible; focal SMA; CD34 negative or peripheral Local recurrence up to 26%; rare nodal and lung metastasis Alves et al. 2014
Atypical (pseudosarcomatous) Pleomorphic plump spindle and polyhedral cells with bizarre nuclei on a background of classic fibrous histiocytoma with peripheral collagen trapping; 1–15 mitoses per 10 high-power fields; atypical mitoses in 20 of 59 3 local recurrences and 2 distant metastases among 21 patients with follow-up Kaddu et al. 2002
Lipidized ("ankle-type") Yellow exophytic nodule; foamy macrophages encircled by sclerotic collagen; not linked to hyperlipidemia No recurrence in limited follow-up Alves et al. 2014
Atrophic Dermal atrophy with sclerotic collagen and low cellularity; scar-like depression Probably an end stage of common type Alves et al. 2014
Deep fibrous histiocytoma Well-circumscribed subcutaneous or deep tumor; diffuse storiform pattern; hemangiopericytoma-like vessels in 42%; CD34 in 40% Local recurrence 22%; metastasis in 2 of 37 with follow-up Gleason and Fletcher 2008

Clear cell fibrous histiocytoma is a very rare variant of sheets of clear cells with vesicular nuclei in the reticular dermis, sometimes extending into the subcutis, with rare atypia and mitoses; it is separated from clear cell sarcoma and metastatic renal cell carcinoma (Alves et al. 2014).

Epithelioid fibrous histiocytoma and ALK rearrangement

Epithelioid fibrous histiocytoma presents as a polypoid red nodule, usually on the limbs, that clinically resembles pyogenic granuloma. It is a well-demarcated papillary and superficial reticular dermal lesion with an epidermal collarette and usually no grenz zone. By definition at least 50% of the lesion consists of epithelioid cells with abundant eosinophilic cytoplasm, and the cells are negative for S100 protein, Melan-A and HMB45, which separates it from Spitz nevus (Alves et al. 2014). Diffuse cytoplasmic ALK expression was found in 29 of 33 epithelioid fibrous histiocytomas (88%), and all 13 ALK-positive cases tested by FISH showed ALK rearrangement. Conventional, cellular, atypical and aneurysmal fibrous histiocytomas, cutaneous syncytial myoepitheliomas and atypical fibroxanthomas were ALK-negative (Doyle et al. 2015). Skin5 reclassifies the tumor among tumours of uncertain differentiation (Goldman-Lévy et al. 2026).

Dermatofibrosarcoma protuberans: clinical features, histology and genetics

  • Clinical features. DFSP begins as a slow-growing, firm, painless dermal plaque, subcutaneous thickening or atrophic non-protuberant lesion and later becomes protuberant. Congenital DFSP presents as an atrophic plaque or a pigmented macule resembling a nevus. Most tumors arise on the trunk (40%–50%), then the proximal extremities (30%–40%) and the head and neck (10%–15%). The annual incidence in the United States was 4.1–4.2 per million (Hao et al. 2020).
  • Histology. Uniform spindle cells grow in a storiform pattern, infiltrate the dermis and subcutis, and surround fat cells in a honeycomb pattern. In early plaque-stage lesions, elongated spindle cells are scattered in the upper dermis (Hao et al. 2020; Remiszewski et al. 2025).
  • Immunophenotype. Spindle cells show strong diffuse CD34 and are negative for smooth muscle actin, factor XIIIa, S100 protein and Melan-A (Hao et al. 2020). CD34 is not specific; it also stains spindle cell lipoma and solitary fibrous tumor (Remiszewski et al. 2025).
  • Genetics. More than 90% of DFSPs carry t(17;22)(q22;q13) or supernumerary ring chromosomes derived from it, which create COL1A1::PDGFB. The fusion places PDGFB exon 2 next to one of COL1A1 exons 6–49 and is detected by FISH or multiplex RT-PCR on paraffin tissue (Hao et al. 2020; Remiszewski et al. 2025). Rare tumors carry COL1A2::PDGFB (Remiszewski et al. 2025). Alternative PDGFD fusions (PDGFD::COL6A3, PDGFD::EMILIN2, PDGFD::TNC) favor the chest of women, subcutaneous location and circumscribed nodular growth without the honeycomb pattern. Their immunophenotype and prognosis match conventional DFSP (Kalmykova et al. 2024).
  • Imatinib. The fusion creates an autocrine PDGFB loop through PDGF receptor beta. Imatinib inhibits this receptor and is used for unresectable, locally advanced or metastatic DFSP, ideally after molecular confirmation (Hao et al. 2020; Remiszewski et al. 2025).
  • Surgery and recurrence. DFSP is a locally aggressive tumor with subclinical spread and rare metastasis. Wide local excision with 2–4-cm margins including the investing fascia, or Mohs micrographic surgery with examination of 100% of the margin, is the primary treatment. Mohs surgery significantly lowered recurrence compared with wide local excision in multiple studies (Hao et al. 2020).
DFSP subtype Diagnostic features Source
Plaque-stage (early) Spindle cells scattered in the upper dermis without involving the grenz zone; strong diffuse CD34 Hao et al. 2020
Myxoid Spindle cells in myxoid stroma; CD34 positive; smooth muscle actin and desmin negative Hao et al. 2020
Pigmented (Bednar tumor) Scattered dendritic melanin-containing cells among CD34-positive spindle cells; pigmented cells S100 and HMB45 positive Hao et al. 2020
Giant cell fibroblastoma Mainly children; wavy spindle cells, dense sclerosis and pseudovascular spaces rimmed by pleomorphic giant cells; same genetic alteration as DFSP, and recurrences show DFSP histology Hao et al. 2020
Sclerotic Spindle cells in hypocellular collagen occupying more than half of the tumor; CD34 positive Hao et al. 2020
Atrophic Thinned dermis with a depressed plaque; CD34 positive Remiszewski et al. 2025
Fibrosarcomatous About 13.5% of DFSPs; fascicular or herringbone atypical spindle cells with increased mitoses, occasional necrosis, higher Ki-67, and reduced or lost CD34 in up to 45% Hao et al. 2020
  • Prognosis of fibrosarcomatous change. In 24 reports (1422 DFSP, 225 fibrosarcomatous DFSP), fibrosarcomatous DFSP had higher local recurrence (29.8% versus 13.7%), metastasis (14.4% versus 1.1%) and death from disease (14.7% versus 0.8%). Outcomes did not differ with the proportion of fibrosarcomatous change, so even a small fibrosarcomatous component indicates a worse outcome (Liang et al. 2014). In 10 recurrent or fibrosarcomatous DFSPs, CD34 was diffuse in 6, partial in 1 and lost in 3, and all retained COL1A1::PDGFB or PDGFB rearrangement, so molecular testing confirms the diagnosis when morphology and CD34 are atypical (Chen et al. 2026).

Dermatofibroma versus DFSP and other CD34-positive dermal lesions

Feature or lesion Dermatofibroma DFSP Plaque-like CD34-positive dermal fibroma Source
Architecture Ill-defined dermal fascicles with focal storiform areas; mixed cells including macrophages and giant cells Monotonous storiform spindle cells Cellular band-like fibroblastic proliferation in the papillary and upper reticular dermis Alves et al. 2014; Hao et al. 2020; Kutzner et al. 2010
Edge and subcutis Peripheral collagen trapping; superficial subcutis in 31% Honeycomb infiltration of fat Usually confined to the upper dermis Alves et al. 2014; Hao et al. 2020; Kutzner et al. 2010
Clinical and epidermal features Small raised hyperkeratotic red-brown nodule; epidermal hyperplasia with basal hyperpigmentation Plaque that becomes protuberant; grenz zone spared in plaque stage Slightly pigmented, indurated plaque on the neck, trunk or extremities Alves et al. 2014; Hao et al. 2020; Kutzner et al. 2010
CD34 and factor XIIIa CD34 negative or focal; factor XIIIa positive CD34 strong and diffuse; factor XIIIa negative CD34 positive West et al. 2014; Kutzner et al. 2010
Genetics Not defined by a fusion; cytogenetic evidence of t(17;22) favors DFSP over cellular fibrous histiocytoma COL1A1::PDGFB in more than 90% COL1A1::PDGFB absent by FISH and RT-PCR Alves et al. 2014; Hao et al. 2020; Kutzner et al. 2010

Plaque-like CD34-positive dermal fibroma, a congenital or acquired plaque, was formerly called medallion-like dermal dendrocyte hamartoma. The descriptive name was proposed because the lesion is neither of dermal dendrocyte lineage nor a true hamartoma. FISH was more reliable than RT-PCR on archival tissue, and RNA from blocks older than 4 years did not amplify (Kutzner et al. 2010). Other CD34-positive mimics of DFSP are solitary fibrous tumor (STAT6 positive), intradermal spindle cell lipoma (Rb loss) and neurofibroma (S100 and SOX10 positive, with CD34-positive fibroblasts) (Hao et al. 2020).

Atypical fibroxanthoma and pleomorphic dermal sarcoma

  • Clinical features. Both tumors present as nonspecific, often ulcerated, skin-colored nodules on chronically sun-damaged skin of elderly men, most often on the head and neck. Atypical fibroxanthoma (AFX) is well demarcated. Pleomorphic dermal sarcoma (PDS) is poorly circumscribed and infiltrative (Helbig et al. 2022; Klein et al. 2025).
  • Histology. Both consist of pleomorphic spindle and epithelioid cells with atypical multinucleated giant cells, and atypical mitoses are common (Helbig et al. 2022).
  • Definition of PDS. AFX is confined to the dermis. PDS involves relevant parts of the subcutis or shows tumor necrosis or perineural infiltration (Helbig et al. 2022). Subcutaneous invasion, tumor necrosis, lymphovascular invasion and perineural invasion are the high-risk features associated with PDS. A superficial biopsy generally cannot make the distinction (Klein et al. 2025). The term "pleomorphic dermal sarcoma" was introduced in 2012 for a dermal-based undifferentiated pleomorphic sarcoma that invades the subcutis (Klein et al. 2025).
  • Diagnosis of exclusion. AFX and PDS are poorly differentiated (grade 3) tumors, and cutaneous sarcomas, undifferentiated carcinomas and melanomas are excluded by immunohistochemistry (Helbig et al. 2022). In a meta-analysis of 45 studies (1516 tumors), CD10 was positive in 94% of AFX and 100% of PDS, and no marker separated AFX from PDS (Ørholt et al. 2022).
  • Molecular findings. AFX and PDS carry a high tumor mutational burden (about 40–70 mutations per megabase) dominated by UV-signature mutations. TP53 is mutated in almost 75% of sequenced tumors, TERT promoter mutations in 67% of tumors examined by targeted sequencing, FAT1 in 40% and CDKN2A in 35%. Loss of 9p is the most frequent copy number change (61%). DNA methylation profiles of AFX and PDS cannot be separated from each other (Klein et al. 2025).
  • Prognosis and treatment. The 5-year risks of local recurrence and metastasis are 17% and 16% for PDS, against 10% and 0.8% for AFX (Klein et al. 2025). Micrographically controlled surgery is the treatment of choice. Complete excision of AFX is assumed curative, and local recurrence of PDS is low after excision with a 2-cm safety margin. Metastasis is mostly associated with very thick or incompletely excised tumors and affects mainly skin and lymph nodes (Helbig et al. 2022).
Mimic of AFX and PDS Excluding markers (AFX and PDS negative) Source
Spindle cell (sarcomatoid) squamous cell carcinoma AE1/AE3, CK5/6, p63 Ørholt et al. 2022
Spindle cell or desmoplastic melanoma S100, SOX10 Ørholt et al. 2022
Leiomyosarcoma and atypical intradermal smooth muscle neoplasm Desmin, SMA Ørholt et al. 2022
Angiosarcoma CD31, ERG Ørholt et al. 2022

Acquired digital fibrokeratoma, superficial acral fibromyxoma, sclerotic fibroma and dermatomyofibroma

Entity Clinical setting Histology and immunophenotype Source
Acquired digital fibrokeratoma Small solitary skin-colored papule on a finger or toe, surrounded by a collar of slightly raised skin; minor trauma is a proposed trigger Dense collagen bundles oriented along the long axis of the lesion, few or absent elastic fibers, hyperkeratotic and acanthotic epidermis Navea et al. 2023
Superficial acral fibromyxoma Middle-aged adults, more often men; slow painless growth on the fingers and toes, mostly near the nail, including periungual and subungual sites Spindle-shaped fibroblasts in fibrous and myxoid stroma with sparse slender vessels; usually CD34 and CD99 positive and less often EMA positive; desmin negative in a reported case Yang et al. 2025
Sclerotic fibroma (storiform collagenoma) Multiple lesions in Cowden syndrome; solitary lesions without Cowden syndrome Paucicellular, well-circumscribed nodule of dense, thin collagen bundles separated by clefts in a storiform pattern; CD34 and SMA negative in a reported case Chapman et al. 1998; Kim et al. 2020
Dermatomyofibroma Young women (40 of 48 with known sex; median age 30 years); shoulder, upper arm and neck Ill-defined plaque-like dermal proliferation of bland spindle cells parallel to the epidermis; SMA in 11 of 48 and focal CD34 in 10 of 45; no recurrence in 38 cases with follow-up Mentzel and Kutzner 2009

Fusion-defined dermal mesenchymal tumors new in the WHO Skin 5th edition

Skin5 name (STB6 name) Clinical features Histology and immunophenotype Genetics Behavior Source
EWSR1::SMAD3-rearranged fibroblastic tumour (SMAD3-rearranged fibroblastic tumor) Dermal tumors with subcutaneous extension, strongly favoring the hands and feet (lower more than upper limbs); female predominance; all ages Cellular fascicles of bland monomorphic spindle cells with central acellular hyalinized zones; strong diffuse nuclear ERG equal to endothelium; CD34, CD31 and keratin negative EWSR1::SMAD3 required; EWSR1 break-apart FISH confirms Benign; recurs after incomplete excision Goldman-Lévy et al. 2026; Kalmykova et al. 2024; Hornick et al. 2026
NTRK-rearranged spindle cell neoplasm (kinase-altered spindle cell neoplasm) Deep dermis and subcutis; children more than adults Spectrum from cellular fibrous septa through fat (lipofibromatosis-like) to cellular fascicles; stromal and perivascular hyalinization, staghorn vessels; CD34, S100 and CD30 co-expression; pan-TRK sensitive but imperfectly specific NTRK1/2/3, BRAF, RAF1, RET, ALK, MET fusions and rare mutations Local recurrence 7%–26%, metastasis 5%–20%; high-grade tumors more aggressive; targeted therapy Goldman-Lévy et al. 2026; Kalmykova et al. 2024; Hornick et al. 2026
Superficial CD34-positive fibroblastic tumour (superficial CD34-positive pleomorphic fibroblastic tumor) Skin and subcutis of the lower extremity, especially the thigh Sheets of epithelioid or spindle cells with glassy eosinophilic cytoplasm, marked pleomorphism and nuclear pseudoinclusions but low mitotic rate; diffuse CD34 and CADM3 (SynCAM3); focal keratin in 70%–80%; WT1 (N-terminus) in about two-thirds PRDM10 fusions in about half Indolent; rare recurrence and nodal metastasis Goldman-Lévy et al. 2026; Kalmykova et al. 2024; Hornick et al. 2026
CRTC1::TRIM11 cutaneous tumour Well-defined dermal nodule of the distal extremities and trunk; more than 40 cases reported Fascicles and nests of epithelioid to spindle cells with prominent nucleoli and fewer than 5 mitoses per 10 high-power fields; no intraepidermal component; SOX10 diffuse, S100 in about 80%, HMB45 or Melan-A in about 80% CRTC1::TRIM11; absence of EWSR1 rearrangement excludes clear cell sarcoma Adverse events in 6 of 38 (local recurrence, nodal or lung metastasis) Goldman-Lévy et al. 2026; Kalmykova et al. 2024
  • Mimics of the fusion-defined tumors. Cellular fibrous histiocytoma can express ERG diffusely, but with weaker intensity than adjacent endothelium, which separates it from EWSR1::SMAD3-rearranged fibroblastic tumour (Kalmykova et al. 2024). Superficial CD34-positive fibroblastic tumour is misdiagnosed as undifferentiated pleomorphic sarcoma, pleomorphic liposarcoma, DFSP or myxoinflammatory fibroblastic sarcoma (Kalmykova et al. 2024). Clear cell sarcoma, a mimic of CRTC1::TRIM11 cutaneous tumour, carries EWSR1::ATF1 or EWSR1::CREB1 and shows wreath-like giant cells (Kalmykova et al. 2024).
  • MITF pathway-activated tumours. Tumours with ACTIN::MITF and MITF::CREM fusions are classified as melanocytomas in the melanocytic chapter of Skin5, and CRTC1::TRIM11 tumours are classified as malignant soft tissue tumours of uncertain differentiation. All three overexpress MITF (Kalmykova et al. 2024).

Cellular neurothekeoma, dermal nerve sheath myxoma and superficial angiomyxoma

Feature Cellular neurothekeoma Dermal nerve sheath myxoma Superficial angiomyxoma (cutaneous myxoma) Source
Patients and sites Female predominance (1.8:1); mean age 25 years, 84% under 40; upper limb 35%, head and neck 33% Mean age 36 years; 86% on the extremities, especially hand and fingers, knee and ankle Median age 45.5 years; trunk, head and neck, lower limbs Hornick and Fletcher 2007; Fetsch et al. 2005; Calonje et al. 1999
Architecture Lobulated or micronodular nests and bundles in the dermis, often extending into superficial fat Multilobular myxoid nodules with a peripheral fibrous border Poorly circumscribed lobules of myxoid stroma with numerous small vessels and acellular mucin pools Hornick and Fletcher 2007; Fetsch et al. 2005; Calonje et al. 1999
Cells Epithelioid to spindle cells with pale eosinophilic cytoplasm separated by hyaline collagen; osteoclastic giant cells in 15%; mild atypia Epithelioid, ring-like, spindled and stellate Schwann cells with cytoplasmic-nuclear invaginations Stellate and bipolar fibroblastic cells, muciphages and neutrophils; epithelial structures in about 20% Hornick and Fletcher 2007; Fetsch et al. 2005; Calonje et al. 1999
Immunophenotype NKI/C3 positive in all; S100, GFAP and Melan-A negative; SOX10 negative; SMA focal in 57%; MITF reported in most cases by some studies and focal or absent in most by others S100, GFAP, NSE and CD57 positive; collagen IV around cells; EMA-positive perineurial cells at the periphery; SOX10 positive in the one case tested in a comparative study S100, SMA and keratin negative Hornick and Fletcher 2007; Fetsch et al. 2007; Page et al. 2004; Fried et al. 2014; Fetsch et al. 2005; Calonje et al. 1999
Behavior Local recurrence in 10 of 133, all marginally excised; atypical features (pleomorphism, fat infiltration, mitoses) without clinical significance Local recurrence in 47% after simple excision Local recurrence in 8 of 39 in one series and 1 of 28 in another Hornick and Fletcher 2007; Fetsch et al. 2005; Calonje et al. 1999; Sharma et al. 2022
Associations Unrelated to nerve sheath myxoma Unrelated to cellular and mixed neurothekeoma Sporadic or associated with Carney complex Fetsch et al. 2005; Fetsch et al. 2007; Sharma et al. 2022

Neurothekeomas are subclassified by myxoid matrix as cellular, mixed or myxoid, and a fibroblastic origin with myofibroblastic differentiation is proposed (Fetsch et al. 2007). Lack of SOX10 in all cellular and mixed neurothekeomas, with SOX10 expression in nerve sheath myxoma, supports separate lineages (Fried et al. 2014).

Cutaneous smooth muscle tumors: pilar leiomyoma, angioleiomyoma and atypical intradermal smooth muscle neoplasm

  • Pilar leiomyoma. Pilar leiomyoma arises from the arrector pili muscle and presents as red-brown firm papules or nodules on the face, trunk and extensor extremities; episodic pain with touch or cold occurs. Histology shows a non-encapsulated dermal proliferation of interlacing fascicles of smooth muscle cells, without atypia or mitoses in a reported case. Pilar leiomyoma is the subtype most associated with HLRCC, and angioleiomyoma is rarely associated (Kim et al. 2023).
  • Cutaneous leiomyoma and HLRCC. Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC, Reed syndrome) is caused by a germline heterozygous FH mutation and predisposes to multiple cutaneous leiomyomas, uterine leiomyomas in women and aggressive renal cell carcinoma. The cutaneous leiomyomas are often painful (Patel et al. 2017). FH mutations were found in 11 of 13 sequenced multiple cutaneous leiomyomas and in 1 of 11 single leiomyomas. All 11 mutated multiple leiomyomas were positive for 2-succinocysteine (2SC), and 6 of 11 showed complete loss of FH staining, so 2SC corresponded to mutation status more closely than FH loss (Buelow et al. 2016).
  • Angioleiomyoma. In 562 cases, angioleiomyoma was more common in women (1.7:1), occurred on the extremities in 89% and caused pain or tenderness in 327 cases. The subtypes were capillary or solid (374), venous (127) and cavernous (61) (Hachisuga et al. 1984). Angioleiomyomas lack the PDGFRB mutations of myofibroma (Agaimy et al. 2017).
  • Atypical intradermal smooth muscle neoplasm (Skin5; previously cutaneous leiomyosarcoma). In 84 tumors there was a 4.3:1 male predominance, mean age 56 years and mean size 1.3 cm, mostly on the trunk and lower extremities. All were confined to the dermis or showed only very superficial focal subcutaneous extension, and 97% were FNCLCC grade 1. All expressed SMA, 98% desmin and 90% caldesmon, and 45% showed focal pankeratin. Follow-up of 52 patients showed no metastasis or tumor-related death. Local recurrence in 18 cases was predicted by positive margins (Kraft and Fletcher 2011).
  • Limits of the term. The tumor must be centered in the dermis with absent or minimal subcutaneous infiltration. Tumors predominantly in the subcutis, often arising from subcutaneous vessels, have a prognosis comparable to deep leiomyosarcoma and are excluded. A poorly differentiated dermal leiomyosarcoma suggests metastasis from a deep primary. The h-CD clone of h-caldesmon is highly specific, and other clones have poor specificity (Kalmykova et al. 2024).

Cutaneous neuromas

  • Traumatic neuroma. A reparative proliferation after nerve injury, composed of disorganized nerve fiber bundles with Schwann cells, perineurial cells, axons and endoneurial fibroblasts in fibrous stroma. It occurs after amputation and other surgery and does not represent tumor recurrence (Chen et al. 2019). Its nerve bundles keep a normal composition, with immunostaining similar to mucosal neuroma: S100-positive Schwann cells, neurofilament-positive axons and EMA-positive perineurium (Takayama et al. 2024).
  • Palisaded encapsulated (solitary circumscribed) neuroma. A small (≤0.5 cm) lesion of the face or near a mucocutaneous junction in middle-aged adults. It is a partially encapsulated mass of bland Schwann cells with numerous small axons in interlacing fascicles. The capsule consists of EMA-positive perineurial cells. It is not associated with neurofibromatosis type 1, and no relationship to MEN2B was found (Fletcher 1989).

Glomus tumor, glomuvenous malformation and other pericytic tumors

  • Glomus tumor. In 60 cutaneous glomus tumors the female-to-male ratio was about 2:1, mean age 40 years, and 21 were subungual. Pain was present in 58, with cold intolerance in 4. Solid glomus tumor consists mainly of glomus cells, glomangioma of glomus cells around numerous vessels, and glomangiomyoma contains abundant vascular smooth muscle (Sun et al. 2024). Glomus cells are positive for SMA and calponin, show net-like pericellular laminin and collagen type IV, and are negative for desmin and S100 protein in gastric glomus tumors, which are phenotypically similar to peripheral glomus tumors (Miettinen et al. 2002).
  • Malignant glomus tumor: current WHO criteria. Malignant glomus tumor shows marked nuclear atypia with any level of mitotic activity, or atypical mitotic figures. A tumor with no criteria for malignancy but at least one atypical feature other than nuclear pleomorphism, such as large size or deep location, is a glomus tumor of uncertain malignant potential. Striking nuclear atypia without any other feature indicating a poor outcome defines symplastic glomus tumor (WHO 4th edition, 2013; Oide et al. 2016).
  • Previous rule (Folpe et al. 2001, adopted in the WHO 3rd edition, 2002). Deep location with size over 2 cm, atypical mitoses, or moderate to high nuclear grade with ≥5 mitoses per 50 high-power fields defined malignancy. Metastasis occurred in 38% of tumors meeting these criteria and in none of the symplastic glomus tumors or glomus tumors of uncertain malignant potential (Folpe et al. 2001). The WHO 4th edition removed deep location with size over 2 cm as a malignant criterion because most large, deep glomus tumors behave in a benign fashion (Oide et al. 2016).
  • Glomuvenous malformation. Glomuvenous malformations are cutaneous venous lesions with glomus cells in the walls of distended vascular lumens. Inherited lesions are caused by loss-of-function mutations in glomulin (GLMN), with a somatic second hit in lesional tissue (Brouillard et al. 2002).
  • Myopericytoma. Numerous thin-walled vessels with concentric perivascular ovoid to spindled myoid cells, with patterns that overlap angioleiomyoma and myofibroma. All tested tumors were SMA positive and 29 of 32 h-caldesmon positive, and desmin was focal in 3 of 33. Two of 46 tumors with follow-up recurred (Mentzel et al. 2006).
  • Myofibroma. Somatic PDGFRB mutations were present in 6 of 8 infantile and 11 of 16 solitary adult myofibromas, and activating germline PDGFRB mutations are linked to familial infantile myofibromatosis (Agaimy et al. 2017). Skin5 places myofibroma among pericytic tumours (Goldman-Lévy et al. 2026).

Vascular Anomalies and Vascular Tumors of Skin, Kaposi Sarcoma and Angiosarcoma, Cutaneous Histiocytic and Mast Cell Infiltrates, and Metastases to Skin

Definition and classification. The WHO Classification of Skin Tumours, 5th edition (Skin5), adds a chapter on metastases to skin and cancer of unknown primary site (CUP), describes ALK-positive histiocytosis and renames indeterminate dendritic cell histiocytosis/tumour (Goldman-Lévy et al. 2026), and regroups intermediate vascular tumors (Kalmykova et al. 2024). The WHO Classification of Soft Tissue and Bone Tumours, 6th edition (STB6, 2026), replaces the names of lesions formerly called hemangiomas and lymphangiomas with vascular anomaly and lymphatic malformation terminology aligned with the International Society for the Study of Vascular Anomalies (ISSVA), restores spindle cell hemangioma, which was omitted from the 2020 volume, and separates YAP1::TFE3 hemangioendothelioma from epithelioid hemangioendothelioma (Hornick et al. 2026).

Related page: Angiosarcoma, Lymphoma and Metastases in the Breast (primary and radiation-associated angiosarcoma of the breast and atypical vascular lesion in the breast setting) Related page: Benign Mesenchymal and Inflammatory Lesions of the Breast (benign vascular lesions of the breast) Related page: Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen (classification, genetics and systemic disease in Langerhans cell histiocytosis, Erdheim–Chester disease, Rosai–Dorfman disease, ALK-positive histiocytosis and juvenile xanthogranuloma) Related page: Mastocytosis, Hypereosinophilic Syndrome and Myeloid/Lymphoid Neoplasms with Tyrosine Kinase Fusions, Chronic Myelomonocytic Leukemia and Other MDS/MPN (types of mastocytosis in WHO-HAEM5 and ICC 2022 and criteria for systemic mastocytosis) Related page: Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging (HHV8-associated lymphoproliferative disorders) Related page: Lymph Node Pathology: Normal Structure, Triage, Reactive and Infectious Lymphadenopathy, Castleman and IgG4-Related Disease, and Metastases to Lymph Node and Marrow (nodal metastases) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (gastrointestinal Kaposi sarcoma) Related page: Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma (hepatic hemangioma, infantile hepatic hemangioma and hepatic angiosarcoma) Related page: Cutaneous Melanoma: Subtypes, AJCC 8th Edition Staging, CAP Reporting, Sentinel Lymph Node and Metastatic Melanoma (satellite, in-transit and distant metastatic melanoma in skin) Related page: Cutaneous Adnexal Neoplasms: Follicular, Sebaceous, Apocrine and Eccrine Tumors, Adnexal Carcinomas, Paget Disease and Associated Syndromes (morphology and molecular genetics of primary adnexal carcinomas) Related page: Fibrohistiocytic, Fibroblastic, Smooth Muscle, Neural and Perivascular Tumors of the Dermis: Dermatofibroma, DFSP, Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma (glomus tumor, glomuvenous malformation and other perivascular tumors) Related page: Skin Infections and Infestations: Bacterial, Mycobacterial, Spirochetal, Fungal, Viral, Protozoal and Parasitic Infections of Skin (bacillary angiomatosis) Related page: Cutaneous Lymphoid and Hematolymphoid Infiltrates: Histologic Approach, Early Mycosis Fungoides and Its Mimics, CD30-Positive Lymphoproliferative Disorders, Rare Cutaneous T-Cell Lymphomas and Reactive Lymphoid Proliferations (cutaneous lymphomas and plasmacytoid dendritic cell proliferations) Related page: Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases (POEMS syndrome)

ISSVA 2025 classification of vascular anomalies and the changes from ISSVA 2018

The ISSVA classification separates vascular tumors, which proliferate, from vascular malformations, which are errors of vascular development. The 2025 update keeps the benign, borderline and malignant tiers of vascular tumors, leaves the malignant list unchanged and reorganizes malformations by flow velocity (Goldenberg et al. 2025).

Element ISSVA 2025 (current) ISSVA 2018 (previous rule, as described in the 2025 update) Source
Main division Vascular tumors, vascular malformations and potentially unique vascular anomalies (PUVA) Vascular tumors, vascular malformations and "provisionally unclassified vascular anomalies" Goldenberg et al. 2025
Benign vascular tumors All histopathologic variants in one list; reactive proliferative vascular lesions listed with benign tumors Lists with "other" and "related lesions" categories Goldenberg et al. 2025
Borderline vascular tumors New terms for aggressive lesions, including those with the Kasabach–Merritt phenomenon; multifocal lymphangioendotheliomatosis with thrombocytopenia added Multifocal lymphangioendotheliomatosis with thrombocytopenia not listed Goldenberg et al. 2025
Primary division of malformations Fast-flow, slow-flow and developmental anomalies of named vessels "Simple" and "combined" malformations, organized by vessel type Goldenberg et al. 2025
Fast-flow malformations Isolated (arteriovenous malformation, intramuscular fast-flow vascular anomaly, arteriovenous fistula), multifocal (capillary malformation–arteriovenous malformation, hereditary hemorrhagic telangiectasia, PTEN hamartoma tumor syndrome) and syndromic Terms "sporadic", "in HHT" and "CM-AVM" used as headings Goldenberg et al. 2025
Slow-flow malformations Capillary, lymphatic, venous and combined, each isolated, multifocal or syndromic Lesions caused by PIK3CA variants scattered across lymphatic, venous and mixed categories Goldenberg et al. 2025
Malformations with other anomalies Category removed; each syndrome placed under its malformation subtype "Vascular malformations associated with other anomalies" Goldenberg et al. 2025
Glossary New "Glossary of Vascular Anomalies" with genetic correlations No glossary Goldenberg et al. 2025
  • Capillary malformations (2025). Nevus simplex (salmon patch), port-wine capillary malformation, reticulate or telangiectatic capillary malformation, geographic-pattern capillary malformation, low-resistance capillary malformation, cutis marmorata telangiectatica congenita, and telangiectasias and spider angiomas. Syndromic port-wine malformations include Sturge–Weber syndrome and diffuse capillary malformation with overgrowth (Goldenberg et al. 2025).
  • Venous and lymphatic malformations (2025). Isolated venous malformations are phlebectatic, spongiform, verrucous venous malformation and fibroadipose vascular anomaly. Multifocal venous malformations include blue rubber bleb nevus syndrome and glomuvenous malformation. Blue rubber bleb nevus syndrome, with cutaneous and pathognomonic gastrointestinal venous malformations, carries somatic TEK (TIE2) mutations (15 of 17 patients), usually two mutations on the same allele with T1105N-T1106P recurrent; common unifocal venous malformation most often carries TEK L914F (Soblet et al. 2017). Syndromic venous malformations include PTEN hamartoma tumor syndrome, CLOVES syndrome and Maffucci syndrome. Isolated lymphatic malformations are macrocystic, microcystic, mixed and angiokeratoma (Goldenberg et al. 2025).
  • Combined malformations (2025). Syndromic combined malformations include the PIK3CA-related overgrowth spectrum, Klippel–Trenaunay syndrome, CLOVES syndrome and Proteus syndrome (Goldenberg et al. 2025).
  • Congenital hemangioma. Its placement as a tumor was debated in the 2025 revision because it resembles infantile hemangioma histologically and resembles some malformations genetically (Goldenberg et al. 2025).

Somatic driver alterations in cutaneous vascular anomalies and tumors

Lesion Alteration Finding Source
Port-wine capillary malformation and Sturge–Weber syndrome GNAQ c.548G>A, p.Arg183Gln (somatic, mosaic) Present in 92% of nonsyndromic port-wine stains and 88% of Sturge–Weber syndrome tissues; mutant allele 1.0%–18.1% Shirley et al. 2013
Isolated lymphatic malformation and Klippel–Trenaunay syndrome PIK3CA (somatic, mosaic) 16 of 17 isolated lymphatic malformations and 19 of 21 Klippel–Trenaunay cases; 5 hotspot variants account for about 80%; many specimens have fewer than 10% mutant cells Luks et al. 2015
Congenital hemangioma (RICH and NICH) GNAQ or GNA11 Gln209 (mutually exclusive) All 8 fresh tumors and 4 of 8 archival tumors; the same variants occur in RICH and NICH Ayturk et al. 2016
Tufted angioma, kaposiform hemangioendothelioma and childhood lobular capillary hemangioma GNA14 p.Gln205Leu; GNA11 p.Arg183Cys Activating Gαq-family variants that upregulate MAPK signaling Lim et al. 2016
Cherry hemangioma GNA14, GNAQ or GNA11 (exon 5; mutually exclusive) Mutations in 82%; GNA14 most frequent Liau et al. 2019
Pyogenic granuloma BRAF p.Val600Glu, KRAS, NRAS BRAF V600E in 8 of 10 pyogenic granulomas arising in port-wine stains and in 3 of 25 sporadic lesions Groesser et al. 2016
Spindle cell hemangioma IDH1 p.Arg132Cys or IDH2 p.Arg172 20 of 28 lesions; absent from 154 other vascular lesions Kurek et al. 2013
Maffucci syndrome Somatic mosaic IDH1 or IDH2 Tumors of 10 of 13 patients; 70% of spindle cell hemangiomas; identical variants in separate lesions of 14 of 16 subjects (Ollier disease and Maffucci syndrome) Pansuriya et al. 2011
Verrucous venous malformation MAP3K3 p.Ile441Met (recurrent) RAS/MAPK/ERK pathway kinase Diociaiuti et al. 2025

Cherry hemangioma, angiokeratoma and venous lake

  • Cherry hemangioma. Cherry hemangioma is the most common hemangioma of adult life. Its capillaries are surrounded by a perivascular hyaline layer, and cherry hemangioma-like lesions can contain dilated cavernous vessels or extend into the deep dermis. GNA14, GNAQ or GNA11 mutations in 82% establish it as a neoplasm (Liau et al. 2019).
  • Angiokeratoma. ISSVA 2025 classifies angiokeratoma as an isolated lymphatic malformation (Goldenberg et al. 2025). Histologically, angiokeratoma shows hyperkeratosis, acanthosis and dilated papillary dermal vascular spaces, with or without organizing thrombi, partly or completely enclosed by elongated rete ridges (Kandalgaonkar et al. 2013). Angiokeratomas occur in 51.5% of patients with Fabry disease, an X-linked lysosomal storage disorder of glycosphingolipid accumulation. Sweat abnormalities are the most common skin manifestation of Fabry disease (57.6%), and enzyme replacement therapy generally does not reduce the skin lesions (Al-Chaer et al. 2025).
  • Venous lake and other vascular lesions of the lip. A venous lake is a dilated venous vessel surrounded by thick fibrous tissue in the upper dermis (Trafalski and Jurczyszyn 2025), arising on sun-damaged skin (Bhingradia et al. 2023) and also on the lips, buccal mucosa and tongue (Trafalski and Jurczyszyn 2025). Among 131 vascular lesions of the lip, pyogenic granuloma (48%) was most frequent, followed by venous lake (17.5%), thrombus (14.5%) and papillary endothelial hyperplasia (9.1%). GLUT1 was positive only in infantile hemangioma, and podoplanin was negative in all these lesions (Tobouti et al. 2017).

Infantile hemangioma and congenital hemangiomas

Infantile hemangioma occurs in up to 5% of infants and is the most common benign tumor of infancy. Growth is fastest between 1 and 3 months of age and is complete by 5 months in most cases (Krowchuk et al. 2019). The lesion enlarges by cellular hyperplasia during the first year and then involutes over several years, and its distinctive histologic features diminish as it involutes (North et al. 2000).

Feature Infantile hemangioma Rapidly involuting congenital hemangioma (RICH) Non-involuting congenital hemangioma (NICH) Source
Presentation and course Appears after birth; proliferates in the first year, then involutes over years Fully formed at birth; rapid postnatal involution Fully formed at birth; static, without involution North et al. 2000; North et al. 2001; Berenguer et al. 2003
Histology Neovasculature intermingled with normal tissue elements Small to large capillary lobules with plump endothelial cells and pericytes in abundant fibrous tissue; central involuting zones with lobular loss and large abnormal draining channels in half; hemosiderin, thrombosis, cysts, calcification, extramedullary hematopoiesis Capillary lobules in dense fibrous stroma with hemosiderin, focal lobular thrombosis and sclerosis, multiple thin-walled vessels; no intermingling with normal tissue North et al. 2001; Berenguer et al. 2003
GLUT1 Intense endothelial staining in more than 50% of lesional microvessels in 97% (139 of 143), in all phases Negative (one exception among the RICH series) Negative; LeY also negative North et al. 2000; North et al. 2001; Berenguer et al. 2003
  • Overlap of RICH and NICH. Both carry the same GNAQ or GNA11 Gln209 variants, so other factors account for their different postnatal behavior (Ayturk et al. 2016). One RICH involuted by 50% in the first year and then stopped regressing; at resection at 18 months it was histologically indistinguishable from NICH. Some NICH resected at 2–4 years showed RICH features, and RICH, NICH and infantile hemangioma overlap clinically and histologically (Berenguer et al. 2003).
  • Partially involuting congenital hemangioma (PICH). PICH presents at birth as a RICH, involutes rapidly during the first 12 to 30 months and then stabilizes as a persistent NICH-like lesion (Nasseri et al. 2014).
  • GLUT1 in the differential diagnosis. No endothelial GLUT1 staining was found in 66 vascular malformations (arteriovenous, venous, lymphatic and port-wine), 20 pyogenic granulomas, 7 granulation tissue specimens, or 5 epithelioid or kaposiform hemangioendotheliomas. Focal GLUT1 staining occurred in 3 of 12 angiosarcomas (North et al. 2000). Verrucous venous malformation can show focal GLUT1 positivity (Diociaiuti et al. 2025).

Pyogenic granuloma and other benign and borderline cutaneous vascular tumors

Lesion Clinical setting Histology and immunophenotype Genetics and associations Source
Pyogenic granuloma (lobular capillary hemangioma) Rapidly growing angiomatous papule; can arise in a port-wine stain Lobules of capillaries; endothelium GLUT1-negative; an ulcerated nodule of Kaposi sarcoma can mimic it BRAF V600E, KRAS or NRAS; GNA14 or GNA11 in childhood lesions; classified as a benign neoplasm Groesser et al. 2016; Lim et al. 2016; North et al. 2000; Grayson and Pantanowitz 2008
Hobnail hemangioma (targetoid hemosiderotic hemangioma) Median age 30.5 years; lower limb and trunk; median size 1 cm; no recurrence after excision Biphasic: dilated superficial vessels and deeper collagen-dissecting channels; hobnail endothelium with endoluminal papillae; no multilayering, tufting or mitoses; variable hemosiderin; D2-40 positive in all 12 pediatric cases; WT1 negative in 9 of 11 tested Interpreted as a lymphatic malformation in the pediatric series Guillou et al. 1999; Al Dhaybi et al. 2012
Microvenular hemangioma Mean age 39 years; red to purple plaque or nodule of the extremities or trunk Thin-walled branching channels dissecting collagen, each surrounded by a conspicuous pericyte layer; WT1 positive in 9 of 10; podoplanin negative (0 of 12); HHV8 negative (0 of 9) Benign; mimics Kaposi sarcoma Napekoski et al. 2014
Glomeruloid hemangioma Classic cutaneous finding in POEMS syndrome; isolated lesions are exceptionally rare Ectatic dermal capillaries containing intraluminal capillary loops in a glomerulus-like pattern POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes), taught in Plasma Cell Neoplasms and Diseases with Paraproteins: MGUS, Smoldering and Plasma Cell Myeloma, Plasmacytoma, Plasma Cell Leukemia, Amyloidosis, POEMS Syndrome and Heavy Chain Diseases Elhaitamy et al. 2026
Tufted angioma and kaposiform hemangioendothelioma Infancy or early childhood; purpuric macules, papules and plaques; Kasabach–Merritt phenomenon is the most severe complication Dermal tufts of closely packed capillaries in a "cannonball" pattern; tuft endothelium CD31, CD34 and factor VIII positive and podoplanin negative; peripheral crescentic spaces podoplanin positive GNA14; regarded as two ends of one spectrum, kaposiform hemangioendothelioma being the more aggressive Nieto-Benito et al. 2023; Lim et al. 2016
Verrucous venous malformation (formerly verrucous hemangioma) Congenital, sporadic; hyperkeratotic reddish-purple plaque, mostly on the lower extremity Hyperkeratotic epidermis over dilated vessels extending from the superficial dermis into the subcutis; focal GLUT1; variable WT1 MAP3K3 p.Ile441Met; ISSVA 2025 isolated venous malformation Diociaiuti et al. 2025; Goldenberg et al. 2025
Spindle cell hemangioma Dermis and subcutis of the distal extremities of young adults; may be multifocal Cavernous blood vessels with a spindle cell component IDH1 or IDH2 in 16 of 17 sporadic lesions by sensitive sequencing; Maffucci syndrome Ten Broek et al. 2017; Kurek et al. 2013; Pansuriya et al. 2011
Hobnail hemangioendothelioma (Skin5) Intermediate-behavior vascular neoplasm Retiform hemangioendothelioma and papillary intralymphatic angioendothelioma grouped under one name YAP1::MAML2 reported in hobnail (retiform) and composite hemangioendothelioma Kalmykova et al. 2024
  • Previous rule (WHO Skin 4th edition). Retiform hemangioendothelioma and papillary intralymphatic angioendothelioma were separate entities. Skin5 grouped them because their morphology and behavior overlap and their separation is not clinically relevant (Kalmykova et al. 2024).
  • Composite hemangioendothelioma, neuroendocrine variant (Skin5). A retiform or hobnail vascular component is admixed with nests of neuroendocrine cells. It behaves more aggressively than conventional composite hemangioendothelioma and carries PTBP1::MAML2 or EPC1::PHC2 fusions (Kalmykova et al. 2024).

Epithelioid hemangioma (angiolymphoid hyperplasia with eosinophilia) versus Kimura disease

Epithelioid hemangioma, also called angiolymphoid hyperplasia with eosinophilia (ALHE), is a benign vasoproliferative lesion. Kimura disease is a chronic inflammatory disorder. Most authors now regard them as distinct entities (Zou et al. 2021; Bastos et al. 2017).

Feature Kimura disease Angiolymphoid hyperplasia with eosinophilia Source
Typical patient Men aged 20–30 years; more common in Asians; male-to-female ratio 4–7:1 Women aged 30–50 years; all races Zou et al. 2021
Lesions Single or multiple deep subcutaneous masses of the head and neck, 1–20 cm (average 3 cm), over normal skin; salivary gland involvement Usually multiple superficial papules or nodules of the head and neck, especially around the ear, 0.2–10 cm (average 1 cm), over erythematous skin Zou et al. 2021; Bastos et al. 2017
Lymphadenopathy Common (42%–100%) Uncommon Zou et al. 2021
Blood eosinophilia and serum IgE Usually elevated Eosinophilia occasional; IgE usually normal Zou et al. 2021
Systemic associations Glomerulonephritis (membranous or mesangioproliferative), allergic skin disease Rare Zou et al. 2021; Bastos et al. 2017
Depth Subcutis and muscle Dermis and subcutis Zou et al. 2021
Vessels Some vascular proliferation Predominantly vascular; capillaries clustered around a larger vessel; plump cuboidal to dome-shaped (epithelioid) endothelial cells with cytoplasmic vacuoles Zou et al. 2021; Bastos et al. 2017
Inflammation Lymphoid follicles with prominent germinal centers in every case; abundant eosinophils; eosinophilic abscesses Lymphocytes and eosinophils; lymphoid follicles rare or absent; eosinophilic abscesses rare Zou et al. 2021; Bastos et al. 2017
Fibrosis Sclerosis typical Not typical Zou et al. 2021
Treatment Excision, glucocorticoids, cytotoxic therapy, radiotherapy; frequent recurrence Excision; recurrence common Zou et al. 2021

Intravascular papillary endothelial hyperplasia (Masson tumor) versus angiosarcoma

Intravascular papillary endothelial hyperplasia (IPEH) is a reactive papillary proliferation of endothelial cells within normal or dilated vascular spaces, regarded as excessive endothelial proliferation during recanalization of a thrombus. Primary (type I) IPEH arises in a dilated vessel without another vascular anomaly and is the most common type. Secondary (type II) IPEH arises within a pre-existing vascular lesion such as a hemangioma or arteriovenous malformation, and extravascular (type III) IPEH arises in a hematoma (Gutiérrez Fernández de Velasco et al. 2026). The head, neck and upper extremities are the most frequent sites, and among 103 upper-extremity cases the fingers were most often involved. IPEH is distinguished from angiosarcoma by the absence of necrosis, significant cytologic atypia, infiltrative growth and high mitotic activity. Recurrence after complete excision is low (Gutiérrez Fernández de Velasco et al. 2026).

Atypical vascular lesion and post-radiation angiosarcoma of skin

The breast-parenchymal setting of angiosarcoma and atypical vascular lesion (AVL) is taught in Angiosarcoma, Lymphoma and Metastases in the Breast.

Feature AVL, lymphatic type AVL, vascular type Post-radiation (secondary) angiosarcoma Source
Clinical Flesh-colored papules or erythematous patches or plaques in the radiation field, 1–12 years (median 6) after therapy; median size 4 mm Radiation field, as for the lymphatic type Radiation field or chronic lymphedema Patton et al. 2008; Fernandez et al. 2012
Architecture Thin-walled, variably anastomosing lymphatic channels, usually confined to the superficial dermis Small, irregularly dispersed, often blood-filled capillary-sized vessels invested by pericytes in the superficial or deep dermis, with extravasated erythrocytes and hemosiderin; endothelial atypia (nuclear and nucleolar enlargement) in 4 cases Infiltrative vasoformative to solid or epithelioid growth Patton et al. 2008; Grant et al. 2026
Behavior 1 of 21 progressed to well-differentiated angiosarcoma over 5 years Of the 4 patients with endothelial atypia, 1 had extensive residual AVL at mastectomy and 1 developed high-grade angiosarcoma at 14 months; higher risk than lymphatic type Aggressive Patton et al. 2008
MYC Not amplified; MYC protein negative Not amplified; MYC protein negative High-level MYC amplification by FISH and nuclear MYC in 8 of 8; frequencies across series in Angiosarcoma, Lymphoma and Metastases in the Breast Fernandez et al. 2012

Cutaneous angiosarcoma

  • Clinical settings. Primary cutaneous angiosarcoma arises most often on sun-damaged skin of older adults. Secondary cutaneous angiosarcoma follows radiation or chronic lymphedema (Grant et al. 2026). In a series of 60 angiosarcomas, cutaneous tumors of the scalp or face formed 66%, and patients with cutaneous tumors were older than those with non-cutaneous tumors (median 74 versus 56 years). Median overall survival was 11.2 months (Farid et al. 2013).
  • Stewart–Treves syndrome. Stewart–Treves syndrome is angiosarcoma arising in chronically lymphedematous tissue. A systematic review of 369 patients with malignancy in chronic lymphedema found Stewart–Treves syndrome in 331. It began on average 14.9 years after the onset of lymphedema, mortality was 53.9% and 5-year survival 22.4%. Of all 369 patients, 85.9% were women and 68.3% had lymphedema from surgery (Kim et al. 2022). It follows mastectomy with axillary lymph node dissection most often and lower-limb lymphedema occasionally (Elkiran et al. 2026).
  • Histology. Morphology ranges from well-differentiated vasoformative channels to solid and epithelioid patterns (Grant et al. 2026).
  • Immunohistochemistry. CD31, ERG and FLI1 support endothelial lineage. Keratin expression is a diagnostic pitfall (Grant et al. 2026). Focal GLUT1 staining occurs in some angiosarcomas (North et al. 2000). In 9 cutaneous angiosarcomas, CD31 was positive in all, D2-40 and VEGFR-3 in most, factor VIII in 3 of 7, CD34 in about one-third and cytokeratin in none (Donghi et al. 2010).
  • Molecular findings. MYC amplification, detected by FISH or immunohistochemistry, is the hallmark of secondary cutaneous angiosarcoma. Sequencing also identifies MYC and FLT4 co-amplification, ultraviolet mutational signatures and DNA damage response pathway alterations (Grant et al. 2026).

Kaposi sarcoma

Kaposi sarcoma (KS) is a vascular lesion of low-grade malignant potential that presents most often in skin. The patch, plaque and nodular stages are shared by classic, African endemic, transplant-associated and AIDS-associated KS (Grayson and Pantanowitz 2008).

Epidemiologic form Population and setting Clinical behavior Source
Classic Mainly older men of Mediterranean, Middle Eastern and Eastern European origin; about 1 per 100,000 per year in Italian, Druze, Cypriot and Greek populations Visceral involvement <1.4%; can mimic arterial insufficiency or venous stasis Bagratee et al. 2025
Endemic (African) Children with a bimodal peak at 4 and 9 years; male-to-female ratio close to 1:1 Aggressive exophytic lesions, bone invasion in up to 31%, lymphedema in 17%; fewer oral and visceral lesions than AIDS-associated KS Bagratee et al. 2025
AIDS-associated (epidemic) People living with HIV, including those with suppressed viral loads; male-to-female ratio about 2:1 in South Africa Faster progression than classic KS; trunk and lower-extremity skin, mucosa, lymph nodes and gastrointestinal tract Bagratee et al. 2025
Iatrogenic (post-transplant) Kidney, heart and liver transplant recipients and other immunosuppressed patients; corticosteroids are the drugs most often implicated Withdrawal or reduction of immunosuppression is the recommended approach Bagratee et al. 2025
Stage Histology Main mimics Source
Patch "Busy" dermis; slit-like or jagged new vessels around native vessels and adnexa; native vessels protruding into ectatic neoplastic channels (promontory sign); flattened bland endothelium; extravasated erythrocytes; lymphocytes, plasma cells and hemosiderin-laden macrophages Mild inflammatory dermatosis Grayson and Pantanowitz 2008
Plaque Diffuse dermal vascular infiltrate, sometimes into subcutis; short fascicles of spindle cells, sieve-like in cross section; intracellular and extracellular hyaline globules; "autolumination" (an erythrocyte in a paranuclear vacuole); plasma cells and siderophages Tufted angioma, targetoid hemosiderotic hemangioma, microvenular hemangioma, acroangiodermatitis Grayson and Pantanowitz 2008
Nodular Circumscribed dermal nodule of monomorphic spindle cells in fascicles with erythrocytes in slit-like spaces; occasional mitoses; more hyaline globules; peripheral cavernous-like vessels that are lesional Pyogenic granuloma (ulcerated nodules), bacillary angiomatosis, spindle cell hemangioma, kaposiform hemangioendothelioma, fibrohistiocytic tumors, spindle cell melanoma, cutaneous leiomyosarcoma Grayson and Pantanowitz 2008
  • HHV8 immunohistochemistry. Nuclear staining for HHV8 latent nuclear antigen 1 (LANA-1, also written LNA-1) marks the lesional cells, including the cells lining cavernous-like and lymphangioma-like channels. LANA-1 and D2-40 separate lesional from non-lesional endothelium better than CD31 or CD34 and help in superficial or ulcerated biopsies (Grayson and Pantanowitz 2008).
  • Variants. Anaplastic (pleomorphic) KS shows marked pleomorphism, 5–20 mitoses per 10 high-power fields, atypical mitoses and occasional necrosis, and behaves aggressively with deep invasion and increased metastatic capacity. Lymphangioma-like KS accounts for less than 5% of KS, shows ectatic anastomosing channels with a conspicuous promontory sign, and is related to lymphedematous, bullous and hyperkeratotic KS (Grayson and Pantanowitz 2008).
  • Acroangiodermatitis (pseudo-Kaposi sarcoma). A benign reactive angiodysplasia of the cutaneous vasculature, most often associated with chronic venous insufficiency (Mali type). Other settings are congenital arteriovenous malformations, iatrogenic arteriovenous fistulas in chronic renal failure, amputation stumps and paralyzed limbs. It presents as red-violaceous or brown macules, papules, nodules and plaques on the extensor lower limbs and requires histologic separation from KS. Its vessels arise from pre-existing vasculature with fibroblastic activity and are separated by edematous matrix, and CD34 marks only their endothelium, whereas KS vessels have jagged slit-like lumina with a promontory sign and CD34 in both endothelial and perivascular spindle cells (Peddireddy et al. 2025).

Cutaneous mastocytosis: clinical forms and skin biopsy criteria

  • Clinical forms (ECNM, AAAAI and EAACI consensus). Typical maculopapular cutaneous mastocytosis (urticaria pigmentosa) is subdivided into a monomorphic variant of small lesions, typical of adults, and a polymorphic variant of larger lesions of variable size and shape, typical of children. The monomorphic variant often persists into adulthood when it begins in childhood, and the polymorphic variant may resolve around puberty. The consensus removed telangiectasia macularis eruptiva perstans from the classification of cutaneous mastocytosis and dropped "solitary" from "solitary mastocytoma" (Hartmann et al. 2016).
  • Darier sign. Rubbing or scratching a lesion causes mast cell degranulation with release of inflammatory mediators. The sign supports urticaria pigmentosa and raises suspicion of systemic mastocytosis (Cuervo-Pardo et al. 2015).
Skin biopsy finding Data from 32 maculopapular lesions, 15 mastocytomas and 36 controls Weight in the proposed scoring model Source
KIT D816V in formalin-fixed skin Evaluable in 87.5% of maculopapular lesions; 100% sensitivity and specificity Major criterion Gebhard et al. 2022
Mast cell density (CD117 or tryptase) More than 27 per high-power field Major criterion (>95% specific) Gebhard et al. 2022
Mast cell density, lower threshold 62 per mm² of upper dermis (about 12 per high-power field): 92% sensitivity and specificity Minor criterion Gebhard et al. 2022
Interstitial mast cells (away from vessels and adnexa) Indicative of maculopapular lesions Minor criterion Gebhard et al. 2022
Clusters of more than 3 nucleated mast cells per high-power field Found only in maculopapular lesions Minor criterion Gebhard et al. 2022
Increased basal epidermal pigmentation Indicative of maculopapular lesions Minor criterion Gebhard et al. 2022
CD2, CD25 and CD30 Stained T cells; negligible staining of lesional skin mast cells Not a criterion Gebhard et al. 2022
  • Mastocytoma and the scoring model. Mastocytomas were easily identified by densely packed cuboidal mast cells, and the major and minor criteria were combined in a scoring model that predicts maculopapular cutaneous mastocytosis (Gebhard et al. 2022).

Cutaneous histiocytic and dendritic cell proliferations

Entity Clinical presentation in skin Histology Immunophenotype Source
Juvenile xanthogranuloma (JXG) Single to multiple skin lesions of infancy and childhood that tend to heal spontaneously; systemic in less than 5% Histiocytes of variable morphology with some lipidization and Touton giant cells CD68, CD163, CD4, CD14 and factor XIIIa positive; S100 occasionally positive; CD1a and langerin negative Fend et al. 2026
ALK-positive histiocytosis (new in Skin5) Single or multiple papules or nodules or part of systemic disease; multisystem infantile form with female predominance; skin lesions may regress Histiocytes without high-grade atypia, from JXG-like to spindled or epithelioid; RDD-like emperipolesis common ALK (sometimes focal and weak) and at least two histiocytic markers; S100 and OCT2 variable; cyclin D1 positive; CD1a and langerin negative Goldman-Lévy et al. 2026; Fend et al. 2026; Kemps et al. 2022
Solitary reticulohistiocytoma (solitary epithelioid histiocytoma) Solitary superficial papule, median 4 mm; median age 35 years; no recurrence Large epithelioid histiocytes with abundant densely eosinophilic cytoplasm and randomly arranged multinucleated forms in the upper and mid dermis; low mitotic activity CD163 and CD68 positive; focal MITF; sometimes focal factor XIIIa and S100; keratin, HMB45 and CD30 negative Miettinen and Fetsch 2006
Multicentric reticulohistiocytosis Periungual "coral bead" papules and cobblestoned plaques of the dorsal hands; destructive arthritis; predominantly women Histiocytes without xanthomatous change; histology alone is nonspecific CD68, CD163, CD4, CD11c and factor XIIIa positive; CD1a, langerin and S100 negative Fend et al. 2026
Cutaneous Langerhans cell histiocytosis Skin involved in 33% of LCH; congenital self-healing (Hashimoto–Pritzker) variant with skin lesions at or soon after birth, no systemic disease and resolution in days to months Langerhans cells with oval, grooved or kidney-shaped nuclei; eosinophils and multinucleated cells S100, CD1a, langerin (CD207) and CD4 positive; paranuclear dot-like CD68 Fend et al. 2026; Goldman-Lévy et al. 2026; Lima et al. 2022
Indeterminate dendritic cell tumour (Skin5 name) Multiple cutaneous lesions in adults; congenital self-healing form; myeloid neoplasm in about 40% of adult cases Mononuclear cells resembling Langerhans cells, often with ample cytoplasm S100 and CD1a positive; langerin negative Fend et al. 2026
Cutaneous Rosai–Dorfman disease Extranodal sites include skin Large histiocytes with large round nuclei, prominent nucleoli and abundant cytoplasm showing emperipolesis; many lymphocytes and plasma cells S100, CD68, CD163, cyclin D1, OCT2, PU.1 and fascin positive; CD1a and langerin negative Fend et al. 2026; Kiruthiga et al. 2022
  • Previous rule (WHO Skin 4th edition). ALK-positive histiocytosis was not described, and the indeterminate dendritic cell proliferation was called "IDC histiocytosis/tumour". Skin5 uses "IDC tumour" because the lesion is clonal (Goldman-Lévy et al. 2026).
  • Solitary skin ALK-positive histiocytosis and JXG. Solitary cutaneous ALK-positive histiocytosis is morphologically and immunophenotypically indistinguishable from JXG without ALK staining. ALK-positive histiocytosis may imitate virtually any non-Langerhans cell histiocytosis, and almost one-third of cases show classic xanthogranuloma features (Fend et al. 2026; Kemps et al. 2022). ALK immunohistochemistry (clone 1A4 preferred) with FISH or RNA sequencing is recommended for non-Langerhans histiocytoses, with possible exceptions for solitary skin lesions and classic JXG (Fend et al. 2026).
  • Genetics of the cutaneous histiocytoses. Cutaneous JXG has few recurrent alterations, and BRAF V600E and MAP2K1 occur in systemic forms. ALK-positive histiocytosis carries KIF5B::ALK in 70% of rearranged cases, with TPM3, TFG and EML4 among other partners. Indeterminate dendritic cell tumour carries KRAS mutations in 41% and ETV3::NCOA2 in fewer than 20%. A single multicentric reticulohistiocytosis case had a MAP2K1 mutation, and MAPK pathway mutations (NRAS, KRAS, MAP2K1, ARAF) occur in 30%–50% of extracutaneous Rosai–Dorfman disease (Fend et al. 2026; Abla et al. 2018). In LCH, BRAF V600E is associated with risk-organ involvement and relapse; mutation frequencies are given in Histiocytic and Dendritic Cell Neoplasms, Hemophagocytic Lymphohistiocytosis in Tissue and Pathology of the Spleen (Fend et al. 2026).
  • Multicentric reticulohistiocytosis in the Mayo series. All 24 patients had skin and joint involvement; 96% had papulonodular skin lesions, 87% of them periungual and on the dorsal hand, 29% had a concomitant autoimmune disease and 25% had malignancy (melanoma, endometrial, peritoneal and lung carcinoma). Five-year survival was 85% (Sanchez-Alvarez et al. 2020).
  • Rosai–Dorfman disease markers. PU.1 and OCT2 were positive in all 19 cases studied, including cutaneous cases; in two patients with concurrent RDD and LCH, OCT2 stained only the RDD component (Kiruthiga et al. 2022). OCT2, cyclin D1 and PU.1 are shared by subsets of other histiocytoses (Fend et al. 2026).

Metastases to skin and cancer of unknown primary site (Skin5 chapter)

Metastases to skin involve mainly the dermis and subcutis and rarely the epidermis. They are epithelial, melanocytic or mesenchymal, single or multiple, favor the chest, abdomen and scalp, and may rarely be the first sign of the malignancy. The most frequent primary cancers are breast carcinoma in women and melanoma in men. Metastases usually resemble their primary, and the differential diagnosis includes primary cutaneous tumors, desmoplastic lesions such as dermatofibroma, and primary melanoma when a metastasis spreads within the epidermis (Goldman-Lévy et al. 2026).

  • Frequency. Among 4020 patients with metastatic carcinoma or melanoma, 420 (10%) had cutaneous metastases, and breast carcinoma and melanoma were the most common primaries. Skin metastases were often the first sign of extranodal metastatic disease, particularly in melanoma, breast carcinoma and mucosal carcinomas of the head and neck. Adenocarcinoma was the most frequent histology, incisional metastases were common, and mean survival after recognition ranged from 1 to 34 months by tumor type (Lookingbill et al. 1993).
  • Previous rule (WHO Skin 4th edition). The 4th edition had no chapter on metastases to skin. Skin5 added it, with CUP, to align with the other 5th-edition volumes (Goldman-Lévy et al. 2026).
Clinical pattern Features Source
Nodules The most frequent presentation; inflammatory, cicatricial and bullous lesions also occur Lookingbill et al. 1993
Carcinoma erysipeloides Fixed erythematous patch or plaque resembling cellulitis or erysipelas, with a raised edge and edema from lymphatic obstruction; carcinoma cells within dermal vascular channels with a dense perivascular lymphocytic infiltrate; can be the first sign of breast carcinoma Al Ameer et al. 2015
Sister Mary Joseph nodule Umbilical metastasis of advanced abdominopelvic malignancy; poor prognosis; can be the first manifestation, as in ovarian adenocarcinoma Ouchane et al. 2026
Alopecia neoplastica Scalp metastasis producing localized scarring alopecia that mimics alopecia areata; in 123 patients, primaries were gastrointestinal (24.4%), breast (17.9%), kidney (8.1%), lung (7.3%) and thyroid (7.3%); single lesions in 66.1%; diagnosed after the primary in 71.5% Paolino et al. 2019; Kitayama et al. 2023

Primary adnexal carcinoma versus metastatic adenocarcinoma in skin

Marker Primary adnexal carcinoma and other primary skin tumors Cutaneous metastasis Comment Source
p40 80% of primary adnexal carcinomas 8% Most specific marker (92%) with the best positive predictive value Lee et al. 2014
p63 84% of primary adnexal carcinomas; all 10 in an earlier series; all 37 primary skin tumors (benign and malignant adnexal tumors, squamous and basal cell carcinomas) in another 17%; 0 of 14 and 0 of 42 metastatic adenocarcinomas in the other two series Sensitivity, specificity and predictive values of 100% in the 79-case series Lee et al. 2014; Ivan et al. 2005; Plaza et al. 2010
D2-40 (podoplanin) 78.4% of primary skin tumors; all sebaceous, squamous cell, porocarcinoma and trichilemmal carcinomas in a second series (sensitivity 94.5%); 59% of primary adnexal carcinomas in a third 0 of 42 and 0 of 15 metastases; 0 of 7 metastatic breast carcinomas Specificity 97.2% in the blinded test set Plaza et al. 2010; Liang et al. 2007; Valencia-Guerrero et al. 2018
CK5/6 86% of primary adnexal carcinomas 26% Sensitivity similar to p63 Lee et al. 2014
CD117 33% of primary adnexal carcinomas Negative in all metastatic breast carcinomas Negative in all 28 squamous cell carcinomas; studied against metastatic breast carcinoma only Valencia-Guerrero et al. 2018
GATA3 47% of primary adnexal carcinomas 40% Not discriminating Lee et al. 2014
  • Limits. None of p40, p63, CK5/6 or GATA3 separates primary adnexal carcinoma from metastatic salivary gland or bladder carcinoma (Lee et al. 2014). p63 and D2-40 are also expressed by squamous cell carcinoma (D2-40 in 57%), so they do not separate adnexal carcinoma from squamous cell carcinoma with ductal differentiation (Valencia-Guerrero et al. 2018).
  • GATA3 in primary skin tumors. GATA3 stains many benign adnexal tumors, 13 of 14 basal cell carcinomas, 21 of 24 squamous cell carcinomas and all 6 sebaceous carcinomas tested. A GATA3-positive carcinoma of unknown origin in skin therefore includes a primary cutaneous carcinoma in its differential diagnosis (Mertens et al. 2015).

Immunohistochemical work-up of a carcinoma of unknown origin in skin

The first panel for an undifferentiated tumor combines pan-cytokeratin, lymphoid markers (CD45 or CD20 and CD3) and melanocytic markers (S100 and SOX10). The CK7 and CK20 pattern then directs organ-specific markers, which are interpreted as part of a panel (Selves et al. 2018).

CK7/CK20 pattern Main origins Organ-directed markers Source
CK7+/CK20− Breast, lung, Müllerian tract, thyroid GATA3 (92%–100% of ductal and lobular breast carcinomas), ER and PR; TTF-1 (lung and thyroid; about 50% of poorly differentiated lung adenocarcinomas); PAX8 (Müllerian, renal and follicular thyroid carcinomas) Selves et al. 2018
CK7−/CK20+ Colorectum; Merkel cell carcinoma CDX2 with or without SATB2; Merkel cell carcinoma shows dot-like CK20, SATB2, chromogranin, synaptophysin and MCPyV, with CDX2 negative Selves et al. 2018
CK7+/CK20+ Mucinous lung, pancreas, stomach, esophagus, small intestine, mucinous ovary, bladder GATA3 for urothelial carcinoma (70%–90%) Selves et al. 2018
CK7−/CK20− Prostate, kidney, liver, adrenal PSA in men; CD10, CAIX and RCC marker for renal cell carcinoma Selves et al. 2018
  • Cancer of unknown primary site. CUP is confirmed when a disseminated malignancy has no identified primary after a standardized work-up. Molecular testing for microsatellite instability or mismatch repair deficiency and tumor mutational burden can support immune checkpoint inhibitor therapy. Site-specific therapy guided by gene expression profiling has not been shown superior to empiric chemotherapy, and most CUP has a poor prognosis (Goldman-Lévy et al. 2026).

References

  1. Abernethy JL, Soyer HP, Kerl H, et al. Epidermotropic metastatic malignant melanoma simulating melanoma in situ: a report of 10 examples from two patients. Am J Surg Pathol. 1994;18(11):1140–1149. doi:10.1097/00000478-199411000-00008. PMID 7943535 (abstract)
  2. Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131(26):2877–2890. doi:10.1182/blood-2018-03-839753. PMID 29720485
  3. Adkins KE, Busam K, Pulitzer M. Cutaneous neuroendocrine mucinous carcinomas are low-grade but may be associated with other cancers. Am J Surg Pathol. 2023;47(10):1186–1191. doi:10.1097/PAS.0000000000002107. PMID 37530225
  4. Agaimy A, Bieg M, Michal M, et al. Recurrent somatic PDGFRB mutations in sporadic infantile/solitary adult myofibromas but not in angioleiomyomas and myopericytomas. Am J Surg Pathol. 2017;41(2):195–203. doi:10.1097/PAS.0000000000000752. PMID 27776010
  5. Ahkami S, Hahn D, Fowler-Kim H, et al. An expanding large acrochordon on the labia majora requiring surgical intervention. Cureus. 2025;17(2):e79017. doi:10.7759/cureus.79017. PMID 40091971
  6. Ahn CS, Guerra A, Sangüeza OP. Melanocytic nevi of special sites. Am J Dermatopathol. 2016;38(12):867–881. doi:10.1097/DAD.0000000000000568. PMID 27870726 (abstract)
  7. Al Ameer A, Imran M, Kaliyadan F, et al. Carcinoma erysipeloides as a presenting feature of breast carcinoma: a case report and brief review of literature. Indian Dermatol Online J. 2015;6(6):396–398. doi:10.4103/2229-5178.169724. PMID 26753138
  8. Al Dhaybi R, Lam C, Hatami A, et al. Targetoid hemosiderotic hemangiomas (hobnail hemangiomas) are vascular lymphatic malformations: a study of 12 pediatric cases. J Am Acad Dermatol. 2012;66(1):116–120. doi:10.1016/j.jaad.2011.05.025. PMID 21798621
  9. Al-Chaer RN, Folkmann M, Mårtensson NL, et al. Cutaneous manifestations of Fabry disease: a systematic review. J Dermatol. 2025;52(4):571–582. doi:10.1111/1346-8138.17690. PMID 40052625
  10. Alves JV, Matos DM, Barreiros HF, et al. Variants of dermatofibroma: a histopathological study. An Bras Dermatol. 2014;89(3):472–477. doi:10.1590/abd1806-4841.20142629. PMID 24937822
  11. Anand P, Sarin N, Misri R, et al. Eruptive vellus hair cyst: an uncommon and underdiagnosed entity. Int J Trichology. 2018;10(1):31–33. doi:10.4103/ijt.ijt_61_17. PMID 29440857
  12. Aslam A. Microcystic adnexal carcinoma and a summary of other rare malignant adnexal tumours. Curr Treat Options Oncol. 2017;18(8):49. doi:10.1007/s11864-017-0491-z. PMID 28681209
  13. Ayturk UM, Couto JA, Hann S, et al. Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma. Am J Hum Genet. 2016;98(4):789–795. doi:10.1016/j.ajhg.2016.03.009. PMID 27058448
  14. Bagga E, Innes D, Leung E. Looking beyond the surface: Muir Torre syndrome. Arch Clin Cases. 2023;10(3):119–122. doi:10.22551/2023.40.1003.10255. PMID 37736596 (Table 1 reproduces the Mayo Muir–Torre risk score)
  15. Bagratee TJ, Ramsuran V, Msimang M, Ramdial PK. Recent advances in the histopathology, molecular biology, and treatment of Kaposi sarcoma: a contemporary review. Int J Mol Sci. 2025;26(20):10058. doi:10.3390/ijms262010058. PMID 41155351
  16. Bahmad HF, Stoyanov K, Mendez T, et al. Keratoacanthoma versus squamous-cell carcinoma: histopathological features and molecular markers. Dermatopathology (Basel). 2024;11(4):272–285. doi:10.3390/dermatopathology11040029. PMID 39449378
  17. Baklouti M, Sellami K, Mellouli M, et al. Inverted follicular keratosis: a retrospective study over 10 years. Indian J Dermatol. 2023;68(1):122. doi:10.4103/ijd.ijd_968_21. PMID 37151274
  18. Bär M, Tschandl P, Kittler H. Differentiation of pigmented Spitz nevi and Reed nevi by integration of dermatopathologic and dermatoscopic findings. Dermatol Pract Concept. 2012;2(1):13–24. PMID 24765545
  19. Barnachea D, Lee B. Sentinel lymph node biopsy in melanoma: pathologic evaluation and diagnostic considerations. J Pathol Transl Med. 2026;60(5):493–501. doi:10.4132/jptm.2026.07.01. PMID 42675997
  20. Barnhill RL, Elder DE, Piepkorn MW, et al. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis classification schema for melanocytic lesions: a consensus statement. JAMA Netw Open. 2023;6(1):e2250613. doi:10.1001/jamanetworkopen.2022.50613. PMID 36630138
  21. Barysch MJ, Braun RP, Kolm I, et al. Keratinocytic malfunction as a trigger for the development of solar lentigines. Dermatopathology (Basel). 2019;6(1):1–11. doi:10.1159/000495404. PMID 30800656
  22. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239–271. doi:10.1146/annurev-pathol-012513-104658. PMID 24460190
  23. Bastos JT, Rocha CRMD, Silva PMCE, et al. Angiolymphoid hyperplasia with eosinophilia versus Kimura's disease: a case report and a clinical and histopathological comparison. An Bras Dermatol. 2017;92(3):392–394. doi:10.1590/abd1806-4841.20175318. PMID 29186256
  24. Battistella M, Carlson JA, Osio A, et al. Skin tumors with matrical differentiation: lessons from hair keratins, beta-catenin and PHLDA-1 expression. J Cutan Pathol. 2014;41(5):427–436. doi:10.1111/cup.12313. PMID 24673383
  25. Bayraktar EC, Jour G. Pigmented epithelioid melanocytomas and their mimics; focus on their novel molecular findings. Biology (Basel). 2021;10(12):1290. doi:10.3390/biology10121290. PMID 34943205
  26. Beltraminelli H, Shabrawi-Caelen LE, Kerl H, et al. Melan-A-positive "pseudomelanocytic nests": a pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sun-damaged skin. Am J Dermatopathol. 2009;31(3):305–308. doi:10.1097/DAD.0b013e31819d3769. PMID 19384076 (abstract)
  27. Berenguer B, Mulliken JB, Enjolras O, et al. Rapidly involuting congenital hemangioma: clinical and histopathologic features. Pediatr Dev Pathol. 2003;6(6):495–510. doi:10.1007/s10024-003-2134-6. PMID 15018449
  28. Bhingradia YM, Patel AB, Patel NK. Surgical excision and primary closure of venous lake of upper eye lid for better cosmetic outcome: a case report. J Cutan Aesthet Surg. 2023;16(1):62–64. doi:10.4103/JCAS.JCAS_39_21. PMID 37383977 (abstract)
  29. Bittner GC, Cerci FB, Kubo EM, et al. Mohs micrographic surgery: a review of indications, technique, outcomes, and considerations. An Bras Dermatol. 2021;96(3):263–277. doi:10.1016/j.abd.2020.10.004. PMID 33849752
  30. Bowen AR, Thacker BN, Goldgar DE, et al. Immunohistochemical staining with Melan-A of uninvolved sun-damaged skin shows features characteristic of lentigo maligna. Dermatol Surg. 2011;37(5):657–663. doi:10.1111/j.1524-4725.2011.01946.x. PMID 21446989 (abstract)
  31. Brouillard P, Boon LM, Mulliken JB, et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas"). Am J Hum Genet. 2002;70(4):866–874. doi:10.1086/339492. PMID 11845407
  32. Buelow B, Cohen J, Nagymanyoki Z, et al. Immunohistochemistry for 2-succinocysteine (2SC) and fumarate hydratase (FH) in cutaneous leiomyomas may aid in identification of patients with HLRCC (hereditary leiomyomatosis and renal cell carcinoma syndrome). Am J Surg Pathol. 2016;40(7):982–988. doi:10.1097/PAS.0000000000000626. PMID 26945337
  33. Calonje E, Guerin D, McCormick D, et al. Superficial angiomyxoma: clinicopathologic analysis of a series of distinctive but poorly recognized cutaneous tumors with tendency for recurrence. Am J Surg Pathol. 1999;23(8):910–917. doi:10.1097/00000478-199908000-00008. PMID 10435560
  34. Campa M, Patel M, Aubert P, et al. Blue nevus-like metastasis of a cutaneous melanoma identified by fluorescence in situ hybridization. Am J Dermatopathol. 2016;38(9):695–697. doi:10.1097/DAD.0000000000000567. PMID 27097332 (abstract)
  35. Cascarino M, Leclerc-Mercier S. Histological patterns of skin lesions in tuberous sclerosis complex: a panorama. Dermatopathology (Basel). 2021;8(3):236–252. doi:10.3390/dermatopathology8030029. PMID 34287284
  36. Cazzato G, Bellitti E, Trilli I, et al. Endocrine mucin-producing sweat gland carcinoma: case presentation with a comprehensive review of the literature. Dermatopathology (Basel). 2023;10(3):266–280. doi:10.3390/dermatopathology10030035. PMID 37754277
  37. Cazzato G, Cascardi E, Colagrande A, et al. Balloon cell melanoma: presentation of four cases with a comprehensive review of the literature. Dermatopathology (Basel). 2022;9(2):100–110. doi:10.3390/dermatopathology9020013. PMID 35466242
  38. Cha Y, Park E, Roh M. Nipple adenoma mimicking Paget's disease: a case report. Korean J Clin Oncol. 2026;22(2):71–74. doi:10.14216/kjco.26398. PMID 42687518 (abstract)
  39. Chan EF, Gat U, McNiff JM, et al. A common human skin tumour is caused by activating mutations in beta-catenin. Nat Genet. 1999;21(4):410–413. doi:10.1038/7747. PMID 10192393
  40. Chang LM, Cassarino DS. p16 expression is lost in severely atypical cellular blue nevi and melanoma compared to conventional, mildly, and moderately atypical cellular blue nevi. ISRN Dermatol. 2014;2014:348417. doi:10.1155/2014/348417. PMID 24587914 (abstract)
  41. Chapman MS, Perry AE, Baughman RD. Cowden's syndrome, Lhermitte-Duclos disease, and sclerotic fibroma. Am J Dermatopathol. 1998;20(4):413–416. doi:10.1097/00000372-199808000-00017. PMID 9700384
  42. Chavan S, Deshmukh R, Karande P, et al. Branchial cleft cyst: a case report and review of literature. J Oral Maxillofac Pathol. 2014;18(1):150. doi:10.4103/0973-029X.131950. PMID 24959062
  43. Chen LL, Jaimes N, Barker CA, et al. Desmoplastic melanoma: a review. J Am Acad Dermatol. 2013;68(5):825–833. doi:10.1016/j.jaad.2012.10.041. PMID 23267722
  44. Chen QQ, Jiang Y, Guo JR, et al. Diagnostic pitfalls of morphological mimicry and CD34 heterogeneity in recurrent or fibrosarcomatous dermatofibrosarcoma protuberans: a clinicopathological analysis of three molecularly confirmed cases with literature review. J Cutan Pathol. 2026;53(12):1172–1179. doi:10.1111/cup.70172. PMID 42502207 (abstract)
  45. Chen W, Zhang H, Huang J, et al. Traumatic neuroma in mastectomy scar: two case reports and review of the literature. Medicine (Baltimore). 2019;98(15):e15142. doi:10.1097/MD.0000000000015142. PMID 30985684
  46. Cheng TW, Ahern MC, Giubellino A. The spectrum of Spitz melanocytic lesions: from morphologic diagnosis to molecular classification. Front Oncol. 2022;12:889223. doi:10.3389/fonc.2022.889223. PMID 35747831
  47. College of American Pathologists. CAP cancer protocols summary of changes, April 2026. https://www.cap.org/wp-content/uploads/protocols/2026-April-Cancer-Protocol-Summary-of-Changes.pdf (accessed 2026-11-17). Cited as CAP 2026c.
  48. College of American Pathologists. Protocol for the examination of biopsy specimens from patients with invasive melanoma of the skin, version 1.1.0.0. Posted March 2025. https://www.cap.org/wp-content/uploads/documents/New-Cancer-Protocols-March-2025/Skin.Inv_Melanoma.Bx_1.1.0.0.REL.CAPCP.pdf (accessed 2026-11-17). Cited as CAP 2025b.
  49. College of American Pathologists. Protocol for the examination of excision specimens from patients with invasive melanoma of the skin, version 1.2.0.0. Posted March 2025. https://www.cap.org/wp-content/uploads/documents/New-Cancer-Protocols-March-2025/Skin.Inv_Melanoma.Res_1.2.0.0.REL.CAPCP.pdf (accessed 2026-11-17). Cited as CAP 2025a.
  50. College of American Pathologists. Protocol for the examination of specimens from patients with cutaneous carcinoma of the head and neck, version 1.2.0.0. Posted April 2026. https://www.cap.org/wp-content/uploads/protocols/HN.Skin_Cutaneous_1.2.0.0.REL_CAPCP.pdf (accessed 2026-11-17). Cited as CAP 2026a.
  51. College of American Pathologists. Template for reporting results of biomarker testing of specimens from patients with melanoma, version MelanomaBiomarkers 1.0.0.2. Posted February 2019. https://www.cap.org/wp-content/uploads/2026/08/cp-skin-melanoma-15biomarker-1002.pdf (accessed 2026-11-17). Cited as CAP 2019.
  52. Compton LA, Murphy GF, Lian CG. Diagnostic immunohistochemistry in cutaneous neoplasia: an update. Dermatopathology (Basel). 2015;2(1):15–42. doi:10.1159/000377698. PMID 27047932
  53. Cook MG, Massi D, Szumera-Ciećkiewicz A, et al. An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma. Eur J Cancer. 2019;114:1–7. doi:10.1016/j.ejca.2019.03.010. PMID 31005015 (abstract)
  54. Cuervo-Pardo LB, Gonzalez-Estrada A, Ruiz SJ, et al. Hyperpigmented cutaneous lesions that flare-up with scratching: Darier's sign. Oxf Med Case Reports. 2015;2015(2):188–190. doi:10.1093/omcr/omv004. PMID 25988075
  55. Dal Pozzo CA, Cappellesso R. The morpho-molecular landscape of Spitz neoplasms. Int J Mol Sci. 2022;23(8):4211. doi:10.3390/ijms23084211. PMID 35457030
  56. Darling TN, Skarulis MC, Steinberg SM, et al. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol. 1997;133(7):853–857. PMID 9236523
  57. De Giorgi V, Gori A, Salvati L, et al. Clinical and dermoscopic features of vulvar melanosis over the last 20 years. JAMA Dermatol. 2020;156(11):1185–1191. doi:10.1001/jamadermatol.2020.2528. PMID 32785609 (abstract)
  58. De Schrijver S, Theate I, Vanhooteghem O. Halo nevi are not trivial: about 2 young patients of regressed primary melanoma that simulates halo nevi. Case Rep Dermatol Med. 2021;2021:6672528. doi:10.1155/2021/6672528. PMID 33859847
  59. Diociaiuti A, Bellacchio E, Cesario C, et al. Spontaneous regression of a verrucous venous malformation associated with a previously undescribed MAP3K3 variant. Acta Derm Venereol. 2025;105:adv44095. doi:10.2340/actadv.v105.44095. PMID 41051054
  60. Donghi D, Kerl K, Dummer R, et al. Cutaneous angiosarcoma: own experience over 13 years. Clinical features, disease course and immunohistochemical profile. J Eur Acad Dermatol Venereol. 2010;24(10):1230–1234. doi:10.1111/j.1468-3083.2010.03624.x. PMID 20236193 (abstract)
  61. Doyle LA, Mariño-Enriquez A, Fletcher CD, et al. ALK rearrangement and overexpression in epithelioid fibrous histiocytoma. Mod Pathol. 2015;28(7):904–912. doi:10.1038/modpathol.2015.49. PMID 25857825
  62. Duan N, Zhang YH, Wang WM, et al. Mystery behind labial and oral melanotic macules: clinical, dermoscopic and pathological aspects of Laugier-Hunziker syndrome. World J Clin Cases. 2018;6(10):322–334. doi:10.12998/wjcc.v6.i10.322. PMID 30283795
  63. Dubois A, Rannan-Eliya S, Husain A, et al. Squamous cell carcinomas in linear epidermal naevi. Clin Exp Dermatol. 2019;44(2):238–240. doi:10.1111/ced.13704. PMID 29956363
  64. Dutt R, Rabinovitz HS, Singh R, Scope A. Dermoscopic and confocal features of an axillary "special site" nevus. Dermatol Pract Concept. 2017;7(1):55–58. doi:10.5826/dpc.0701a11. PMID 28243497
  65. Elder DE, Bastian BC, Cree IA, et al. The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med. 2020;144(4):500–522. doi:10.5858/arpa.2019-0561-RA. PMID 32057276 (abstract; summarizes the WHO Classification of Skin Tumours, 4th edition)
  66. Elder DE. Melanoma diagnosis in the Mihm era—and beyond. J Cutan Pathol. 2026;53(1):16–22. doi:10.1111/cup.14742. PMID 39489491
  67. Elhaitamy S, Elloudi S, Kozmane S, et al. Dermoscopic features of a solitary glomeruloid hemangioma: a rare nonsyndromic presentation. Cureus. 2026;18(9):e115994. doi:10.7759/cureus.115994. PMID 42857146
  68. Elibol BN, Erduran F, Orhun HS. Acantholytic acanthoma arising in severely photodamaged skin: a case report. Cureus. 2025;17(11):e97539. doi:10.7759/cureus.97539. PMID 41446445
  69. Elkiran YM, Elsaadany NA, Elkiran YY, et al. Stewart Treves syndrome as a catastrophic sequela of chronic lymphedema: clinical spectrum, management challenges, and outcomes. J Vasc Surg Cases Innov Tech. 2026;12(3):102191. doi:10.1016/j.jvscit.2026.102191. PMID 41938482
  70. Farid M, Ong WS, Lee MJ, et al. Cutaneous versus non-cutaneous angiosarcoma: clinicopathologic features and treatment outcomes in 60 patients at a single Asian cancer centre. Oncology. 2013;85(3):182–190. doi:10.1159/000354215. PMID 24008869
  71. Fend F, Dirnhofer S, Egan C, et al. Histiocytoses and reactive proliferations of histiocytes: current state of the art and evolving concepts—a report from the joint CSHP-EA4HP-SH workshop 2024. Virchows Arch. 2026;488(2):245–262. doi:10.1007/s00428-025-04096-4. PMID 40210741
  72. Fernandez AP, Sun Y, Tubbs RR, et al. FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations. J Cutan Pathol. 2012;39(2):234–242. doi:10.1111/j.1600-0560.2011.01843.x. PMID 22121953
  73. Ferrara G, Argenziano G. The WHO 2018 classification of cutaneous melanocytic neoplasms: suggestions from routine practice. Front Oncol. 2021;11:675296. doi:10.3389/fonc.2021.675296. PMID 34277420
  74. Fetsch JF, Laskin WB, Hallman JR, et al. Neurothekeoma: an analysis of 178 tumors with detailed immunohistochemical data and long-term patient follow-up information. Am J Surg Pathol. 2007;31(7):1103–1114. doi:10.1097/PAS.0b013e31802d96af. PMID 17592278
  75. Fetsch JF, Laskin WB, Miettinen M. Nerve sheath myxoma: a clinicopathologic and immunohistochemical analysis of 57 morphologically distinctive, S-100 protein- and GFAP-positive, myxoid peripheral nerve sheath tumors with a predilection for the extremities and a high local recurrence rate. Am J Surg Pathol. 2005;29(12):1615–1624. doi:10.1097/01.pas.0000173025.87476.a4. PMID 16327434
  76. Fletcher CD. Solitary circumscribed neuroma of the skin (so-called palisaded, encapsulated neuroma): a clinicopathologic and immunohistochemical study. Am J Surg Pathol. 1989;13(7):574–580. doi:10.1097/00000478-198907000-00005. PMID 2660609
  77. Folpe AL, Fanburg-Smith JC, Miettinen M, et al. Atypical and malignant glomus tumors: analysis of 52 cases, with a proposal for the reclassification of glomus tumors. Am J Surg Pathol. 2001;25(1):1–12. doi:10.1097/00000478-200101000-00001. PMID 11145243
  78. Fried I, Sitthinamsuwan P, Muangsomboon S, et al. SOX-10 and MiTF expression in cellular and 'mixed' neurothekeoma. J Cutan Pathol. 2014;41(8):640–645. doi:10.1111/cup.12301. PMID 24475873
  79. Frischhut N, Zelger B, Andre F, et al. The spectrum of melanocytic nevi and their clinical implications. J Dtsch Dermatol Ges. 2022;20(4):483–504. doi:10.1111/ddg.14776. PMID 35446494
  80. Gassenmaier M, Hahn M, Metzler G, et al. Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas. Cancers (Basel). 2021;13(15):3864. doi:10.3390/cancers13153864. PMID 34359765
  81. Gebhard J, Horny HP, Kristensen T, et al. Validation of dermatopathological criteria to diagnose cutaneous lesions of mastocytosis: importance of KIT D816V mutation analysis. J Eur Acad Dermatol Venereol. 2022;36(8):1367–1375. doi:10.1111/jdv.18143. PMID 35412687
  82. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492. doi:10.3322/caac.21409. PMID 29028110
  83. Gleason BC, Fletcher CD. Deep "benign" fibrous histiocytoma: clinicopathologic analysis of 69 cases of a rare tumor indicating occasional metastatic potential. Am J Surg Pathol. 2008;32(3):354–362. doi:10.1097/PAS.0b013e31813c6b85. PMID 18300816
  84. Goldenberg DC, Vikkula M, Penington A, et al. Updated classification of vascular anomalies. A living document from the International Society for the Study of Vascular Anomalies Classification Group. J Vasc Anom (Phila). 2025;6(2). doi:10.1097/JOVA.0000000000000113. PMID 40636925
  85. Goldman-Lévy G, Barnhill R, Bastian BC, et al. WHO classification of skin tumours: key updates in the fifth edition. Histopathology. 2026;88(3):555–568. doi:10.1111/his.15562. PMID 41263762 (summarizes the WHO Classification of Skin Tumours, 5th edition)
  86. Grant KG, Thatiparthi A, Motaparthi K. Cutaneous angiosarcoma: clinicopathologic spectrum, immunohistochemical features, and diagnostic pearls. Int J Surg Pathol. 2026. doi:10.1177/10668969261478605. PMID 42789362 (abstract)
  87. Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol. 2008;3:31. doi:10.1186/1746-1596-3-31. PMID 18655700
  88. Grcar-Kuzmanov B, Bostjancic E, Bandres JAC, et al. Sclerosing melanocytic lesions (sclerosing melanomas with nevoid features and sclerosing nevi with pseudomelanomatous features) - an analysis of 90 lesions. Radiol Oncol. 2018;52(2):220–228. doi:10.2478/raon-2018-0003. PMID 30018527
  89. Green AC, Mundra PA, Grant M, et al. Frequency of naevus cells in lymph nodes of melanoma and breast cancer patients. Pathol Res Pract. 2024;254:155106. doi:10.1016/j.prp.2024.155106. PMID 38271783 (abstract)
  90. Groesser L, Peterhof E, Evert M, et al. BRAF and RAS mutations in sporadic and secondary pyogenic granuloma. J Invest Dermatol. 2016;136(2):481–486. doi:10.1038/JID.2015.376. PMID 26802240
  91. Guillou L, Calonje E, Speight P, et al. Hobnail hemangioma: a pseudomalignant vascular lesion with a reappraisal of targetoid hemosiderotic hemangioma. Am J Surg Pathol. 1999;23(1):97–105. doi:10.1097/00000478-199901000-00011. PMID 9888709
  92. Gutiérrez Fernández de Velasco M, Ruiz Quintero GR, Cabezuelo Adame X, et al. Intravascular papillary endothelial hyperplasia of the upper limb mimicking a vascular neoplasm: case report and literature review. EJVES Vasc Forum. 2026;66:77–88. doi:10.1016/j.ejvsvf.2026.07.003. PMID 42699648
  93. Hachisuga T, Hashimoto H, Enjoji M. Angioleiomyoma: a clinicopathologic reappraisal of 562 cases. Cancer. 1984;54(1):126–130. doi:10.1002/1097-0142(19840701)54:1<126::aid-cncr2820540125>3.0.co;2-f. PMID 6722737
  94. Haddock ES, Cohen PR. Fibroepithelioma of Pinkus revisited. Dermatol Ther (Heidelb). 2016;6(3):347–362. doi:10.1007/s13555-016-0123-8. PMID 27329375
  95. Hao X, Billings SD, Wu F, et al. Dermatofibrosarcoma protuberans: update on the diagnosis and treatment. J Clin Med. 2020;9(6):1752. doi:10.3390/jcm9061752. PMID 32516921
  96. Harms KL, Healy MA, Nghiem P, et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann Surg Oncol. 2016;23(11):3564–3571. doi:10.1245/s10434-016-5266-4. PMID 27198511
  97. Harms PW, Harms KL, Moore PS, et al. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nat Rev Clin Oncol. 2018;15(12):763–776. doi:10.1038/s41571-018-0103-2. PMID 30287935
  98. Harnisch K, Kalmykova A, McKee P. Low-grade sweat gland carcinomas: a review—a CME article. Am J Dermatopathol. 2026;48(8):569–583. doi:10.1097/DAD.0000000000003163. PMID 42485130
  99. Harris GR, Shea CR, Horenstein MG, et al. Desmoplastic (sclerotic) nevus: an underrecognized entity that resembles dermatofibroma and desmoplastic melanoma. Am J Surg Pathol. 1999;23(7):786–794. doi:10.1097/00000478-199907000-00006. PMID 10403301 (abstract)
  100. Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137(1):35–45. doi:10.1016/j.jaci.2015.08.034. PMID 26476479
  101. Helbig D, Ziemer M, Dippel E, et al. S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). J Dtsch Dermatol Ges. 2022;20(2):235–243. doi:10.1111/ddg.14700. PMID 35099104
  102. Helm TN, Helm MF, Helm KF. Melanoma arising in a persistent nevus: melanoma where 'pseudomelanoma' is expected. JAAD Case Rep. 2021;12:5–7. doi:10.1016/j.jdcr.2021.03.045. PMID 33997217
  103. Ho J, Collie CJ. What's new in dermatopathology 2023: WHO 5th edition updates. J Pathol Transl Med. 2023;57(6):337–340. doi:10.4132/jptm.2023.09.22. PMID 37840244
  104. Hoang VT, Trinh CT, Nguyen CH, et al. Overview of epidermoid cyst. Eur J Radiol Open. 2019;6:291–301. doi:10.1016/j.ejro.2019.08.003. PMID 31516916
  105. Hornick JL, Bovee JVMG, Antonescu CR, et al. The 2026 World Health Organization Classification of Tumors of Soft Tissue and Bone: 6th Edition. Am J Surg Pathol. 2026;50(12):e48–e64. doi:10.1097/PAS.0000000000002624. PMID 42839882 (summarizes the WHO Classification of Tumours of Soft Tissue and Bone, 6th edition)
  106. Hornick JL, Fletcher CD. Cellular neurothekeoma: detailed characterization in a series of 133 cases. Am J Surg Pathol. 2007;31(3):329–340. doi:10.1097/01.pas.0000213360.03133.89. PMID 17325474
  107. Hosler GA, Moresi JM, Barrett TL. Nevi with site-related atypia: a review of melanocytic nevi with atypical histologic features based on anatomic site. J Cutan Pathol. 2008;35(10):889–898. doi:10.1111/j.1600-0560.2008.01041.x. PMID 18822061 (abstract)
  108. Hwang SH, St John M. Cutaneous squamous cell carcinoma in immunocompromised patients. Cancers (Basel). 2025;17(21):3476. doi:10.3390/cancers17213476. PMID 41228268
  109. Idriss MH, Rizwan L, Sferuzza A, et al. Nevoid melanoma: a study of 43 cases with emphasis on growth pattern. J Am Acad Dermatol. 2015;73(5):836–842. doi:10.1016/j.jaad.2015.07.003. PMID 26299955 (abstract)
  110. Ivan D, Hafeez Diwan A, Prieto VG. Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol. 2005;18(1):137–142. doi:10.1038/modpathol.3800263. PMID 15389254
  111. Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149(4):402–410. doi:10.1001/jamadermatol.2013.2456. PMID 23325457
  112. Jarutatsanangkoon K, Purngpiputtrakul P, Hanamornroongruang S, et al. Diagnostic utility of PRAME and SOX10 immunostaining for vulvar melanocytic lesions. Cureus. 2026;18(2):e103309. doi:10.7759/cureus.103309. PMID 41835772
  113. Jia JL, Wang JY, Chan WH, et al. Identification of activating hotspot mutations in acrochordons through next-generation sequencing. JAAD Int. 2025;18:17–19. doi:10.1016/j.jdin.2024.08.011. PMID 39553486
  114. Jin M, Hampel H, Pilarski R, et al. Phosphatase and tensin homolog immunohistochemical staining and clinical criteria for Cowden syndrome in patients with trichilemmoma or associated lesions. Am J Dermatopathol. 2013;35(6):637–640. doi:10.1097/DAD.0b013e31827e28f7. PMID 23715080
  115. Jung JM, Lee SH, Won CH, et al. A case of multiple epidermolytic acanthoma of the scrotum: is the human papillomavirus a culprit? Ann Dermatol. 2015;27(5):633–634. doi:10.5021/ad.2015.27.5.633. PMID 26512188
  116. Kaddu S, McMenamin ME, Fletcher CD. Atypical fibrous histiocytoma of the skin: clinicopathologic analysis of 59 cases with evidence of infrequent metastasis. Am J Surg Pathol. 2002;26(1):35–46. doi:10.1097/00000478-200201000-00004. PMID 11756767
  117. Kalmykova AV, Baranovska-Andrigo V, Michal M. Update on cutaneous mesenchymal tumors in the 5th edition of WHO classification of skin tumors with an emphasis on new fusion-associated neoplasms. Virchows Arch. 2024;485(5):777–792. doi:10.1007/s00428-024-03925-2. PMID 39264472
  118. Kamposioras K, Pentheroudakis G, Pectasides D, et al. Malignant melanoma of unknown primary site: to make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol. 2011;78(2):112–126. doi:10.1016/j.critrevonc.2010.04.007. PMID 20570171 (abstract)
  119. Kandalgaonkar S, Tupsakhare S, Patil A, et al. Solitary angiokeratoma of oral mucosa: a rare presentation. Case Rep Dent. 2013;2013:812323. doi:10.1155/2013/812323. PMID 23936686 (abstract)
  120. Karia PS, Morgan FC, Califano JA, et al. Comparison of tumor classifications for cutaneous squamous cell carcinoma of the head and neck in the 7th vs 8th edition of the AJCC Cancer Staging Manual. JAMA Dermatol. 2018;154(2):175–181. doi:10.1001/jamadermatol.2017.3960. PMID 29261835
  121. Kasprzak JM, Xu YG. Diagnosis and management of lentigo maligna: a review. Drugs Context. 2015;4:212281. doi:10.7573/dic.212281. PMID 26082796
  122. Kemps PG, Picarsic J, Durham BH, et al. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood. 2022;139(2):256–280. doi:10.1182/blood.2021013338. PMID 34727172
  123. Kerl H, Soyer HP, Cerroni L, et al. Ancient melanocytic nevus. Semin Diagn Pathol. 1998;15(3):210–215. PMID 9711671 (abstract)
  124. Kerl H, Wolf IH, Kerl K, et al. Ancient melanocytic nevus: a simulator of malignant melanoma. Am J Dermatopathol. 2011;33(2):127–130. PMID 21399448 (abstract)
  125. Kervarrec T, Pissaloux D, Paindavoine S, et al. Recurrent PAK2 rearrangements in poroma with folliculo-sebaceous differentiation. Histopathology. 2023;83(2):310–319. doi:10.1111/his.14940. PMID 37199682 (cited as Kervarrec et al. 2023b)
  126. Kervarrec T, Pissaloux D, Poilane J, et al. Recurrent FOXK1::GRHL and GPS2::GRHL fusions in trichogerminoma. J Pathol. 2022;257(1):96–108. doi:10.1002/path.5872. PMID 35049062
  127. Kervarrec T, Tallet A, Macagno N, et al. Sweat gland tumors arising on acral sites: a molecular survey. Am J Surg Pathol. 2023;47(10):1096–1107. doi:10.1097/PAS.0000000000002098. PMID 37505808 (cited as Kervarrec et al. 2023a)
  128. Kervarrec T, Westphal D, Pissaloux D, et al. Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases. Histopathology. 2024;85(4):566–578. doi:10.1111/his.15214. PMID 38785043
  129. Kim DH, Kim HK, Lee JW, et al. A case of cutaneous bronchogenic cyst presenting with lymphoid follicles. Ann Dermatol. 2011;23(3):392–395. doi:10.5021/ad.2011.23.3.392. PMID 21909217
  130. Kim JH, Shin CH, Kim DC, et al. Solitary sclerotic fibroma on the thigh. Arch Craniofac Surg. 2020;21(5):323–325. doi:10.7181/acfs.2020.00360. PMID 33143403
  131. Kim JW, Shin JW, Cho A, et al. Hereditary leiomyomatosis and renal cell cancer: a case report of pilar leiomyomatosis with history of kidney cancer and review of the literature. Ann Dermatol. 2023;35(Suppl 1):S14–S18. doi:10.5021/ad.20.287. PMID 37853857
  132. Kim PJ, Mufti A, Sachdeva M, et al. Stewart-Treves syndrome and other cutaneous malignancies in the context of chronic lymphedema: a systematic review. Int J Dermatol. 2022;61(1):62–70. doi:10.1111/ijd.15736. PMID 34196958
  133. Kim Y, Kim H. The cutaneous ciliated cyst in young male: the possibility of ciliated cutaneous eccrine cyst. Case Rep Med. 2015;2015:589831. doi:10.1155/2015/589831. PMID 26491452
  134. Kinsler VA, O'Hare P, Bulstrode N, et al. Melanoma in congenital melanocytic naevi. Br J Dermatol. 2017;176(5):1131–1143. doi:10.1111/bjd.15301. PMID 28078671
  135. Kinsler VA, Thomas AC, Ishida M, et al. Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol. 2013;133(9):2229–2236. doi:10.1038/jid.2013.70. PMID 23392294
  136. Kiratikanon S, Fukui A, Hirata M, et al. Diagnostic algorithm for secondary extramammary Paget disease from institutional cases and literature review. Cancers (Basel). 2025;17(24):4014. doi:10.3390/cancers17244014. PMID 41463263
  137. Kiruthiga KG, Younes S, Natkunam Y. Strong coexpression of transcription factors PU.1 and Oct-2 in Rosai-Dorfman disease. Am J Clin Pathol. 2022;158(6):672–677. doi:10.1093/ajcp/aqac119. PMID 36239684
  138. Kitayama S, Katsuumi K, Takatsuka S, et al. Alopecia neoplastica: a manifestation of metastatic breast cancer. Skin Health Dis. 2023;3(6):e302. doi:10.1002/ski2.302. PMID 38047252
  139. Klein JC, Wilky BA, Ford HL. Molecular characterization of atypical fibroxanthoma and pleomorphic dermal sarcoma. Cancers (Basel). 2025;17(11):1785. doi:10.3390/cancers17111785. PMID 40507266
  140. Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous "leiomyosarcoma". Am J Surg Pathol. 2011;35(4):599–607. doi:10.1097/PAS.0b013e31820e6093. PMID 21358302
  141. Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1):e20183475. doi:10.1542/peds.2018-3475. PMID 30584062
  142. Kucher C, Zhang PJ, Pasha T, et al. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. Am J Dermatopathol. 2004;26(6):452–457. doi:10.1097/00000372-200412000-00002. PMID 15618925 (abstract)
  143. Kurek KC, Pansuriya TC, van Ruler MA, et al. R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformations. Am J Pathol. 2013;182(5):1494–1500. doi:10.1016/j.ajpath.2013.01.012. PMID 23485734
  144. Kutzner H, Mentzel T, Palmedo G, et al. Plaque-like CD34-positive dermal fibroma ("medallion-like dermal dendrocyte hamartoma"): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans. Am J Surg Pathol. 2010;34(2):190–201. doi:10.1097/PAS.0b013e3181c7cf11. PMID 20061935
  145. Laeijendecker AE, El Sharouni MA, Sigurdsson V, et al. Desmoplastic melanoma: the role of pure and mixed subtype in sentinel lymph node biopsy and survival. Cancer Med. 2020;9(2):671–677. doi:10.1002/cam4.2736. PMID 31804771
  146. Lalloo F, Kulkarni A, Chau C, et al. Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome. Eur J Hum Genet. 2023;31(11):1261–1269. doi:10.1038/s41431-023-01448-z. PMID 37607989
  147. Leblebici C, Bambul Sığırcı B, Kelten Talu C, et al. CD10, TDAG51, CK20, AR, INSM1, and nestin expression in the differential diagnosis of trichoblastoma and basal cell carcinoma. Int J Surg Pathol. 2019;27(1):19–27. doi:10.1177/1066896918781719. PMID 29938548
  148. Lee J, Kim M, Moon J, et al. Pagetoid Bowen disease initially misdiagnosed as ectopic extramammary Paget's disease. Ann Dermatol. 2018;30(2):218–221. doi:10.5021/ad.2018.30.2.218. PMID 29606821
  149. Lee JJ, Mochel MC, Piris A, et al. p40 exhibits better specificity than p63 in distinguishing primary skin adnexal carcinomas from cutaneous metastases. Hum Pathol. 2014;45(5):1078–1083. doi:10.1016/j.humpath.2014.01.006. PMID 24746214
  150. Legrand M, Louveau B, Osio A, et al. Primary cutaneous NUT adnexal carcinoma: morphologic, genetic and methylation analysis of seven new cases with comparison to extracutaneous NUT carcinoma and NUTM1-rearranged porocarcinoma. Histopathology. 2025;87(3):375–387. doi:10.1111/his.15444. PMID 40125640
  151. Lezcano C, Jungbluth AA, Nehal KS, et al. PRAME expression in melanocytic tumors. Am J Surg Pathol. 2018;42(11):1456–1465. doi:10.1097/PAS.0000000000001134. PMID 30045064
  152. Lezcano C, Pulitzer M, Moy AP, et al. Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am J Surg Pathol. 2020;44(4):503–508. doi:10.1097/PAS.0000000000001393. PMID 31633488
  153. Liang CA, Jambusaria-Pahlajani A, Karia PS, et al. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol. 2014;71(4):781–786. doi:10.1016/j.jaad.2014.03.018. PMID 24755121 (abstract)
  154. Liang H, Wu H, Giorgadze TA, et al. Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. Am J Surg Pathol. 2007;31(2):304–310. doi:10.1097/01.pas.0000213388.47913.f1. PMID 17255777 (abstract)
  155. Liau JY, Lan J, Hong JB, et al. Frequent PIK3CA-activating mutations in hidradenoma papilliferums. Hum Pathol. 2016;55:57–62. doi:10.1016/j.humpath.2016.04.014. PMID 27184479
  156. Liau JY, Lee JC, Tsai JH, et al. High frequency of GNA14, GNAQ, and GNA11 mutations in cherry hemangioma: a histopathological and molecular study of 85 cases indicating GNA14 as the most commonly mutated gene in vascular neoplasms. Mod Pathol. 2019;32(11):1657–1665. doi:10.1038/s41379-019-0284-y. PMID 31189994
  157. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet. 2009;41(1):112–117. doi:10.1038/ng.283. PMID 19098912
  158. Lim YH, Bacchiocchi A, Qiu J, et al. GNA14 somatic mutation causes congenital and sporadic vascular tumors by MAPK activation. Am J Hum Genet. 2016;99(2):443–450. doi:10.1016/j.ajhg.2016.06.010. PMID 27476652
  159. Lima LPN, Amorim CV, Marinho RM, et al. Congenital solitary reticulohistiocytosis (Hashimoto–Pritzker). An Bras Dermatol. 2022;97(6):778–782. doi:10.1016/j.abd.2022.01.005. PMID 36153176
  160. Lin LY, Lee NG, Yoon MK, et al. Clear cell syringoma of the eyelids, a distinctive histopathologic variant associated with diabetes mellitus. Ophthalmic Plast Reconstr Surg. 2023;39(1):e20–e22. doi:10.1097/IOP.0000000000002254. PMID 36136737
  161. Liu Q, Wu W, Lu J, et al. Steatocystoma multiplex is associated with the R94C mutation in the KRT17 gene. Mol Med Rep. 2015;12(4):5072–5076. doi:10.3892/mmr.2015.4063. PMID 26165312
  162. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. 2008;3:32. doi:10.1186/1750-1172-3-32. PMID 19032739
  163. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol. 1993;29(2 Pt 1):228–236. doi:10.1016/0190-9622(93)70173-q. PMID 8335743
  164. Löper R, Abels L, Otero Baguer D, et al. Artificial intelligence for lentigo maligna: automated margin assessment via Sox-10-based melanocyte density mapping. Dermatopathology (Basel). 2025;13(1):1. doi:10.3390/dermatopathology13010001. PMID 41562710
  165. Lopes ML, Silva Junior FL, Lima KC, et al. Clinicopathological profile and management of 161 cases of actinic cheilitis. An Bras Dermatol. 2015;90(4):505–512. doi:10.1590/abd1806-4841.20153848. PMID 26375219
  166. Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 2015;166(4):1048–1054. doi:10.1016/j.jpeds.2014.12.069. PMID 25681199
  167. Macagno N, Sohier P, Kervarrec T, et al. Recent advances on immunohistochemistry and molecular biology for the diagnosis of adnexal sweat gland tumors. Cancers (Basel). 2022;14(3):476. doi:10.3390/cancers14030476. PMID 35158743
  168. Martín-Sanz R, Sayagués JM, García-Cano P, et al. TP53 abnormalities and MMR preservation in 5 cases of proliferating trichilemmal tumours. Dermatopathology (Basel). 2021;8(2):147–158. doi:10.3390/dermatopathology8020021. PMID 34070291
  169. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–179. PMID 26029015
  170. Mason AR, Mohr MR, Koch LH, Hood AF. Nevi of special sites. Clin Lab Med. 2011;31(2):229–242. doi:10.1016/j.cll.2011.03.001. PMID 21549237 (abstract)
  171. Mazza M, Cavallin F, Galasso E, et al. Sentinel lymph node biopsy in atypical Spitz tumor: a systematic review. J Clin Med. 2024;13(11):3232. doi:10.3390/jcm13113232. PMID 38892943
  172. Mentzel T, Dei Tos AP, Sapi Z, et al. Myopericytoma of skin and soft tissues: clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol. 2006;30(1):104–113. doi:10.1097/01.pas.0000178091.54147.b1. PMID 16330949
  173. Mentzel T, Kutzner H. Dermatomyofibroma: clinicopathologic and immunohistochemical analysis of 56 cases and reappraisal of a rare and distinct cutaneous neoplasm. Am J Dermatopathol. 2009;31(1):44–49. doi:10.1097/DAD.0b013e3181914e6f. PMID 19155724
  174. Mertens RB, de Peralta-Venturina MN, Balzer BL, et al. GATA3 expression in normal skin and in benign and malignant epidermal and cutaneous adnexal neoplasms. Am J Dermatopathol. 2015;37(12):885–891. doi:10.1097/DAD.0000000000000306. PMID 26595821
  175. Meyer T, Stockfleth L, Lang K, et al. From molecular alterations to risk prediction: biomarkers of actinic keratosis progression to cutaneous squamous cell carcinoma. Cancers (Basel). 2026;18(19):3221. doi:10.3390/cancers18193221. PMID 42882915
  176. Micali G, Verzì AE, Puglisi DF, et al. Balloon cell nevus in children: report of three cases of the scalp and review. Pediatr Dermatol. 2021;38(1):198–201. doi:10.1111/pde.14372. PMID 32985713 (abstract)
  177. Miettinen M, Fetsch JF. Reticulohistiocytoma (solitary epithelioid histiocytoma): a clinicopathologic and immunohistochemical study of 44 cases. Am J Surg Pathol. 2006;30(4):521–528. doi:10.1097/00000478-200604000-00014. PMID 16625100
  178. Miettinen M, Paal E, Lasota J, et al. Gastrointestinal glomus tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 32 cases. Am J Surg Pathol. 2002;26(3):301–311. doi:10.1097/00000478-200203000-00003. PMID 11859201
  179. Mohanty SK, Sardana R, McFall M, et al. Does immunohistochemistry add to morphology in differentiating trichoepithelioma, desmoplastic trichoepithelioma, morpheaform basal cell carcinoma, and microcystic adnexal carcinoma? Appl Immunohistochem Mol Morphol. 2022;30(4):273–277. doi:10.1097/PAI.0000000000001002. PMID 35384877
  180. Nagy N, Dubois A, Szell M, et al. Genetic testing in CYLD cutaneous syndrome: an update. Appl Clin Genet. 2021;14:427–444. doi:10.2147/TACG.S288274. PMID 34744449
  181. Napekoski KM, Fernandez AP, Billings SD. Microvenular hemangioma: a clinicopathologic review of 13 cases. J Cutan Pathol. 2014;41(11):816–822. doi:10.1111/cup.12386. PMID 25263662
  182. Nasseri E, Piram M, McCuaig CC, et al. Partially involuting congenital hemangiomas: a report of 8 cases and review of the literature. J Am Acad Dermatol. 2014;70(1):75–79. doi:10.1016/j.jaad.2013.09.018. PMID 24176519 (abstract)
  183. Navea OV, Navea MB, De la Fuente R. Acquired digital fibrokeratoma. Cureus. 2023;15(10):e47997. doi:10.7759/cureus.47997. PMID 38034253
  184. Nieto-Benito LM, Huerta-Aragonés J, Parra-Blanco V, et al. Kaposiform hemangioendothelioma and tufted angioma: two entities of the same clinicopathological spectrum. An Bras Dermatol. 2023;98(3):391–394. doi:10.1016/j.abd.2021.07.010. PMID 36604299
  185. North PE, Waner M, James CA, et al. Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma. Arch Dermatol. 2001;137(12):1607–1620. doi:10.1001/archderm.137.12.1607. PMID 11735711
  186. North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31(1):11–22. doi:10.1016/s0046-8177(00)80192-6. PMID 10665907 (abstract)
  187. Ntinidi C, Tomos I, Matthaiou AM, et al. Birt-Hogg-Dubé syndrome: a mini review of the clinical manifestations, investigation, and management. J Pers Med. 2025;15(12):583. doi:10.3390/jpm15120583. PMID 41440946
  188. Oide T, Yasufuku K, Shibuya K, et al. Primary pulmonary glomus tumor of uncertain malignant potential: a case report with literature review focusing on current concepts of malignancy grade estimation. Respir Med Case Rep. 2016;19:143–149. doi:10.1016/j.rmcr.2016.10.002. PMID 27752464
  189. Okamura K, Suzuki T. Genetic pigmentary disorders: from molecular mechanisms to clinical manifestations. J Dermatol. 2026;53(2):169–179. doi:10.1111/1346-8138.70024. PMID 41127964
  190. Ørholt M, Abebe K, Aaberg F, et al. Immunohistochemical characteristics of atypical fibroxanthoma and pleomorphic dermal sarcoma: a systematic review and meta-analysis. Am J Dermatopathol. 2022;44(12):913–920. doi:10.1097/DAD.0000000000002305. PMID 36395448 (abstract)
  191. Ouchane K, Bourhafour M, Belhouari M, et al. Sister Mary Joseph nodule revealing an ovarian carcinoma: a case report and review of the literature. J Med Case Rep. 2026;20(1). doi:10.1186/s13256-026-06083-y. PMID 42121256
  192. Ozarslan B, Russo T, Argenziano G, et al. Cutaneous findings in neurofibromatosis type 1. Cancers (Basel). 2021;13(3):463. doi:10.3390/cancers13030463. PMID 33530415
  193. Page RN, King R, Mihm MC Jr, et al. Microphthalmia transcription factor and NKI/C3 expression in cellular neurothekeoma. Mod Pathol. 2004;17(2):230–234. doi:10.1038/modpathol.3800043. PMID 14685254
  194. Palla B, Su A, Binder S, et al. SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics. Am J Dermatopathol. 2013;35(5):576–581. doi:10.1097/DAD.0b013e31827a0b98. PMID 23291581 (abstract)
  195. Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011;43(12):1256–1261. doi:10.1038/ng.1004. PMID 22057234
  196. Paolino G, Donati M, Didona D, et al. Histology of non-melanoma skin cancers: an update. Biomedicines. 2017;5(4):71. doi:10.3390/biomedicines5040071. PMID 29261131
  197. Paolino G, Pampena R, Grassi S, et al. Alopecia neoplastica as a sign of visceral malignancies: a systematic review. J Eur Acad Dermatol Venereol. 2019;33(6):1020–1028. doi:10.1111/jdv.15498. PMID 30767283
  198. Park S, Yun SJ. Acral melanocytic neoplasms: a comprehensive review of acral nevus and acral melanoma in Asian perspective. Dermatopathology (Basel). 2022;9(3):292–303. doi:10.3390/dermatopathology9030035. PMID 35997352
  199. Patel VM, Handler MZ, Schwartz RA, et al. Hereditary leiomyomatosis and renal cell cancer syndrome: an update and review. J Am Acad Dermatol. 2017;77(1):149–158. doi:10.1016/j.jaad.2017.01.023. PMID 28314682
  200. Patsatsi A, Lazaridou E, Fotiadou C, et al. Large cell acanthoma: a debate throughout the decades. Dermatol Pract Concept. 2014;4(1):43–45. doi:10.5826/dpc.0401a05. PMID 24520512
  201. Patton KT, Deyrup AT, Weiss SW. Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma. Am J Surg Pathol. 2008;32(6):943–950. doi:10.1097/pas.0b013e31815bf8fe. PMID 18551753
  202. Pe'er J. Pathology of eyelid tumors. Indian J Ophthalmol. 2016;64(3):177–190. doi:10.4103/0301-4738.181752. PMID 27146927
  203. Peddireddy G, Raviprakash D, Dennis Joseph L, et al. Diverse and atypical presentations of acroangiodermatitis of Mali: diagnostic insights from three cases. Cureus. 2025;17(12):e98861. doi:10.7759/cureus.98861. PMID 41523513
  204. Pedrosa AF, Lopes JM, Azevedo F, Mota A. Spitz/Reed nevi: a review of clinical-dermatoscopic and histological correlation. Dermatol Pract Concept. 2016;6(2):37–41. doi:10.5826/dpc.0602a07. PMID 27222770
  205. Pilarski R. PTEN hamartoma tumor syndrome: a clinical overview. Cancers (Basel). 2019;11(6):844. doi:10.3390/cancers11060844. PMID 31216739
  206. Plaza JA, Ortega PF, Stockman DL, et al. Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. J Cutan Pathol. 2010;37(4):403–410. doi:10.1111/j.1600-0560.2010.01517.x. PMID 20377670 (abstract)
  207. Plotzke JM, Wang G, Bresler SC, Harms PW. Molecular diagnosis of melanocytic neoplasia: updates and challenges. Cancers (Basel). 2026;18(20):3330. doi:10.3390/cancers18203330. PMID 42938866
  208. Quddus MR, Rashid LB, Sung CJ, et al. Atypical melanocytic nevi of genital type: a distinctive pigmented lesion of the genital tract often confused with malignant melanoma. Dermatol Online J. 2010;16(2):9. doi:10.5070/D332J249D8. PMID 20178705 (abstract)
  209. Ramaswamy AS, Manjunatha HK, Sunilkumar B, et al. Morphological spectrum of pilar cysts. N Am J Med Sci. 2013;5(2):124–128. doi:10.4103/1947-2714.107532. PMID 23641374
  210. Rashid M, van der Horst M, Mentzel T, et al. ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma. Nat Commun. 2019;10(1):2213. doi:10.1038/s41467-019-09979-0. PMID 31101826
  211. Reinehr CPH, Bakos RM. Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects. An Bras Dermatol. 2019;94(6):637–657. doi:10.1016/j.abd.2019.10.004. PMID 31789244
  212. Remiszewski P, Taczała J, Rosiński M, et al. Dermatofibrosarcoma protuberans (DFSP): diagnostics and molecular pathology. Curr Treat Options Oncol. 2025;26(11):950–966. doi:10.1007/s11864-025-01350-4. PMID 41032154
  213. Riachi M, Polubothu S, Stadnik P, et al. Molecular genetic dissection of inflammatory linear verrucous epidermal naevus leads to successful targeted therapy. J Invest Dermatol. 2021;141(12):2979–2983.e1. doi:10.1016/j.jid.2021.02.765. PMID 34116062
  214. Riva HR, Sohail N, Shalabi MMK, et al. Surgical treatment of pilomatrix carcinoma: a systematic review. Int J Dermatol. 2025;64(6):1021–1026. doi:10.1111/ijd.17596. PMID 39628433
  215. Roberts ME, Riegert-Johnson DL, Thomas BC, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med. 2014;16(9):711–716. doi:10.1038/gim.2014.19. PMID 24603434 (abstract)
  216. Roh NK, Hahn HJ, Lee YW, et al. Clinical and histopathological investigation of seborrheic keratosis. Ann Dermatol. 2016;28(2):152–158. doi:10.5021/ad.2016.28.2.152. PMID 27081260
  217. Russell-Goldman E, Hanna J. MAML2 gene rearrangement occurs in nearly all hidradenomas: a reappraisal in a series of 20 cases. Am J Dermatopathol. 2022;44(11):806–811. doi:10.1097/DAD.0000000000002276. PMID 35925563
  218. Samia AM, Donthi D, Nenow J, et al. A case study and review of literature of eruptive syringoma in a six-year-old. Cureus. 2021;13(4):e14634. doi:10.7759/cureus.14634. PMID 34046271
  219. Sanchez-Alvarez C, Sandhu AS, Crowson CS, et al. Multicentric reticulohistiocytosis: the Mayo Clinic experience (1980–2017). Rheumatology (Oxford). 2020;59(8):1898–1905. doi:10.1093/rheumatology/kez555. PMID 31742640
  220. Sardana K, Chakravarty P, Goel K. Optimal management of common acquired melanocytic nevi (moles): current perspectives. Clin Cosmet Investig Dermatol. 2014;7:89–103. doi:10.2147/CCID.S57782. PMID 24672253
  221. Scurtu LG, Scurtu F, Dumitrescu SC, et al. Squamous cell carcinoma in situ: the importance of early diagnosis in Bowen disease, vulvar intraepithelial neoplasia, penile intraepithelial neoplasia, and erythroplasia of Queyrat. Diagnostics (Basel). 2024;14(16):1799. doi:10.3390/diagnostics14161799. PMID 39202286
  222. Sekine S, Kiyono T, Ryo E, et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest. 2019;129(9):3827–3832. doi:10.1172/JCI126185. PMID 31145701
  223. Sellheyer K, Nelson P, Kutzner H, et al. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. J Cutan Pathol. 2013;40(4):363–370. doi:10.1111/cup.12085. PMID 23398472
  224. Selves J, Long-Mira E, Mathieu MC, et al. Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. Cancers (Basel). 2018;10(4):108. doi:10.3390/cancers10040108. PMID 29621151
  225. Sharma A, Agrawal S, Dhurat R, et al. An unusual case of facial steatocystoma multiplex: a clinicopathologic and dermoscopic report. Dermatopathology (Basel). 2018;5(2):58–63. doi:10.1159/000488584. PMID 29998099
  226. Sharma A, Khaitan N, Ko JS, et al. A clinicopathologic analysis of 54 cases of cutaneous myxoma. Hum Pathol. 2022;120:71–76. doi:10.1016/j.humpath.2021.12.003. PMID 34968506
  227. Sharma R, Verma P, Yadav P, et al. Proliferating trichilemmal tumor of scalp: benign or malignant, a dilemma. J Cutan Aesthet Surg. 2012;5(3):213–215. doi:10.4103/0974-2077.101394. PMID 23112524
  228. Shen AS, Peterhof E, Kind P, et al. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum. Hum Pathol. 2015;46(2):272–276. doi:10.1016/j.humpath.2014.11.002. PMID 25532942
  229. Sherrill AM, Crespo G, Prakash AV, Messina JL. Desmoplastic nevus: an entity distinct from Spitz nevus and blue nevus. Am J Dermatopathol. 2011;33(1):35–39. doi:10.1097/DAD.0b013e3181e5dfa0. PMID 21124206 (abstract)
  230. Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013;368(21):1971–1979. doi:10.1056/NEJMoa1213507. PMID 23656586
  231. Sidiropoulos M, Sholl LM, Obregon R, et al. Desmoplastic nevus of chronically sun-damaged skin: an entity to be distinguished from desmoplastic melanoma. Am J Dermatopathol. 2014;36(8):629–634. doi:10.1097/DAD.0000000000000069. PMID 25051041 (abstract)
  232. Sinson H, Karayan-Tapon L, Godet J, et al. Immunohistochemistry, molecular biology, and clinical scoring for the detection of Muir-Torre syndrome in cutaneous sebaceous tumors: which strategy? Dermatology. 2023;239(6):889–897. doi:10.1159/000534126. PMID 37717564
  233. Soblet J, Kangas J, Nätynki M, et al. Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations. J Invest Dermatol. 2017;137(1):207–216. doi:10.1016/j.jid.2016.07.034. PMID 27519652 (abstract)
  234. Sohier P, Macagno N, Tallet A, et al. Methylation analysis as a diagnostic tool for sweat gland tumours classification with emphasis on the distinction between digital papillary adenocarcinoma and mimickers. Histopathology. 2025;87(4):618–623. doi:10.1111/his.15479. PMID 40494812
  235. Sun J, Karasaki KM, Farma JM. The use of gene expression profiling and biomarkers in melanoma diagnosis and predicting recurrence: implications for surveillance and treatment. Cancers (Basel). 2024;16(3):583. doi:10.3390/cancers16030583. PMID 38339333
  236. Sun Y, Qi R, Wu Z, et al. The clinicopathologic and immunohistochemical features of 60 cutaneous glomus tumor: a retrospective case series study. An Bras Dermatol. 2024;99(2):238–243. doi:10.1016/j.abd.2023.03.005. PMID 38001018
  237. Swetter SM, Ecker PM, Johnson DL, et al. Primary dermal melanoma: a distinct subtype of melanoma. Arch Dermatol. 2004;140(1):99–103. doi:10.1001/archderm.140.1.99. PMID 14732666 (abstract)
  238. Syed MMA, Amatya B, Sitaula S. Median raphe cyst of the penis: a case report and review of the literature. J Med Case Rep. 2019;13(1):214. doi:10.1186/s13256-019-2133-5. PMID 31301740
  239. Szumera-Ciećkiewicz A, Donizy P, Kervarrec T, et al. An updated European Organization for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for Merkel cell carcinoma (MCC). Eur J Cancer. 2026;237:116587. doi:10.1016/j.ejca.2026.116587. PMID 41724115 (abstract)
  240. Tahara U, Ishihara S, Aoki S, et al. Rolled hairs in two cases of naevus comedonicus of the scalp. Acta Derm Venereol. 2021;101(9):adv00549. doi:10.2340/00015555-3920. PMID 34490469
  241. Takayama Y, Yokoo S, Yamaguchi T, et al. A case series study of solitary mucosal neuroma: rare cases of benign peripheral neurogenic tumours. Clin Pathol. 2024;17:2632010X241306593. doi:10.1177/2632010X241306593. PMID 40321435
  242. Tan XL, Patel P, Cernova J, et al. Squamoid eccrine ductal carcinoma: case series of a rare, potentially aggressive skin cancer associated with immunosuppression. J Cutan Pathol. 2026;53(12):1088–1096. doi:10.1111/cup.70127. PMID 42420217
  243. Tellechea O, Cardoso JC, Reis JP, et al. Benign follicular tumors. An Bras Dermatol. 2015;90(6):780–796. doi:10.1590/abd1806-4841.20154114. PMID 26734858
  244. Ten Broek RW, Bekers EM, de Leng WWJ, et al. Mutational analysis using Sanger and next generation sequencing in sporadic spindle cell hemangiomas: a study of 19 cases. Genes Chromosomes Cancer. 2017;56(12):855–860. doi:10.1002/gcc.22501. PMID 28845532
  245. Thomas AC, Zeng Z, Rivière JB, et al. Mosaic activating mutations in GNA11 and GNAQ are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis. J Invest Dermatol. 2016;136(4):770–778. doi:10.1016/j.jid.2015.11.027. PMID 26778290
  246. Tinguria M. Primary mucinous carcinoma of skin: a rare cutaneous neoplasm. Clinicopathologic features, differential diagnoses, and review of literature. Am J Dermatopathol. 2024;46(2):114–120. doi:10.1097/DAD.0000000000002591. PMID 38055969
  247. Tobouti PL, Olegário I, de Sousa SC. Benign vascular lesions of the lips: diagnostic approach. J Cutan Pathol. 2017;44(5):451–455. doi:10.1111/cup.12911. PMID 28111788 (abstract)
  248. Trafalski M, Jurczyszyn K. Contemporary methods of treating venous lake lesions on the oral mucosa: a literature review. Adv Clin Exp Med. 2025;34(6):1039–1051. doi:10.17219/acem/188464. PMID 39318240 (abstract)
  249. Tsatsou F, Trakatelli M, Patsatsi A, et al. Extrinsic aging: UV-mediated skin carcinogenesis. Dermatoendocrinol. 2012;4(3):285–297. doi:10.4161/derm.22519. PMID 23467430
  250. Usmani A, Qasim S. Clear cell acanthoma: a review of clinical and histologic variants. Dermatopathology (Basel). 2020;7(2):26–37. doi:10.3390/dermatopathology7020005. PMID 32854184
  251. Valencia-Guerrero A, Dresser K, Cornejo KM. Utility of immunohistochemistry in distinguishing primary adnexal carcinoma from metastatic breast carcinoma to skin and squamous cell carcinoma. Am J Dermatopathol. 2018;40(6):389–396. doi:10.1097/DAD.0000000000001025. PMID 29781860 (abstract)
  252. van Akkooi AC, Spatz A, Eggermont AM, et al. Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. Eur J Cancer. 2009;45(16):2736–2742. doi:10.1016/j.ejca.2009.08.015. PMID 19767199 (abstract)
  253. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599–602. doi:10.1038/nature07586. PMID 19078957
  254. Verkouteren BJA, Cosgun B, Reinders MGHC, et al. A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome). Br J Dermatol. 2022;186(2):215–226. doi:10.1111/bjd.20700. PMID 34375441
  255. Voiculescu VM, Popescu AI, Costache M. Immunohistochemistry for skin cancers: new insights into diagnosis and treatment of melanoma. Cancers (Basel). 2025;17(11):1769. doi:10.3390/cancers17111769. PMID 40507250
  256. Weigelt MA, Sciallis AP, McIntire PJ, et al. Nipple adenoma: clinicopathologic characterization of 50 cases. Am J Surg Pathol. 2023;47(8):926–932. doi:10.1097/PAS.0000000000002063. PMID 37272622 (abstract)
  257. West KL, Cardona DM, Su Z, et al. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75. Am J Dermatopathol. 2014;36(5):414–419. doi:10.1097/DAD.0b013e3182a70396. PMID 24162384
  258. Wiedemeyer K, Ferreira I, Adams DJ, et al. Cutaneous neoplasms with sebaceous differentiation: a comprehensive update on clinical, histopathological and molecular classification. Cancers (Basel). 2026;18(19):3209. doi:10.3390/cancers18193209. PMID 42882904
  259. Wieland R, Adhikari P, North J. The utility of p63, CK7, and CAM5.2 staining in differentiating pagetoid intraepidermal carcinomas. J Cutan Pathol. 2023;50(12):1110–1115. doi:10.1111/cup.14446. PMID 37203381 (abstract)
  260. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43(10):1018–1021. doi:10.1038/ng.910. PMID 21874003
  261. Wollina U. Recent advances in managing and understanding seborrheic keratosis. F1000Res. 2019;8:F1000 Faculty Rev-1520. doi:10.12688/f1000research.18983.1. PMID 31508199
  262. Yang C, Lu B, Lin Z. Superficial acral fibromyxoma on the palm: a case report. J Med Case Rep. 2025;19(1):13. doi:10.1186/s13256-024-05020-1. PMID 39799373
  263. Yanofsky VR, Mercer SE, Phelps RG. Histopathological variants of cutaneous squamous cell carcinoma: a review. J Skin Cancer. 2011;2011:210813. doi:10.1155/2011/210813. PMID 21234325
  264. Yeh I, Lang UE, Durieux E, et al. Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi. Nat Commun. 2017;8(1):644. doi:10.1038/s41467-017-00758-3. PMID 28935960
  265. Zagala R, Dalle S, Balme B, et al. Prognostic classification of skin adnexal carcinomas: results from a prospective study of 980 patients in the French CARADERM network. Eur J Cancer. 2026;239:116710. doi:10.1016/j.ejca.2026.116710. PMID 41935490
  266. Zhao Q, Zhou H, Geng S. Multiple warty dyskeratoma on the scalp. An Bras Dermatol. 2019;94(5):630–631. doi:10.1016/j.abd.2019.09.015. PMID 31777373
  267. Zou A, Hu M, Niu B. Comparison between Kimura's disease and angiolymphoid hyperplasia with eosinophilia: case reports and literature review. J Int Med Res. 2021;49(9):3000605211040976. doi:10.1177/03000605211040976. PMID 34525882